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Figures 
Figure 1: Here, a schematic description of the therapeutic cassette pEMTAR.bi-RANTES.tk including 
the selection gene is shown. The LTR sequences were part of the viral system facilitating an 
insertion of the gene, which was embedded between both LTR sequences. The HSV-TK gene 
was under the control of an inducible promoter, called RANTES. This RANTES promoter 
generally is inducible with pro-inflammatory cytokines e.g. TNFα and IFNγ. The HA-tag was 
attached to the kinase, which allowed a detection with accordant antibodies for measurement 
through flow cytometry. The enzyme PAC deactivated the cytoxin puromycin by acetylation. This 
enzyme was expressed continuously because it was under the control of a constitutive promoter 
(pPGK) allowing a selection by puromycin during cultivation. The WPRE sequence enhanced the 
stability of the transcribed transgene increasing proten expression [278]. ................................... 34 
Figure 2: This flow chart presents the comparison approach of the human and the porcine-derived cell 
therapy products. Both species cells derived from the bone marrow and were produced in the 
same way. After the first detachment, the cells were split into a naïve line and into a line that was 
transduced with the HSV-TK vecotor. Testing was performed on several different steps of the 
MSC product. In vivo studies were performed with porcine MSCs only. ...................................... 53 
Figure 3: Before the first media change, no adherent cells were visible (A) since erythrocytes 
completely masked the plastic surface. The succesive media changes reduced the amount of 
suspension cells dramatically until only adherent cells remained in the cultivation flask. Here, 
stromal cells (B) built up adherent colonies that showed a circular proliferation with a high cell 
density at the inner part. Within days, the colonies grew up until they got in touch with each 
other. Not later than 14 days, the cells were split and scattered for further proliferation. Scale bar: 
(A) 100 µm and (B) 500 µm. ......................................................................................................... 54 
Figure 4: Porcine (A, batch: Porcine 0) and Human MSCs from donor 1 (B, batch: Human 1) in low-
density seed showed fibroblast-like morphology. Microscopy showed that human MSCs tended 
to be larger than their porcine counterparts and were slightly more spindle-shaped. After 
seeding, both species showed nearly complete adherence in less than 2 h. Scale bar: 250 µm. 55 
Figure 5: The human donor 2 (A, batch: Human 3) and donor 3 (B, batch: Human 5) were comparable 
in morphology to donor 1 and the porcine MSCs. Comparing donor 2 to the other human donors, 
a more flattened and enlarged size was visible. Scale bar: 250 µm. ........................................... 55 
Figure 6: In general, porcine and human MSCs showed a similar set of surface markers (also viability). 
The criteria of the ISCT were fulfilled. In contrast to CD90, CD105 was significantly less 
presented on porcine MSCs, which was further evaluated in Figure 7. CD45+, a typical 
haematopoietic marker, was not present on both species. HLA-DR was found on human MSCs 
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(see Figure 8) but not on porcine MSCs. More comparison stainings could not be performed due 
to the lack of commercially available antibodies for porcine cells. Statistics: two-way ANOVA. .. 57 
Figure 7: In contrast to other positive MSC markers like CD90 (A), a small sub-population of CD105 
negative porcine MSCs (B) could be observed (see arrow). The porcine MSCs showed a single 
population overlapping with the isotype control. A second population of positive cells could be 
discriminated. ................................................................................................................................ 58 
Figure 8: The presence of TNFα and IFNγ induced no up-regulation of HLA-DR on porcine MSCs in 
contrast to human MSCs. MSCs of both species were cultivated w/wo pro-inflammatory 
cytokines and stained for HLA-DR. The naïve and genetically modified batches were grouped. 
Porcine MSCs did not show any HLA-DR presentation on their surface whether stimulated or not. 
Human MSCs increased HLA-DR presentation under stimulation significantly. Statistics: two-way 
ANOVA. ........................................................................................................................................ 60 
Figure 9: Both porcine (A) and human (B) MSCs showed an adipogenic lineage potential. Defined 
stimulation media induced the cell differentiation. After 10 d, first fat vacuoles were observed. Not 
earlier than 14 d after the start of differentiation, the cells were washed and stained. The reddish 
colour of the droplets was caused by the red oil, which was used to detect the fat vacuoles more 
easily. The same commercial differentiation media were used for both species (the used media 
were indicated for human MSCs only). The human donors generally showed more lipid vacuoles 
than the pig (see Table 15). The human batch 1 (C) showed a significantly higher sensitivity for 
differentiation because the appearance large fat vacuoles was observable. In addition, small 
vacuoles lined up in a row (see arrows) at the edge of nearly all cells. (D) Appropriate controls 
showed no red oil staining although very small vacuoles could be observed in some sections. 
Scale bar: 250 µm for (A,B,C) and 25 µm for (D) (all sections had the same optical 
magnification). ............................................................................................................................... 62 
Figure 10: Both species (porcine (A), human (B)) showed strong calcium enrichment. No signifcant 
difference between the batches and species could be observed. The porcine MSCs were 
equivalent to the human MSCs in their osteogenic potential with the human stimulation media. (C 
porcine, D human) Controls for both species showed no calcium enrichment if cultivated with the 
accordant standard media. Scale bar: 250 µm. ............................................................................ 63 
Figure 11: The mean population doubling time (PDT) of porcine and human MSCs was comparable. 
The mean PDT of the porcine batches was 62 h and while it was 58 h for the human batches. 
Obviously, a donor dependency could be observed indicating different doubling times for each 
donor. The porcine batches showed a similar population doubling time. Both batches of each 
donor showed similar population doubling times varying fron 30 h to 100 h. Statistics: two-tailed, 
unpaired t-test. .............................................................................................................................. 65 
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Figure 12: Successful transduction was identified by flow cytometry measuring a second population 
(B) in contrast to a single population of naïve cells (A). (A) Naïve cells showed a typical negative 
population in the SS / flourescence plot. (B) The heterogeneous cell population of transduced 
and naïve cells showed a partial shift creating a diffuse second population. Isotype-controlled 
gating showed more than 46% cells expressing the transgene. .................................................. 67 
Figure 13: (A) Transducing MSCs with the same vector/cell ratio and the same method led to 
comparable mean transgene rates in both species. The human batches 2 and 6 had slightly 
reduced insertion rates, whereas Human 4 was quite similar to Porcine 4. (B) If only the method 
of transduction was changed (same vector / cell ratio), the insertion rate varied significantly. 
Method B showed the highest efficiency while method A and C did not show any statistical 
relevant changes. Statistics: (A) ordinary One-Way ANOVA and (B) ordinary Two-Way ANOVA.
 ...................................................................................................................................................... 68 
Figure 14: (A) The selection by puromycin killed most of the adherent cells visible as detached, 
spheric units. (B) As soon as the selection medium was depleted and a standard medium was 
given into the culture, the MSCs started to proliferate again, indicated by small, not flattened 
cells. Scale bar: 250 µm. .............................................................................................................. 69 
Figure 15: (A) Naïve porcine cells showed a typical population distribution in the flourescence / SS 
depiction. (B) After transduction and selection without RANTES activation, background 
expression of the not induced promoter was detectable (37%). Here, the cells distributed on both 
sides of the gate. (C) If pro-inflammatory cytokines were given into the medium, a single 
population of porcine HSV-TK expressing cells was identified. ................................................... 70 
Figure 16: Stimulation of the human RANTES promoter with pro-inflammatory cytokines led to 
increased HSV-TK expression in both species. Although the RANTES promoter was isolated 
from human cells, it showed functionality in porcine MSCs. Slight background expression was 
detectable in both species in comparison to naïve cells as the negative control. Statistics: paired 
t-test for columns A/B and C/D and Welch´s test (unpaired t-test, non-equal stdv) for the 
comparison of porcine to human batches. .................................................................................... 71 
Figure 17: Porcine (A) and human MSCs (B-D) expressing HSV-TK showed a higher sensitivity to 
GCV than their naïve counterpart. Increasing the GCV concentration in a logarithmic scale 
showed an earlier effect on transduced MSCs, decreasing the amount of living cells. The cell line 
HT1080 and the porcine cell line K67 did show a GCV sensitivity profile (E) like naïve MSCs. 
Statistics: nonlinear regression (dose response inhibition), goodness of fit for each figure A-E: 
R>0.9. ........................................................................................................................................... 73 
Figure 18: The EC50 (half-maximal effectivity of GCV) of all non-transduced MSCs and cell lines were 
more than 100-fold lower than HSV-TK expressing cells. The porcine cells showed sensitivity 
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differences of nearly 1000-fold. Statistics: standard deviation bases on the 95% confidence 
interval of the nonlinear regression. .............................................................................................. 74 
Figure 19: (A) Naïve porcine MSCs did not react with massive apoptosis if GCV was added to the 
medium. The naïve cells showed good adherence and only occasional deatchment was visible 
although GCV was present. (B) The treatment of HSV-TK expressing MSCs with GCV led to a 
massive accumulation of cells and cell debris in the supernatant, which could be seen on day 
five. (C) Depleting the medium only occasionally showed adherent cells. Scale bar: 250 µm. ... 76 
Figure 20: The treatment (pro-inflammatory cytokines + GCV) of HSV-TK expressing cells showed 
significant reduction in cell proliferation in contrast to also treated naïve cells. All groups were 
additionally cultivated without treatment as negative control. At the end of the assay, the cell 
counts of the treated groups were normalized to the negative control and the reduction was 
calculated. Both species showed a comparable percentage of killed cells during treatment for 
HSV-TK expressing and naïve cells. Statistics: paired t-test for columns Porcine 1 / Porcine 2-4 
(HSV-TK) and Human 1,3,5 / Human 2,4,6 (HSV-TK) and Welch´s test (unpaired t-test, non-
equal stdv) for the comparison of porcine to human batches. ...................................................... 77 
Figure 21: GCV-treated, HSV-TK expressing porcine MSCs in contrast to non-treated MSCs: 
Morphological changes correlated with different stages of apoptosis. (A) Non-treated MSCs were 
characterized by one population in the FS / SS plot. (B) If this population was stained for 7-AAD 
and Annexin-V, a slight drift to Annexin-V positive cells was observable. Very small amounts of 
cells were 7-AAD positive indicating dead cells. (C) Since no further populations were visible, the 
gating showed no cells. (D) Treatment of HSV-TK expressing cells generated a second, smaller 
but more granular population in the FS / SS plot. (E) Staining with 7-AAD and Annexin-V for cells 
gated on the “normal population“ showed mainly Annexin-V positive cells and a smaller Annexin-
V and 7-AAD negative population indicating living cells. 7-AAD cells were increased if compared 
to the amount of 7-AAD in (B). (F) Gating on the smaller and more granular population (here 
“shrunken population“) showed that nearly all cells were 7-AAD and Annexin-V positive. A 
smaller sub-population was Annexin-V positive only. ................................................................... 78 
Figure 22: Porcine and human HSV-TK expressing MSCs became smaller and more granular if they 
were treated with pro-inflammatory cytokines and GCV. In this figure, the distributions of the cells 
in the FS / SS are summarized for all batches after treatment following the gating strategy of 
Figure 21. Naïve cells of both species primarily showed a normal morphology in the FS / SS with 
more than 80% in the “normal population” gate in spite of the treatment. HSV-TK expressing 
MSCs showed a change to more granular and smaller cells. Human HSV-TK MSCs showed 
about 30% of shrunken cells but porcine HSV-TK MSCs showed up to 70% of shrunken cells. 
Statistics: two-way ANOVA; following comparisons did not show a significant difference: Porcine 
1 and Human 1,3,5 for normal and shrunken population (p=0.34 and p=0.56); Human 1,3,5 and 
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Human 2,4,6 for shrunken population (p=0.05). All other comparisons did show a significant 
difference (p<0.05). ....................................................................................................................... 79 
Figure 23: (A) Annexin-V stains phosphatidylserine as apoptotic marker and was significantly higher 
presented on HSV-TK expressing MSCs under treatment. All naïve and HSV-TK expressing 
batches were cultured with or without treatment on day three, four and five. On day five, the cells 
were detached and stained with Annexin-V. In contrast to naïve cells under treatment, the 
increase in Annexin-V for all HSV-TK expressing batches was significant. If naïve cells were 
treated, they showed a trend to be more Annexin-V positive although this was not statistically 
significant. (B) HSV-TK expressing cells showed also a statistically significant shift to 7-AAD. All 
batches were treated the same way as described in section 7.5. Here, only Annexin-V positive 
cells were gated for 7-AAD following the described gating strategy (see Figure 21). This increase 
was statistically significant only in porcine cells. Human MSCs expressing HSV-TK showed the 
tendency to be more 7-AAD positive, which cannot be confirmed statistically (p=0.23). Statistics: 
two-way ANOVA. .......................................................................................................................... 80 
Figure 24: The growth speed of a population correlated with the reduction of cells due to GCV-initiated 
apoptosis. All HSV-TK expressing batches were counted before seeding and after cultivation in 
the standard medium (after harvest). This growth is described by percentage in the horizontal 
axis. All HSV-TK expressing batches were treated over five days. The amount of killed cells of 
each batch was normalized to the seeded cells cultivated in the standard medium. Irrespective of 
the species, the killing efficacy correlated with the growing speed of a population. Statistics: 
linear regression, R
2
=0.92. ........................................................................................................... 81 
Figure 25: Porcine and human HSV-TK MSCs reduced the amount of the porcine and the human cell 
line during co-cultivation and treatment. (A) If HT1080 were co-cultivated with naïve cells, no 
significant shifts could be observed between porcine and human cells. But there were less 
HT1080 cells present in the population if cultivated with porcine cells. The killing of HT1080 cells 
by both species was comparable. (B) K67, the porcine cell line, was killed by both species with 
the same efficacy. In contrast to naïve porcine MSCs, the naïve human cells also showed anti-
proliferating effects: the batch Human 5 and, partially, Human 1 showed an inhibition of the 
proliferation since less than 50% K67 cells were left after treatment although no HSV-TK 
expressing cells were present. This effect was species-specific as no similar observations could 
be made if co-cultivated with naïve porcine MSCs. Statistics: ordinary one-way ANOVA for each 
graph, referring to first column in graph A and to second column in graph B. ............................. 83 
Figure 26: MSCs of both species induced the apoptotic cascade in HT1080 as shown by a 
simultaneos increase of Annexin-V and 7-AAD. (A) Naïve porcine or human MSCs did not induce 
any significant increase of Annexin-V or 7-AAD in HT1080 cells. HT1080 cells in mono-
cultivation served as control. HSV-TK expressing human and porcine MSCs raised the mean 
percentage of Annexin-V positive HT1080 to 93% respectively 88%. (B) Also, the amount of 7-
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AAD positive cells increased in the presence of HSV-TK expressing MSCs. Human HSV-TK 
expressing MSCs did not induce a statistically significant increase (p=0.06). Porcine HSV-TK 
expressing MSCs caused an accumulation of 7-AAD positive cells of 40%. Statistics: two-way 
ANOVA. ........................................................................................................................................ 84 
Figure 27: As well as HT1080, K67 cells were killed by in an apoptotic mode of action by both species. 
(A) Annexin-V was significantly increased for HSV-TK expressing, porcine and human MSCs. 
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naïve porcine MSCs. This effect differed significantly from HSV-TK expressing human MSCs. (B) 
7-AAD was increased, too, although it was overall lower than observed for HT1080. Statistics: 
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Figure 28: Porcine MSCs (A) and Human MSCs (B) showed no significant reduction in proliferation if 
they stayed in the cryopreservation medium for 120 min (A) or respectively 90 min (B) after 
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significant difference after 120 min in contrast to the same amount of cells, which were sowed 
out immediately after thawing. Statistics: one-way ANOVA (all data were compared to point in 
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Figure 29: (A) Blood samples were aspirated through a peripheral venous catheter, which was 
implanted into an ear vein (see arrow). (B) The cells were infused into the jugularis vein by a 
catheter that was fixed at the nape to reduce possible damage by the pigs´ movement after 
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Figure 30; Pig 1: Intravenously administered cells could be detected in the peripheral blood stream by 
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to hours, infrequent signals could be detected. In the end, a strong signal could be identified after 
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Tables 
Table 1: This overview represents the nomenclature and properties of human and porcine MSCs in the 
generation of the cell products. The human donors were chosen based on a thorough medical 
anamnesis following the accordant laws (actual, german tissue and transplantation law). The 
pig´s cells isolation was performed by members of the Lehrstuhl für Biotechnologie der Nutztiere 
from the Technische Universtiät München. The mini-pig derives from an isogenetic inbreed. This 
animal is isogenetic to the pigs that were used during the biodistribution study (see 7.7). .......... 28 
Table 2: Description of the cultivation media. Bio-1 was used for human MSCs. This media does not 
contain FBS but platelet lysate that is based on a patent, referenced in 4.1. All other media, also 
for porcine MSCs, had FBS as an ingredient. The recipe for the porcine MSCs cultivation media 
is based on personal communication with the working group of Prof. Angelika Schnieke of the 
Technische Universität München leading the “Chair of Livestock Biotechnology”. ...................... 32 
Table 3: Description of the cryopreservation media used for different types of cells [279]. 10% DMSO 
was used for all cell types to reduce the amount of crystallization during the freezing process. 
Hydroxyethyl starch served as the cryoprotective supplemental protecting the cell surface [280].
 ...................................................................................................................................................... 36 
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1  Introduction 
1.1 Multipotent Mesenchymal Stromal Cells (MSCs) 
Friedenstein et al. described multipotent stromal or mesenchymal stem cells for the first 
time in 1968 [1]. These are non-haematopoietic, multipotent cells that were isolated from 
the bone marrow and could easily be cultured due to their plastic adherence. Friedenstein 
et al. could show that these cells support the haematopoiesis and are able to differentiate 
into osteogenic cells [2]. 
More than 45 years of research on MSCs have been performed since discovery. In spite of 
all efforts, the clear identity and all in vivo functions are still unclear [3]. The “International 
Society of Cell Therapy” (ISCT) defined the nomenclature and essential properties of MSCs 
to harmonize controversies and to get a uniform understanding. The three criteria: plastic 
adherence, differentiation potential and defined surface proteins gave an important but 
minimalistic basis [4, 5]. The heterogeneity of the population [6], the pro- or anti-
inflammatory switching phenotype [7, 8] and the numerous tissues from which so-called 
MSCs were derived [9] are still questionable and cannot be answered by the ISCT criteria 
alone. Also regulatory authorities understand the inconsistencies of MSC-based medicinal 
products as an important question [10]. Unlike HSCs, the MSC role in the bone marrow 
stem cell niche is still under investigation and it seems that they are strong supporters of the 
HSC niche [11]. The proof of a highly primitive stem cell character – as it is shown for 
HSC´s bone marrow re-population in irradiated mice [12-14] – could not be performed yet 
since defining accurate assays is complex although transplantation of so called “heterotopic 
ossicles” could be performed [15]. 
Despite the biological questions in the field of MSCs, the enormous therapeutic potency of 
these cells becomes obvious when treating Graft-versus-host disease (GvHD) [16] or 
osteogenesis imperfecta [17]. In 2012, Prochymal® was the first approved MSC-based drug 
showing a benefit treating pediatric patients suffering from advanced GvHD [18, 19]. Many 
successful applications and treatments of inflammatory diseases like Crohn´s [20], joint 
diseases [21] or other autoimmune diseases [22] underlined the immunomodulatory and 
regenerative capability of MSCs. Moreover, the constant increase of clinical trials, which are 
listed on www.clinicaltrials.gov with the term “mesenchymal stem cell”, is raising hope to 
patient’s needs.  
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Even if many therapeutic applications are promising, it is a path of trial and tribulation [23-
25]. Many cornerstones are still unknown and clinical setbacks have to be overcome. The 
hallmark of MSCs, a real stem cell defining set of surface proteins and the control of their 
variable properties are still milestones in this field [26]. 
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1.2 The Identity of MSCs and Their Heterogeneity 
First, these cells were called non-hematopoietic, “osteogenic cells” and later on the term 
“stromal stem cells” was established [2, 27]. Arnold Caplan broadened the concept to 
“mesenchymal stem cells” [28]. Because of many controversies and a little accordance in 
the nomenclature, the ISCT suggested “multipotent mesenchymal stromal cells” in 2005, 
excluding the word “stem” since the real stem cell character could not be shown yet [4]. 
One year later, the ISCT also demanded a by now generally accepted, valid set of 
requirements, which ex vivo expanded MSCs have to fulfill. Firstly, the cells must adhere to 
plastic. A simple seeding of the bone marrow or other tissue shows colony forming units 
(CFUs). Secondly, defined media with stimulating cytokines and drugs can induce a 
differentiation into adipocytes, osteocytes and chondrocytes [5, 29]. After a defined 
incubation time with an e.g. adipocyte stimulation media, fat vacuoles are observed in the 
cells and are easily stained with lipophilic dyes. Even if these assays show the multipotency 
of MSCs, there is still criticism regarding functional proofs of the differentiated cells [30]. 
The most valuable and last assay of the ISCT proposal is the verification of certain surface 
proteins discriminating MSCs from hematopoietic cells. While CD90 (Thy-1), CD73 (ecto 5` 
nucleotidase) and CD105 (endoglin) are typical positive marker, other proteins like CD45 
(pan-leukocyte marker), CD34 (primitive hematopoietic progenitor), CD14 and CD11β 
(monocytes and macrophages) CD79α and CD19 (B-lymphocyte marker) must not be 
identified in vitro. Appropriate flow cytometry can easily recognize an MSC population by 
suitable antibody staining [5].  
Following the fundamental requirements of a medicinal product from a pharmaceutical point 
of view, the active substance must be described by identity, purity and content. The minimal 
criteria are helpful to describe MSCs, but recent publications show that these are not 
sufficient because the pharmacological activity of MSCs is highly variable and does not 
mandatorily correlate to known markers [31-33]. Therefore, the hidebound check for the 
previously defined surface proteins to determine e.g. the purity of the active substance may 
raise false-positive results, as these markers may not present the desired phenotype [34]. 
The preparation of MSCs by adherent culture is a source of heterogeneity since the donor, 
the chosen tissue, purification steps, culture media, cytokines, passaging and expansion 
time have great impact on the phenotype of the cells without losing the ISCT prerequisites 
[6, 35]. Therefore, accurate potency assays for the intended indication characterizing the 
wanted properties rightly are heavily needed [36, 37] since describing the identity is 
obviously a tough task.  
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MSCs react on IFN stimulation by expressing immunomodulatory cytokines and presenting 
MHC-II on their surface. Additionally, MSCs are able to switch from their mostly observed 
anti-inflammatory to a pro-inflammatory phenotype expressing different interferons (IFNs) 
[31, 38, 39]. This can be induced by an anti-inflammatory milieu [39, 40]. Nonetheless, 
transient markers which correlate with the actual phenotype are lacking and hence the 
phenotype of MSCs has to be described mostly by functional assays e.g. a T-cell 
proliferation assay [41]. This ex vivo change of the phenotype is described in 1.3. 
Apart from the phenotype, the heterogeneity of the isolated, adherent cells [42, 43] requires 
a unique stem cell marker which may identify the “true” stem cell sub-population. Great 
efforts are made screening for the most potent subset of cells. SSEA-3 (stage-specific 
embryonic antigen-3) [44] and CD146 (cell surface glycoprotein MUC18) [45] are auspicious 
markers that were found on MSCs sub-populations [46]. Especially CD146 showed a good 
CFU-F enrichment after sorting [42]. Other markers like CD349 (frizzled-9) [47], GD2 (a 
neural ganglioside) [48] or CD49f (a6-integrin) [49] correlate with better CFU-F enrichment 
or a more effective differentiation. But all these markers are also presented on other cell 
types too and are therefore helpful, but not unique. Additionally, the subset of positive 
markers differs from tissue to tissue from which MSCs are derived [46]. 
Unless a sole marker correlating to a stem cell-like sub-population was identified by 
accurate functional assays, it makes sense to follow the ISCT recommendations and to call 
the adherent cells “multipotent mesenchymal stromal cells” and to exclude the term “stem”. 
MSC is hence a concept, which describes the whole population of all adherent cells from an 
isolation fulfilling the minimal ISCT criteria [4, 5]. 
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1.3 MSCs Change their in vivo Phenotype by ex vivo Manipulation 
The in vivo phenotype of MSCs is still not fully understood [3]. Often, these cells are directly 
linked to pericytes [50, 51] or fibroblasts [34, 52, 53] since they share many similarities. 
Especially pericytes are in the focus because they are able to beneficially stimulate their 
tissue site with a panel of cytokines. There is increasing evidence that MSCs remain also in 
a perivascular niche [50] and are activated if the tissue site is injured [54]. Studies in animal 
models underline the vascular thesis since the CFU-F of MSCs and the blood vascular 
density seem to correlate [55]. 
MSCs are highly affected by ex vivo expansion [35]. On one hand, it is difficult to 
understand how the used protocols impact the MSCs and leads to unwelcomed stimulation. 
On the other hand, MSCs may be understood as a platform, ready to be conditioned for 
treating a chosen indication. Several studies investigated the impact of elemental culture 
manipulations: hypoxic conditions, addition of pro- or anti-inflammatory cytokines and the 
mechanical interaction with 2D- or 3D-layer. These culture conditions led to different profiles 
and amounts of secreted cytokines, reviewed by Madrigal et al. [32]. 
MSCs cultured under hypoxia express several growth factors like vascular endothelial 
growth factor (VEGF), fibroblast growth factor 2 (FGF-2), hepatocyte growth factor (HGF) 
and insuline like growth factor 1 (IGF-1) in dependence of NF-kappa β. These growth 
factors support angiogenesis, anti-apoptosis and may maintain the stem cell character of 
MSCs [56-58] as well as the immunomodulatory capacities mediated by increased 
expression of indolamine 2,3 deoxygenase (IDO) [59]. This modulated phenotype is also in 
vivo significant and may lead to better neuronal regeneration after brain injury [60] or 
reduces the effects of diabetic cardiomyopathy [61]. In general, hypoxic condition is a potent 
manipulation to enhance regenerative effects of MSCs [60]. 
It is well described that human, but also canine and murine MSCs are HLA-DR positive [62] 
and show MHC-II on their surface and an increase of IDO expression if stimulated with IFNγ 
and TNFα [63-65]. These cytokines are potent inducers to generate an anti-inflammatory 
phenotype [31], which can be proofed by the T-cell proliferation assay [41]. IDO, as well as 
prostaglandine-2 (PGE-2), transforming growth factor β (TGF-β) and galectin-9 (Gal-9) are 
prominent anti-inflammatory markers [66-68] and are essential for the anti-inflammatory 
potency.  
GvHD is a life-threatening disease and is often successfully treated with MSCs. These 
treatments are well studied [16, 18, 19, 69, 70]. Increasing the potency on these indications 
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with pre-stimulation may promise better efficacy [71] in these critical, inflammatory 
indications. 
Beside the chemical-biological milieu, the mechanistic interaction of MSCs with their 
environment may have great impact, too. 3D-culture systems mimic the stem cell niche 
more than standard 2D monolayers do. These spheroid cultures stimulate the secretion of 
trophic factors. For example, TNF-stimulated gene 6 protein (TSG-6), an anti-inflammatory 
protein, is only expressed in 3D culture flasks, which may vary the treatment outcome [72]. 
Although, the diversity of culture systems will differently impact the cells properties, 
spheroids in general seems to promote an anti-inflammatory phenotype [73, 74]. 
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1.4 A Drug-Delivery System: Pharmacokinetics of MSCs 
The pharmaceutical industry regularly designs new drugs following the “Rule of Five” to 
enhance a good systemic absorption after oral intake [75]. These drug properties are 
investigated in extensive studies on absorption, distribution, metabolism and elimination 
(ADME) [76]. New to this field, biopharmaceutical products gain also center stage in ADME 
evaluations [77].  
The pharmacokinetics of small molecule drugs is passive, controlled by the biology of the 
body and its biochemical processes. This fact challenges the pharmaceutical industry for 
appropriate design of small molecules because little alterations on the chemical compound 
may have great impact on the drugs pharmacological profile [75, 78]. Beside vaccines, 
antibodies are the first generation of biologicals, which found their way into clinical 
pharmacy. Therapeutic antibodies show a great field of usage in cancer therapy as drug 
delivery systems e.g. Adcetris® or as agents acting directly against the tumor e.g. Erbitux®. 
Nevertheless, antibodies follow the rules of passive diffusion gradients as well as small 
molecules and only increase their therapeutic efficacy by their high specificity to target 
structures. In contrast to these classical medicinal product groups, many research groups 
promise a new class of pharmacokinetics for cells, especially for MSCs: directed targeting 
respectively the so-called homing.  
Successful clinical results treating osteogenesis imperfecta showed the therapeutic potency 
of the bone marrow and its cells in the early 2000s [17, 79]. Good clinical response of 
MSCs-treated children indicated an engraftment of the donor cells into the patients’ bone 
after intravenous administration. This basic proof of concept – the feasibility of treatment 
with MSCs by intravascular application– facilitated many new clinical approaches and 
applications for other indications suitable for MSC treatment e.g. GvHD [80], cancer (MSCs 
as drug-delivery system) [81-83] or regenerative indications [84]. Systemic transplantation 
of MSCs seemed to be performed quite easily. Since then, many in vivo studies have been 
performed to examine the pharmacokinetics of MSCs, summarized in several reviews [85-
88].  
Beside the therapeutic success, the method of detection is a major hurdle to track MSCs in 
vivo and to define the biodistribution of MSCs. Approaches range from labeling with 
radioactive systems, fluorescent vital dyes, contrast agents, reporter genes or cell-specific 
DNA markers (microsatellites) [89-93]. Some of the detection systems can only be used for 
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short time-intervals or do not distinguish between living and dead cells. This makes the 
evaluation of the generated data difficult.  
In spite of the tracking method challenges, it is well understood that intravenous 
administered MSCs mainly residue in the lungs´ vascular system for the first hours after 
administration [72, 94, 95]. It is still a matter of debate whether the cells´ size or surface 
proteins regulate this interaction. The average diameter of MSCs is about 16-53 µm 
dependent on tissue origin, culture conditions, passage and several other factors [96].  
HSCs are about 4 - 12 µm large. Therefore, obstructive processes in the pulmonary 
capillaries (<10 µm diameter [97]) are probable. Preclinical studies proofed a pulmonary 
first-pass effect after systemic infusion in small and large animal models [72, 92, 98, 99]. 
This effect might be reduced if a vasodilation is performed by administration of nitroprusside 
[100] underlining the importance of the cells´ size and the steric interaction. 
In spite of these steric issues, it is evident that surface molecules of MSCs also interact with 
endothelial cells. Although CXCR4, a prominent homing receptor, is absent on culture-
expanded MSCs [101, 102] (and is only broadly present after induction [103]), adhesion 
molecules like vascular cell adhesion molecule (VCAM-1) are involved in endothelial 
interaction [101]. VCAM-1 and the surface protein very late antigen-4 (VLA-4) are immanent 
for the firm adhesion of MSCs to the endothelium [104]. Studies on different enzyme 
treatment during harvesting show the important role of the adhesion markers. Different 
enzymes used for detachment alter the lung clearance significantly [105]. This was also 
underlined by results indicating a correlation between the whole surface profile and its 
markers and lung clearance [106]. In contrast to intravenous administration, intra-arterial 
applications avoid the first-pass effect in the lungs and show an increased uptake in 
inflammatory sites [107] and therapeutic efficacy [108, 109]. But, intra-arterial infusions are 
more complex to be handled in a clinical setting. 
After the first hours to days in the lungs vascular system, MSCs relocate throughout the 
body. Here, inflamed tissues seem to attract the - mostly immunosuppressive - cells [89, 
110]. Tumors and their immunological microenvironment are highly complex and seem to 
be an attractive target for MSCs [111-114]. The physiological role of stromal cells as e.g. 
tumor-associated fibroblasts is still unclear although there is evidence that MSC can inhibit 
or contribute to growth of solid tumors dependent on the preclinical setting. It is obvious that 
MSCs play a role in the tumor microenvironment. Niess et al. evaluated these contradictory 
reports in a review [115]. This involvement of MSCs in the tumor stroma led to therapeutic 
approaches bringing a suicide gene next to the tumor cells. Several authors examined this 
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MSC based drug-delivery system [116-118]. The efficiency of homing (and the efficacy of 
the therapeutic suicide gene) is still challenging this therapeutic approach. 
Preclinical models with myocardial infarction allow a good insight into the MSC homing. 
Here, MSCs have been observed to accumulate at ischemic sites [119, 120]. Interestingly, 
transgenic mice expressing CCR2 in cardiac muscle cells have a significant higher 
recruiting rate of MSCs [121]. But, it is still unclear if MSCs are temporarily or constantly 
incorporated into the cardiac tissue. 
More cues than evidences have been shown for kidney diseases. Although the therapeutic 
usability of MSCs in kidney indications was proofed, the mechanisms beyond that are not 
yet understood [122]. The fact that also MSC derived microvesicles showed therapeutic 
effects in an acute kidney injury mouse model [123] as well as MSCs themselves [124, 125] 
queries direct correlations between pharmacodynamics and pharmacokinetics and therefore 
the homing of MSCs into the site. 
Gholamrezanezhad et al. provided evidence of the biodistribution in humans by 
measurement of radioactive 111In-oxine labeled MSCs [110]. Here, the cells passaged the 
lung successfully. Hours to days later, the MSCs migrated into the liver of patients with liver 
cirrhosis. Cells could also be detected in the spleen. Intriguingly, a recruitment of cells into 
the injured liver of mice could not be shown [126] underlining the difficulty of translational 
studies. 
The work of Horwitz and colleagues [17, 79] indicated a successful engraftment of MSCs 
into the bone marrow of children with osteogenesis imperfect as referenced before (see 
1.1). In contrast to these data, it is evident that donor MSCs do not generally engraft in 
allogeneic hosts [127-129]. Especially long-time culture can reduce the homing capacities of 
MSCs dramatically [130]. 
Besides the fact that MSCs show an accumulation at inflamed sites, the ratio of homing 
MSCs vs. infused MSCs is still hard to determine. The methodological limits often reduce 
the meaningfulness of quantitative assessments. Descriptive data are mostly relative to the 
accordant methodological controls only allowing vague statements. Systemically infused 
MSCs show both migration to the pathological site [110, 121, 131] and distribution 
throughout other organs [89, 93, 132]. Absolute cell numbers are seldom stated in 
publications. 
The possibility of using cryopreserved MSCs for clinical trials is very popular since planning 
and therefore costs may be reduced. At any given moment, the medicinal product may be 
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freshly thawed just before administration. But, cryopreservation also alters the physiological 
activity and cellular structure and therefore the biodistribution. Galipeau et al. published 
disillusioning results of cryopreserved MSCs in contrast to living MSCs regarding desired 
pharmacokinetics [133] and good pharmacodynamics [134, 135] suggesting to use cultured 
MSCs for immunosuppressive indications. Several working groups got aware of this 
challenge and tried to optimize their cryopreservation and thawing protocols to improve cell 
viability and function for their MSC based products [136-138]. The pro of cryopreservation to 
save costs and the con of reduced migration capabilities and therefore therapeutic efficacy 
of MSCs should be carefully weighed and possibly answered by appropriate dosing.  
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1.5 Therapeutic Gene Modification of Stem Cells and Usage of 
Inducible Promoters 
In general, gene modification can be separated into an in vivo and an ex vivo approach. The 
in vivo way is the direct administration of gene modifying particles into the body. Ex vivo 
approaches include a cultivation step of the target cells outside the body. During this phase, 
the gene modification of the cells is performed before they will be given back to the patient. 
In contrast to germ cells (e.g. sperms, eggs), stem cells (e.g. HSC, MSC) are also a 
possible target of gene therapy from a regulatory point of view.  
Both approaches, in vivo and ex vivo have proven their usability treating difficult diseases 
despite setbacks in the past. Trials like the CUPID study (Calcium Up-Regulation by 
Percutaneous Administration of Gene Therapy in Cardiac Disease) showed a safe 
application of adeno-associated virus carrying a therapeutic gene for heart failure in a 
phase 2b clinical trial [139, 140]. Ex vivo approaches did surely dominate the treatment of 
monogenic diseases. Severe diseases like the severe combined immunodeficiency (SCID) 
[141] or Wiskott-Aldrich syndrome [142] were successfully treated in the past and become 
to be first line therapy [143]. The increasing number of gene therapy clinical trials is 
impressive: before 2000, overall 484 studies were initiated. Since beginning of 2000, 1729 
studies were recorded with more than 60% treating cancer. The second largest group build 
up the monogenic diseases (10%) followed by cardiovascular and infectious diseases (each 
7%) [144].  
Although adenoviral vectors or naked DNA are often used as delivery system, they are not 
integrating into the DNA and therefore do not show a stable expression. For stable 
expression, integrating vector systems e.g. gamma-retroviral or lentiviral vectors are 
prevalent. Lentiviral vectors integrate more safely into dividing and non-dividing cells but are 
more complex to manufacture than gamma-retroviral vectors and are therefore more 
expensive for clinical usage [144]. In addition, gamma-retroviral vectors have the tendency 
to integrate into transcriptional start sites in contrast to lentiviral vector, which obviously 
choose safer sites [145] [146]. This implies a potential higher risk for insertional 
mutagenesis for gamma-retroviral delivery systems. Especially, if high vector copy number 
in the target population is achieved, the possibility of a clonogenic outgrowth raises. A small 
vector copy numbers leads to high insertions rates in a very small fraction of a transduced 
population. [147, 148] [149]. But, risk mitigation by controlled transduction conditions and an 
appropriate vector system is realizable. Known titers of vector supernatant and a defined 
cell count allow constant transduction processing. Also, the development of better vectors 
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e.g. self-inactivating vectors (SIN) that have weaker enhancers (LTR regions) [150, 151] or 
targeted gene editing system e.g. nucleases like ZFN or TALENs [152] can increase the 
safety and reduce the risk of Insertional mutagenesis. The therapeutic approach itself can 
also lead to a higher safety profile e.g. suicide gene therapy systems. Cells with transgene 
integration after exposure to a viral vector will be killed due to the suicide gene system 
[153]. Here, sponsors of these kinds of studies potentially have more safety arguments that 
may answer regulatory demands better.  
Promoters used for gene therapy are mainly divided into two groups: constitutive and 
inducible promoters. Constitutive promoters allow a constant expression independent of the 
cells status. They often derive from eukaryotic cells (e.g. elongation factor-1 (EFS), 
eukaryotic translation elongation factor 1 alpha 1 (EF1alpha) or phosphoglycerate kinase 1 
(PGK)) or can be isolated from viruses (e.g. cytomegalovirus (CMV) or simian vacuolating 
virus 40 (SV40)). Viral derived promoters often show very high expression rate in the 
beginning but become quickly silenced in eukaryotic cells due to inherent mechanisms 
against infections. In contrast, EFS, EF1alpha or PGK do not show the same level of 
expression but are less silenced and therefor allow a more stable expression over time 
[154, 155].  
Inducible promoters either increase expression if certain cytokines are present (e.g. 
RANTES (regulated upon activation, normal T-cell expressed and secreted) promoter) [156] 
or are activated if the cell differentiates e.g. Tie2-expressing monocytes [157]. In contrast to 
other systems like “Tet-On” promoter, which react very tightly on the presence of 
tetracycline [158, 159], the RANTES promoter reacts on different pro-inflammatory signals 
[156, 160]. 
The advantage of inducible promoter is the selective activation of the therapeutic gene in a 
defined environment or in a defined status of the cell. Especially pharmacological highly 
active agents that typically show large side effects can be introduced reasonably by cell-
based delivery systems. A controlled, tissue-specific expression of the active protein or an 
enzyme, which regulates the translation of a prodrug, can reduce adverse effects [161]. 
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1.6 The Suicide Gene “Herpes Simplex Virus Thymidine Kinase” 
and Apoptosis of Cells 
GCV (Cymeven®) is authorized as standard treatment of cytomegalovirus infections and 
therefore widely used. GCV acts as a competitive inhibitor of deoxyguanosine triphosphate 
inhibiting viral DNA synthesis after intracellular activation and leading to cell death if 
incorporated into the genome DNA [162-165]. Besides that, the HSV-TK / GCV system has 
been established as a suicide gene therapy approach in clinical trials. After insertion of 
HSV-TK into the target cells by retro- or adenoviral vectors, GCV is administered 
intravenously days later. HSV-TK expressing cells translate GCV into its toxic counterpart 
and induce cell death by DNA damage [166-169]. Tested in vitro and in vivo, many 
therapeutic approaches aimed to treat difficult diseases e.g. glioblastoma [170, 171]. 
Although the safety and the proof of concept of direct viral transfection of the pathological 
tissue could be shown, the results were not as satisfactory as desired. This raised the idea 
of cell-based drug delivery systems e.g. MSCs [172, 173] to increase the efficacy at the 
desired site. Gap junctions between migrated MSCs and the target cell mediate the transfer 
of activated cytostatic agents (“bystander effect”) like phosphorylated GCV [174-176] and 
initiate the apoptotic cascade in MSCs and tumor cells [177-180]. The amount of 
intercellular connections is critical for the desired therapeutic effect [181]. The execution of 
apoptosis itself is led by mitochondrial perturbation [182] after previous rise of p53 and can 
be inhibited by accordant resistance mechanisms of the tumor cells [183, 184]. Additional 
apoptosis inducing signals strongly enhance the initiation of the cell death e.g. TNF or 
TRAIL [185]. 
During apoptosis, the cell passes through different membrane alterations and morphological 
changes. These changes can be accordantly identified and quantified by flow cytometry 
[186-189]. Especially, the differentiation between necrotic and apoptotic cells can be made 
by single cell measurement. Staining of Phosphatidylserine (PS) can be measured as direct 
indicator for the stage of apoptosis. PS is normally arranged asymmetrically on the bilayer 
membrane by ATP-dependent flippases and orientated to the inner site. During apoptosis, a 
mega-channel opening of the mitochondrion leads to an irreversible loss of the cells vital 
function: the production of ATP. This “point of no return” represents the commitment of 
apoptosis of the cell [190-192]. Also the activity of the ATP-dependent flippases stops, 
allowing PS to turn to the outer site of the bilayer. If exposed on the surface, it serves as 
“eat-me” signal of apoptotic cells for phagocytic cells [193-195] (PS has also other function 
e.g. regulating the blood coagulation on thrombocytes [196]). 
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These PS lipids on the membrane surface can be stained with Annexin-V conjugates in 
dependency of calcium and easily measured by flow cytometry [197, 198]. In later stages of 
apoptosis, the cells membrane also becomes permeable for DNA dyes like 7-AAD. This 
combination allows the differentiation between earlier and later stages of apoptosis in a cell 
population and differentiate necrotic from apoptotic cells [199, 200]. 
In spite of the surface changes, apoptosis induces a cytoplasmic volume condensation. This 
shrinkage is due to volume-regulatory chloride and potassium channels, which have altered 
activities during apoptosis resulting in more granular and smaller cells. At the end, the 
apoptotic process leads to the death and a total integrity loss sets all remaining, intracellular 
structure free [201-203]. 
  
Introduction 
 
 
 
 15 
1.7 The Pig and its Role as Large Animal Model (LAM) for 
Preclinical Studies 
Regulatory Authorities demand toxicological studies in non-rodent mammals before entering 
clinical trials [204]. Ethical aspects regarding preclinical studies with non-rodent mammals 
e.g. the pig are therefore first to address before these trials may be performed [205]. Any 
concerns should be discussed seriously. A thorough literature research should be done to 
evaluate the most compliant animal model with the best chances to generate valid data. 
Then, a risk-benefit analysis for the planned studies should be the basis for any preclinical 
testing. In sum, the design of preclinical studies should follow the 3R-principle by Russell 
and Burch described in 1959: “replacement, reduction and refinement” as it was laid down 
in European law [206].  
Compared with other large animal models like horses or non-human primates, pigs have a 
little reproduction time and grow very fast in their first year after birth. Already after six 
months, they are sexually matured and a new generation of pigs is available after four 
months of pregnancy. In the field of gene and cell therapy, a lot of working groups prefer the 
pig, particularly the mini-pig, since it shows physiological and anatomical comparability with 
humans [207-211]. Regulatory authorities demand toxicological data for medicinal products 
before clinical trials may be initiated. Regarding large animal models, the pig with his high 
comparability makes it to a well-reputed animal for toxicological testing [212-214]. 
Also surgical interventions were often tried for the first time in the swine to develop new 
therapy options. Still, medical training is frequently performed on pigs. The close 
physiological relation is also found in the field of medicinal products: porcine insulin was 
used regularly for diabetes patients (e.g. Insulin Hypurin Porcine®) and cardiac valves from 
the pig are still an option as biological alternative to synthetic imitations [215]. 
In spite of surgical indications, the research in the swine and its biology made significant 
advances over the last decades: the whole genome of pigs is known [144], induced 
pluripotent stem cells are available [216-218], transgenic animals have been developed and 
somatic cell cloning to replicate identical animals is possible [219-221]. As all animal 
models, every species has its own model history for its typical field of diseases. Pigs are 
often related to cardiovascular or metabolic diseases and many trials have been performed 
to treat e.g. ischaemic diseases of the heart on a cell-based approach [222]. Furthermore, 
the spectrum of genetically modified pig models for human diseases becomes constantly 
wider [223, 224] e.g.: models for skin inflammatory diseases [225], diabetes [226], severe 
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combined immunodeficiency (SCID) [227], cystic fibrosis [228] and further indications like 
alzheimer´s disease, retinitis pigmentosa or spinal muscular atrophy are available as listed 
by Prather et al. [229]. Altogether, the pig is an attractive model for preclinical studies [211, 
213, 214] although the cost per animal is obviously significant higher than e.g. per mouse. 
In contrast to rodents, the reproduction time of several months makes strategic planning 
more difficult since the flexibility to design preclinical studies and the time needed to 
generate new data is longer. 
At the end, it should be mentioned that the public sees less ethical concerns on preclinical 
testing with pigs than with e.g. non-human primates or dogs.  
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1.8 Modelling human MSCs: Porcine MSCs (in contrast to rodent 
MSCs) 
The immunological barrier of a healthy animal is a major hurdle for preclinical testing of 
ATMPs. If the human cell therapy product is administered into animals, immunological 
reactions may vary preclinical results in an undesired manner. Homologous MSCs offers an 
alternative, avoiding any immunological effects. Still, poor cell characterization of the animal 
species may lead to false results since they could show other pharmacokinetics and -
dynamics than expected as for their human counterpart. It is hard to define accurate models 
and homologous products [230].  
The good characterization of the animals’ cells is a major key to perform relevant preclinical 
studies and to overweigh potential arguments that these cells are not the “original” cells. 
Moreover, the characterization and applicability of animal MSCs must be shown sufficiently 
to convince the regulatory authorities approving the initiation of clinical trials [212, 230]. 
These circumstances are often complicated by poor literature for homologous cell products 
since publication mostly concentrate on preclinical experiments and not on the cells 
characterization. Nevertheless, several working groups did characterization work for porcine 
MSCs as follows. 
Like human MSCs, porcine MSC were already isolated from different tissues e.g. bone-
marrow [231-234], umbilical cord blood [235, 236], endometrium [237], skin [238-240] or 
adipose tissue [241, 242]. Comparison analyses between theses origins regarding 
proliferation, differentiation, functional properties or molecule markers showed significant 
differences and potential influence on preclinical study outcomes might be relevant [243-
245] – as it is for human MSCs [46, 246-248]. In pigs, the adipose tissue offers easy 
isolation practices since they naturally gain weight easily [249]. The identification of porcine 
MSCs is equivalent to human MSCs following the ISCT criteria for different markers e.g. 
CD70+, CD90+, CD105+, CD45- [5]. The scarce availability of commercial, porcine specific 
antibodies unfortunately limits the characterization of surface markers to smaller panels. 
Beside the plastic adherence, the trilineage differentiation of porcine MSCs is essential for 
defining MSCs. This could be also shown well for porcine MSCs [235, 240, 243, 250, 251]. 
But, the differentiation potential is highly affected by the used protocol and tissue origin, 
which makes comparison hard between different working groups regarding differentiation 
efficacy [251], also summarized by Barthi et al. [252]. 
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In preclinical studies, the pig is well known for its suitability in cardiovascular disease 
modelling. Mostly pigs and their cells generated great value in cell-based therapy 
approaches for ischaemic infarcts, extensively reviewed by van der Spoel et al. [222]. 
Although dog and sheep participated in this development, studies with pigs constitute the 
majority. Porcine MSCs proofed their preclinical value also in other indications with 
therapeutic need such as liver failure [249, 253], skin regeneration [254, 255] or 
osteochondral defects [255, 256]. Also, pharmacokinetics studies in the pig showed great 
significance [99]. 
Even though there are good evidences for high comparability of other mammals, 
inconsistencies between the results of clinical trials and preclinical studies with MSCs 
occurred [257]. Comparison studies on the immunomodulatory properties of MSCs from 
different species showed varieties, e.g.: IDO synthesis in human und monkey MSCs 
increases if they are stimulated with pro-inflammatory cytokines. Mice MSCs mainly react 
with an increased expression of inducible nitric oxide synthase (iNOS) to mediate an anti-
inflammatory effect [258]. IDO and prostaglandin E2 play a major role for the 
immunosuppressive properties of human MSCs [259]. Connected to that, it could be shown 
that antibacterial properties of human MSCs, which are mediated by an increase of IDO, are 
not present in murine MSCs [260]. Furthermore, there are evidences that murine MSCs 
have other intracellular pathways to react on cytokine stimulation [63]. 
Rodent MSCs also differ in the expression of surface proteins like CD90 and CD73 in 
dependency of passage and tissue [261]. This observation was also made for human MSCs 
from different origin. Although all markers suggested by the ISCT were present, the 
expression rate differed significantly [262]. Interestingly, the presence or absence of CD105 
directly correlates with functional properties of this sub-population in murine MSCs [263].  
Beside functional properties and presence/absence of surface markers, murine MSCs show 
spontaneous transformation into malignant cells. This expansion phase can endure several 
weeks. Transformations were already observed during cultivation passage three or four 
[264-267]. Subsequent in vivo experiments showed the malignant potential of these murine 
cells [268]. Chromosomal stability of MSC culture is essential to meet the specifications and 
cell dosages as defined in clinical protocols of more than 0.5x106°cells/kg bodyweight [69, 
81]. It is probable that this critically affects preclinical studies and their value for clinical 
trials.  
Spontaneous transformation of human MSCs is still in an open discussion although there 
are several cues indicating no spontaneous transformation of human MSCs. There are data 
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negating malignancy [269] and showing a cultivation until senescence of human MSCs 
[270]. Working groups describing an occurrence of high proliferating, spheroid-forming cells 
[271, 272] had to contradict themselves since this cell line was a contaminant during long 
time culture in the laboratory [273, 274]. Until now, no reports are available describing 
results of long-time cultivated porcine MSCs regarding possible transformation.  
It is quite obvious that porcine MSCs show high potential to be a feasible cell model system 
in contrast to murine MSCs. Availability of transgenic and disease-modelling pigs as well as 
the high comparability of the pigs´ physiology to humans underlines this usability for 
modelling cell-based therapeutics. 
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2 Aim of This Work 
Mesenchymal Stem Cells are the basis for a new class of cell therapy products and offer 
novel opportunities to treat difficult diseases. These MSC-based drugs are regulatory called 
“Advanced Therapy Medicinal Products” (ATMPs) and have to be tested in preclinical 
studies before they may enter clinical trials. These studies have to give proof of a safe and 
efficient drug product in vitro and in vivo. Especially, safety should also be shown in large 
animal models [204]. 
Testing the clinical human-based product in animals may lead to undesired immunological 
reactions, which are not representing the clinical setting correctly. The option of immune-
compromised or -deficient rodents may mitigate these reactions, but significantly changes 
the model system and interactions between the immune system and the cell-based 
therapeutic. Testing the animal-based cell product of a chosen species in the species itself 
requires sufficiently characterized cells because they possibly do not correctly represent the 
“human” product [275]. In addition, the costs and the dependency of human bone marrow 
donors complicate the preclinical testing program. 
The miniature pig is known to be highly comparable to humans in regard to anatomy and 
physiology – especially in contrast to other small or large mammalians. It is therefore a very 
attractive model for preclinical drug testing. Although the usefulness is highly indicated, no 
systematic characterization to proof the suitability of this cell model platform for an MSC-
based suicide gene therapeutic was done before.  
The aim of this work was to show that porcine MSCs represent a good model system for the 
characterization and manufacturing of a cell therapy product. Here, the HSV-TK system is 
described for the first time in porcine MSCs in parallel with the product for a clinical trial [81]. 
This question of comparability was evaluated in three in vitro and one in vivo part discussing 
the model product only: 
1. Characterization of adherent cells as MSCs 
2. Controlled insertion of therapeutic suicide gene and proof of functionality 
3. Characterization of the therapeutic effect 
4. Experimental in vivo investigation on pharmacokinetics 
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3 Summary 
Model cells in syngeneic animals are a potential alternative in the field of preclinical 
development of ATMPs (Advanced Therapy Medicinal Products) because they do not 
trigger any immune response. But these model cells have to mimic the human derived 
counterpart sufficiently. To assure this, a previous characterization of the model cells is 
required to allow a translation of these results into clinical trials.  
In the present work, porcine MSCs (Mesenchymal Stromal Cells) expressing HSV-TK 
(Herpes Simplex Virus Thymidine Kinase) are described and compared to human MSCs, 
which are engineered for a human cell therapy product [81]. It was the aim of this work to 
show that the porcine HSV-TK MSCs cells are comparable and therefore useful for 
preclinical development of an equivalent human cell-based therapeutic. This goal was 
systematically pursued comparing the human MSCs with the pig-derived model MSCs 
during production and testing of the generated batches. The suicide gene therapy concept 
was also investigated and subsequently characterized in vitro comparing both species. 
Consecutive in vivo studies in the mini-pig were performed in an experimental approach 
with porcine MSCs. 
It could be shown that porcine MSCs share nearly all properties with human MSCs 
regarding identity as they match the specifications of the International Society for Cellular 
Therapy. The plastic adherence and the fibroblast-like morphology could be clearly shown. 
The general presence of CD90 and CD105 and the absence of CD45 were similar with 
human MSCs. A sub-population of CD105 negative porcine MSCs was observed that was 
not described for human MSC but for murine MSCs before. HLA-DR (Human Leukocyte 
Antigen – antigen D Related) expression could not be shown whether the cells were 
induced with cytokines or not. The differentiation into adipogenic and osteogenic cells was 
successful using commercial available differentiation media that were compiled for human 
MSCs. A similar population doubling time could be shown, too, although the human derived 
batches highly varied. The examined MSCs of human and porcine origin showed many 
similarities although slight differences in the surface marker were observed, as it is also 
known for other animal-derived MSCs. 
The successful transduction with the same retroviral vector enabled the expression of the 
HSV-TK gene that was also used for human MSCs. The resulting vector-copy numbers 
were comparable after a successful selection. The inducible RANTES (Regulated upon 
Activation, Normal T cell Expressed and Secreted) promoter isolated from human cells was 
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inducible in both species and showed comparable up-regulations. It could be clearly shown 
that HSV-TK expressing cells are multiple fold higher sensitive to GCV (Ganciclovir) than 
naïve cells. Here, the porcine MSCs were even more sensitive. Resulting apoptosis due to 
activated GCV was comparable and could be well described by appropriate Annexin-V and 
7-AAD (7-Aminoactinomycin) staining. Cell count reduction occurred also in co-cultured cell 
lines that did not express HSV-TK. It could be proven throughout all species arrangements 
of HSV-TK expressing MSCs that the targeted cell lines undergo apoptosis. As control for 
these apoptosis experiments, naïve MSCs were used. Interestingly, in one setting also 
naïve human MSCs showed anti-proliferative effects on the porcine-derived cell line. 
The following experimental in vivo studies with mini-pigs confirmed the expectation that 
intravenously (i.v.) infused MSCs show extra-ordinary pharmacokinetics. Before the cells 
were systematically available, a delay could be observed. MSCs interact with the epithelium 
of the lungs vascular system before they enter the peripheral arterial bloodstream. This first-
pass effect of i.v. administered MSCs is well described in the literature. This phenomenon 
was not reproducible in a second animal. Here, a severe pneumonia was identified. The 
well-known migration of MSCs to pro-inflammatory tissues could have led to an enduring 
engraftment in the lung. Remaining MSCs in the bloodstream probably undercut the 
detection limit of the assay. 
Altogether, this work shows the usability of porcine MSCs as a model system for a clinical 
cell therapy product in vitro and also in vivo. It could be proven that porcine MSCs are 
modeling human MSCs beside minor differences.  
 
Abbreviations & Units 
 
 
 
 23 
4 Abbreviations & Units 
4.1 Abbreviations 
7-AAD  7-Aminoactinomycin D 
ADME  absorption, distribution, metabolism, elimination 
ANOVA  Analysis of Variance  
ATMP  advanced therapy medicinal product 
BALT Bronchus-associated lymphoid tissue 
Bio-1 Expansion Medium for CD34-Negative Stem Cells (Patent, 
US201101834141 A1) 
CCR2  C-C chemokine receptor type 2 
CD   Cluster of Diferentiation 
CFU   colony forming units 
CT   cycle threshold 
DMEM  Dulbecco's Modified Eagle Medium 
EC50   half maximal effective concentration 
ECD   phycoerythrin-Texas Red conjugate 
EDTA  ethylenediaminetetraacetic acid 
EFS   elongation factor short 
EMA   European Medicines Agency 
FBS   fetal bovine serum 
FFPE   formalin-fixed paraffin-embedded 
FGF-2  fibroblast growth factor 2 
FITC   fluorescein isothiocyanate 
FS   forward scatter 
(e)GFP  (enhanced) green fluorescent protein 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HT1080  human, fibrosarcoma cell line 
HSV-TK  herpes simplex virus thymidine kinase 
ICH   International Council for Harmonisation 
iNOS   inducible nitric oxide synthase 
ISCT   International Society of Cellular Therapy 
K67   Neo3-14/K67/1.1+cMyc; immortalized porcine cell line 
LAM   large animal model 
LTR   long terminal repeats 
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LSM   lymphocyte separation media 
MFI   mean fluorescence intensity 
MGH   Massachusetts General Hospital 
MHC   major histocompatibility complex 
MNC   mononuclear cells 
MOI   Multiplicity of Infection 
MSC   multipotent mesenchymal stromal cell 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NADH  nicotinamide adenine dinucleotide 
NADPH  nicotinamide adenine dinucleotide phosphate 
NEAA  Non-Essential Amino Acids 
PAC   puromycin N-acetyl-transferase 
PBS   phosphate-buffered saline 
PC7   phycoerythrin cyanine dye 7 
PCR   polymerase chain reaction 
hPGK  human phosphoglycerate kinase  
PE   phycoerythrin 
PI   propidiumiodide 
PLL   poly-L-lysine 
PS   phosphatidylserine 
RANTES  regulated upon activation, normal T-cell expressed and secreted 
real-time PCR real-time polymerase chain reaction 
SCG   Single Copy Gene 
SCID   severe combined immunodeficiency 
SS   side scatter 
STDV  standard deviation 
ST CTRL  staining control 
TD   transduced / transduction 
TC treated  Tissue Culture treated 
TRAIL  TNF-related apoptosis-inducing ligand 
TRIS   Tris(hydroxymethyl)-aminomethan 
qPCR  see real-time PCR 
VCAM-1  vascular cell adhesion molecule 1 
VCN   vector copy number (mean transgenes per cell) 
w/wo   with or without 
WPRE  Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element 
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4.2 Units 
°C   degrees Celsius 
%   percentage 
cm   centimeter 
cm2   square centimeter 
CT value  quantity of PCR doublings before detection of significant flourescence 
d   days 
h   hours 
L   liter 
mL   milliliter 
min   minutes 
M   molar 
µg   microgram 
µL   microliter 
µm   micrometer 
µM   micro molar 
nm   nano meter 
g   standard acceleration due to gravity 
sec   seconds 
 
Material 
 
 
 
 26 
5 Material 
5.1 Consumables / Liquids (Media, Solutions, Kits, Chemicals) 
Solutions, Media and Chemicals Manufacturer 
  
2-Propanol 99.9% Carl Roth 
10% Formalin, neutral buffered Sigma Aldrich 
10cm dishes, TC-treated Corning 
96-well flat clear bottom black polystyrene plates Greiner Bio One 
Alizarin Red S Sigma Aldrich 
BacT/ALERT SA, Standard Aerobic bioMérieux 
BacT/ALERT SN, Standard Anaerobic bioMérieux 
Blood & Tissue Kit Quiagen 
CellSTACK (1, 2 or 5 layer), TC-treated Corning 
CellTiter 96® Non-Radioactive Cell Proliferation Assay Promega 
Centrifugation Tubes / Falcons (1.5°mL, 2°mL, 15°mL, 50°mL) Eppendorf / Corning 
Culture Flasks (25°cm², 75°cm², 175°cm², 225°cm²), TC-treated Corning  
Culture well plates (6-, 12-, 24-, 48-, 96-wells), TC-treated Corning 
Cytofix/Cytoperm Fixation and Permeabilization Solution BD Biosciences 
Deionized Water Laboratory Water System 
Discovery DAB Map Detection Kit Roche Diagnostics 
DMEM Biochrom 
FACS buffer (1% FBS, 99% PBS) 
FBS 
see FBS and PBS 
Biochrom 
HEPES Buffer Solution [1M] Gibco 
Mayer’s Hematoxylin Sigma Aldrich 
Non-essential amino acids Gibco 
Red Oil Sigma Aldrich 
PBS Dulbecco Biochrom 
Perm/Wash Buffer BD Biosciences 
Pipet Tips (10µL, 20µL, 100µL, 200µL, 1000µL) Greiner Bio One 
Pipets (Serological, 2°mL, 5°mL, 25°mL, 50°mL) Corning 
PLL 0,01% Sigma Aldrich 
Puromycin Sigma-Aldrich 
StemMACS AdipoDiff Media, human Miltenyi Biotec 
StemMACS OsteoDiff Media, human Miltenyi Biotec 
Trypan Blue Sigma Aldrich 
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5.2 Equipment and Software 
Equipment / Software Manufacturer 
  
Balance EW 600 2M 
BX51 microscope Leica 
Centrifuge Heraeus Fresco 21 Thermo Fisher Scientific 
Centrifuge Eppendorf Centrifuge 5810R 
CO2-Incubator (#1) Sanyo MCO-20AIC 
CO2-Incubator (#2) ThermoScientific Heaerus BBD6220 
Counting Chamber C-Chip Disposable Hemocytometer NanoEnTek 
DMI6000B microscope Leica 
DNA / RNA safety working bench DNA/RNA UV-Cleaner UVC/T-M-AR Biosan 
Flow Cytometry Cytomics FC 500 Beckman-Coulter 
Kaluza Beckman-Coulter 
Infinite 200 PRO microplate reader Tecan 
Laminar Flow Working Bench Herasafe HS15 Heraeus 
Las X Leica 
Lightcycler 480 II Roche 
Mr. Frost Freezing Container Thermo Fischer Scientific 
NanoPhotometer Implen 
Pipets Eppendorf 
Pipetboy Integra 
Waterbath Memmert WNB 14 
5.3 Cell Lines 
Cell Line Description Supplier 
   
HT1080 Human Fibrosarcoma cells ATCC 
K67 Neo3-14/K67/1.1+cMyc; immortalized 
porcine cell line; generated originally from a 
pMSC (Pietrain Landrace Pig) [276] 
Technical University of Munich 
(Working Group, Prof. Dr. Schnieke, 
Anja Saalfrank, Chair of Livestock 
Biotechnology) 
 
5.4 Antibodies 
Antibodies are listed within the accordant Methods.  
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6 Methods 
6.1 Isolation of Adherent, Mononuclear Cells from Bone Marrow 
 Donor characterization 6.1.1
The following table shows all specifications and characteristics of the human and porcine 
donors from whom MSCs were isolated. A batch nomenclature was introduced to 
differentiate gene-modified batches from naïve batches. 
Table 1: This overview represents the nomenclature and properties of human and porcine MSCs in the 
generation of the cell products. The human donors were chosen based on a thorough medical anamnesis 
following the accordant laws (actual, german tissue and transplantation law). The pig´s cells isolation was 
performed by members of the Lehrstuhl für Biotechnologie der Nutztiere from the Technische Universtiät 
München. The mini-pig derives from an isogenetic inbreed. This animal is isogenetic to the pigs that were used 
during the biodistribution study (see 7.7). 
Species 
(Mini-) Pig 
Sus scrofa domesticus 
Human 
Homo sapiens 
Tissue 
Bone marrow 
Both Femur and tibia 
Bone marrow 
Iliac crest 
Volume 
Unspecified 
(whole marrow taken) 
Each 75-100 mL 
Method Of 
Harvesting 
Narcotization and necrospy, then 
Flush and Scrape out 
Aspiration under short-time anaesthesia 
Donor 1 1 2 3 
Gender Male Male Female Female 
Age 3 months 31 years 32 years 20 years 
Health Status 
no clinical observations by 
veterinarian 
according to german law: healthy; based on blood, urine, 
serum measurements and medical anamnesis, also free of 
relevant infectious markers  
(e.g. CMV, HIV,  hepatitis virus, etc.) 
Batch 
Nomenclature 
Porcine 
1 
Porcine 
2 
Porcine 
3 
Porcine 
4 
Human 
1 
Human 
2 
Human 
3 
Human 
4 
Human 
4 
Human 
5 
Transduction 
Method 
n.a. A B C n.a. C n.a. C n.a. C 
Selection No Yes No Yes No Yes No Yes 
Cryo-
preservation 
Yes 
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 Isolation of human MSCs 6.1.2
Aspirates the bone marrow were collected from volunteers in accordance to the regulatory 
demands. A physician performed the aspiration under standard clinical and aseptic 
conditions. Volunteers received a short-time anaesthesia and the needle was brought into 
the iliac crest aspirating a bone-marrow volume of 75-100 mL by several punctures. The 
marrow was transported in sterile containers to the laboratory. 
The cultivation started in less than 24 h after extraction. The bone marrows of the human 
donors were seeded without any previous purification or manipulation steps. Therefore, a 
cell stack system was used and the bone marrow was suspended in >150 μL/cm2 Bio-1 
medium, cultured under 5% CO2, 37°C temperature and more than 90% humidity. New 
adhesion after trypsinization takes minutes to hours. Because of that, the bone marrow and 
medium containing supernatant was completely changed with a delay of at least 48 h to 
allow enough time for adherence, but not later than 96°h to assure a sufficient nutrition. 
These colonies could be observed and were split by trypsinization and EDTA within 
14 days, counted (see 6.2.4) with a Neubauer Zählkammer, and seeded again. 
 Isolation of porcine MSCs 6.1.3
Bone marrow was isolated from the femur and tibia of both hind legs of a three months old 
male MGH miniature pig. Prior to isolation, the equipment was disinfected with 80% ethanol. 
The epiphyses of the bones were opened with a saw and bone marrow was flushed with 
25 mL of pre-warmed Hank`s salt solution supplemented with 1000 U/mL heparin. Several 
25 mL samples of aspirate were layered over 25 mL lymphocyte separation medium (LSM-
1077) and centrifuged at 1000× g for 20 min with slow acceleration and deceleration. The 
mononuclear cell fraction was collected from the interphase, transferred to another 
centrifuge tube and washed with 35 mL Hank`s salt solution. After centrifugation at 600× g 
for 10 min, the cell pellet was suspended in porcine MSC culture medium (Advanced 
DMEM, 2mM GlutaMAX®, 1x NEAA, 10% FCS, 5 ng/mL FGF-2, 0.1 mM 2-
mercaptoethanol) supplemented with 100 µg/mL Penicillin/Streptomycin and 100 µg/mL 
Amphotericin B, plated into five 150 cm2 flasks and incubated at 37°C with 5%°CO2 in 
humidified atmosphere. After 24 h, cells were washed twice with PBS and medium replaced 
to remove all non-adherent cells (e.g. hematopoietic cells). 
For the first three days medium was supplemented with antibiotics and antimycotics and 
changed daily. After three days half of the cells were cultured without antibiotics and 
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antimycotics, the rest of the cells after five days. Seven days after isolation, cells were split 
(1:3 or 1:5 depending on confluence; passage 1) using Accutase® and cultured in MSC 
medium without antibiotics and antimycotics for a further three days and then 
cryopreserved. 
The isolation of the porcine MSCs was perfomed by personnel of the Lehrstuhl für 
Biotechnologie der Nutztiere of the Technische Universität München. 
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6.2 In Vitro Cultivation 
 General 6.2.1
All working steps with open flasks and tubes were performed under sterile conditions. A 
laminar flow working bench was used to handle all cell culture experiments. All cells were 
cultured under 5% CO2, humidity of more than 90% and 37±1 °C conditions. Necessary 
equipment was disinfected properly with ethanol. Plastic or other consumable materials 
were sterilized before usage (see 5.1).  
 Thawing of cells 6.2.2
Cryopreservation vials were taken out of the vapor phase of liquid nitrogen and brought into 
a water bath (37°C) for at least two min until no ice crystals could be seen anymore. After 
proper disinfection, the vials were transferred into the laminar flow of a working bench. The 
tube was opened, re-suspended and diluted with the cultivation media for at least 10:1 in a 
50 mL tube before given into a cell culture flask. A sufficient dilution of the DMSO was 
necessary to mitigate possible cell proliferation inhibitions by DMSO (see 6.4.2). The next 
working day, the cells attached completely and the whole media was change to delete the 
DMSO.  
 Standard in vitro cultivation and detachment of cells 6.2.3
Half of the medium was changed every two to four days of a cell culture flask depending on 
the confluency. If the cells were nearly 70-90% confluent, they were detached from the 
plastic surface by using an EDTA and trypsin containing solution. After a washing step with 
PBS, the suspension was given into the flask. The cell culture flask was then put into the 
incubator for three to ten min, if the cells have not detached meanwhile. Then, at least the 
same amount of medium was added to stop the trypsination process. The cell suspension 
was aspirated and given into an appropriate tube (1.0 mL – 50 mL tube). The culture flask 
was additionally washed with PBS to assure a quantitative transfer of all cells in to the tube. 
After a centrifugation of 5 min with 300 g, the supernatant was deleted and the cell pellet 
was suspended in PBS. After cell count determination (see 6.2.4), the cells were seeded 
into a medium containing cell culture flask with a determined ratio of cells/cm² depending on 
the type of cell between 500 to 5000 cells/cm². 
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 Table 2: Description of the cultivation media. Bio-1 was used for human MSCs. This media does not contain 
FBS but platelet lysate that is based on a patent, referenced in 4.1. All other media, also for porcine MSCs, had 
FBS as an ingredient. The recipe for the porcine MSCs cultivation media is based on personal communication 
with the working group of Prof. Angelika Schnieke of the Technische Universität München leading the “Chair of 
Livestock Biotechnology”. 
Cells Cultivation Media 
Porcine MSCs 
88% Advanced DMEM 
10% FBS 
1% Non-Essential Amino Acids 
1% Glutamax 
Porcine Cell Lines 
Human MSCs 100% Bio-1 (see Abbreviations: 3) 
Bio-M: 
87% DMEM 
10% FBS 
2.5% HEPES 
Human Cell Lines 
89% DMEM 
10% FBS 
1% Glutamax 
 Cell count determination 6.2.4
The cells are suspended in an appropriate amount of PBS after detachment and washing 
(see 6.2.3.). After distribution of the cells by several slight inversions of the tube, 50 µL of 
the suspension was taken and given into 50 µL trypan blue. 10 µL of this suspension was 
given into a Neubauer Zählkammer, counted and the cell concentration per mL calculated. 
Based on this calculation, new cell seeding were performed. Where needed, the cell count 
determination was performed more than once to facilitate a higher assurance and less 
variance of the result. 
 Isolation of single cell line clone (after transduction with a GFP gene) 6.2.5
If an isolation of a population by a selection agent (e.g. puromycin) could not be performed, 
a single cell seeding was pipetted to generate a new population out of one cell. The cells 
were detached (see 6.2.3) and washed. The cell suspension was counted with a Neubauer 
Zählkammer (see 6.2.4) and seeded into at least one 96-well plate with a cell density of 
0.1cells/well (theoretically calculated value). It was statistically assumed that in every tenth 
well one cell clone would exist. This single cell proliferated to a colony, which was detached 
and seeded (see 6.2.3 and 6.2.4) into a new flask as soon as the colony was detectable by 
microscopy. If a second colony or no colony was detected in a well, the cells of this well 
were discarded. An appropriate population was expanded until a sufficient amount of cells 
was available to measure for e.g. GFP by flow cytometry. Based on this measurement, the 
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desired cell clone was chosen, expanded and cryopreserved (see 6.2.3) for further 
experiments. 
 Calculation of the population doubling time 6.2.6
The doubling time of a cell population was calculated based on following formula: 
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑇𝑖𝑚𝑒 [ℎ] =
𝑑𝑎𝑦𝑠 𝑓𝑟𝑜𝑚 𝑃0 𝑡𝑜 𝑐𝑟𝑦𝑜 ∗ 24
(
𝐿𝑜𝑔10 (
𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡𝑐𝑟𝑦𝑜
𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡𝑃0
)
𝐿𝑜𝑔10 (2)
)
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6.3 Insertion of Genes 
Cells were transduced with SIN-gamma retroviral vectors to tag them (e.g. GFP) or express 
functional genes (e.g. HSV-TK). The HSV-TK vector backbone (see Figure 1) and producer 
cell line based on the work of an external working group [277]. Both, the self-produced and 
externally manufactured vector supernatant were stored at -80 °C. To thaw the viral 
solution, the tubes were thawed at 37 °C in a water bath until no more small ice crystals 
were visible. Then the tubes were put under the laminar flow of a working bench. As soon 
as no more ice crystals could be observed, the solutions were mixed gently with a 
micropipette.  
 
Figure 1: Here, a schematic description of the therapeutic cassette pEMTAR.bi-RANTES.tk including the 
selection gene is shown. The LTR sequences were part of the viral system facilitating an insertion of the gene, 
which was embedded between both LTR sequences. The HSV-TK gene was under the control of an inducible 
promoter, called RANTES. This RANTES promoter generally is inducible with pro-inflammatory cytokines e.g. 
TNFα and IFNγ. The HA-tag was attached to the kinase, which allowed a detection with accordant antibodies for 
measurement through flow cytometry. The enzyme PAC deactivated the cytoxin puromycin by acetylation. This 
enzyme was expressed continuously because it was under the control of a constitutive promoter (pPGK) 
allowing a selection by puromycin during cultivation. The WPRE sequence enhanced the stability of the 
transcribed transgene increasing proten expression [278]. 
Since the viral vector load and the cell count were known, a ratio of 3 (three viral vector 
particles / one cell: MOI = 3) was chosen. For the production of all batches a ratio of three 
viral vectors to one cell was chosen to maintain comparable transduction conditions. The 
cell lines were transduced with a higher viral load per cell to facilitate an easy recognition 
while measured by flow cytometry. Following transduction methods were performed: 
 Transduction by direct seeding (Method A) 6.3.1
This virus solution was mixed with 0.01% PLL with a 100:1 ratio (99 parts virus solution and 
1 part PLL solution). The cells were added to the virus / PLL solution and mixed gently to 
selection cassette therapeutic cassette enhancing sequence 
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generate a homogenous suspension. If the suspension volume for seeding was less than 
125 µL/cm2, PBS was added to ensure a sufficient distribution of the volume over the whole 
culture flasks surface. The seeding density was determined to result in a confluence of 20-
30%.  
 Transduction on PLL plates (Method B) 6.3.2
A solution of PLL 0.01% is given into 6-well pates and centrifuged for 30 min at 4 °C and 
2000x g. Afterwards, the supernatant was deleted and the plates were washed with PBS. 
The PLL adhered at the plastic and these molecules charged the plastic surface positive. 
The negative charged virus particles attached at the surface and interacted with the cell 
surface. The seeding density was determined to result in a confluence of 20-30%. 
 Transduction in suspension (Method C) 6.3.3
This virus solution was mixed with 0.01% PLL before a defined amount of cells was added. 
Over three hours, this transduction mix was inversed every 15 min to assure a good 
distribution of the cell-vector mix. Afterwards, the mix was diluted with the appropriate 
serum containing culture medium and seeded into the culture flasks. The seeding density 
was determined to result in a confluence of 20-30%. 
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6.4 Selection, Expansion and Cryopreservation of Cells 
 Selection 6.4.1
Cells transduced with the pEMTAR.bi-RANTES.tk vector were selected using puromycin not 
earlier than 48 h after transduction. Half of the medium was deleted and medium with a 
concentration of 6 µg/mL was added, resulting in a final concentration of 3 µg/mL. Two days 
later, half of the medium was deleted and fresh medium with 3 µg/mL puromycin was added 
again to continue the selection process. Not earlier than five days after the start of the 
selection, the whole medium was changed to delete dead cells, cell debris and remaining 
puromycin. Afterwards, the cells were cultured in a standard medium to allow proliferation of 
the selected population as described before (see 6.2). 
 Expansion and cryopreservation 6.4.2
The expansion procedure after selection was carried out in accordance to 6.2 until the 
desired cell count was reached. The following detachment was performed as described 
before (see 6.2.3). After washing, the cell count was determined and the cells were 
suspended in a concentration of between 5 to 10×106 cells/mL in the accordant 
cryopreservation medium (see Table 3). 
Table 3: Description of the cryopreservation media used for different types of cells [279]. 10% DMSO was 
used for all cell types to reduce the amount of crystallization during the freezing process. Hydroxyethyl starch 
served as the cryoprotective supplemental protecting the cell surface [280]. 
Cells Cryopreservation Media 
Porcine MSCs 
45% hydroxyethyl starch 
45% porcine serum 
10% dimethyl sulfoxide 
Human MSCs 
45% hydroxyethyl starch 
45% human albumin 
10% dimethyl sulfoxide 
Cell Lines 
90% fetal bovine serum 
10% dimethyl sulfoxide 
 
Aliquots of 1.5 mL were pipetted and transferred into the freezing containers (“Mr. Frosty”). 
Then, the freezing containers were put into a freezer with a temperature of minus 80°C. 
These containers controlled the temperature reduction in a time dependent manner lowering 
the temperature by one degree Celsius per minute. As a consequence, the temperature 
reduction from room temperature (about +20 °C) to -80 °C lasted 100 min. Afterwards, the 
vials were transferred into the vapor phase of liquid nitrogen tanks at -196°C.  
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6.5 Differentiation into Osteocytes and Adipocytes and Staining 
Commercial differentiation media compiled for human MSCs (see 5.1) were used for 
porcine and human MSCs following the manufacturer instructions. In short, the cells were 
seeded into 12-well plates and cultured under standard conditions (see 6.2) until 100% 
confluence. Then, the medium was deleted and the differentiation medium was added. The 
differentiation itself took 14 to 21 days. Half of the medium was changed every 2-3 days. At 
the end, the supernatant was deleted; the culture flasks were washed with PBS twice. Then, 
the staining was as described in 6.5.1 and 6.5.2. Accordant controls cultivated using a 
standard medium were stained, too. 
 Staining of osteocytes and analysis 6.5.1
The staining of osteocytes was done utilizing a fixation with a neutral buffered 10% formalin 
solution at room temperature. After an incubation time of 30-45 min, the formalin 
supernatant was deleted and the wells were washed twice with deionized water. A freshly 
prepared alizarin red solution (2.0 g/mL) was given into the wells for 30-45 min. Afterwards, 
the cells were washed again with deionized water for two times. PBS was added to assure 
that the preparation does not run dry. A microscopic analysis was performed and 
representative photos were taken of sections of ~750 µm × 1000 µm. 
 Staining of adipocytes and analysis 6.5.2
To stain adipocytes, the cells were fixed with a neutral buffered 10% formalin solution for 
30-45 min at room temperature. Then, the formalin was deleted and the cells were washed 
with non-sterile water two times. An additional fixation was done with 60% isopropanol for 
3 -5 min at room temperature. A freshly prepared Red Oil solution was added and incubated 
for 5 - 10 min at room temperature. After washing with PBS twice, Mayer's Hematoxylin 
Solution was given into the wells for 1 - 5 min at room temperature and the wells were 
washed with non-sterile water twice. PBS was added to assure that the preparation does 
not run dry. A microscopic analysis was performed and representative photos were taken. 
All adipogenic cells were counted in three representative sections of ~750 µm × 1000 µm. 
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6.6 Measurements by Flow Cytometry 
 Identification of surface markers 6.6.1
MSCs have a determined set of proteins, which are presented on their surface. These can 
be identified by accurate staining and flow cytometry measurements. For this, the cells were 
detached as described before (see 6.2), washed twice with PBS and counted (see 6.2.4). 
Multiple 100 µL PBS aliquots with a cell concentration of 1×106 - 2×106 cells/mL were 
generated as needed. The accordant antibody was added to the cell suspension and mixed. 
After an incubation time of 20 min at room temperature, the cells were washed with PBS 
two times again. Then, the cells were measured. If needed, accurate compensation was 
performed. At least 10,000 events were measured per analysis. Isotype controls for each 
antibody and fluorophore were used to set appropriate gates for the measurement. 
The antibodies listed in Table 4 were used for porcine MSCs. The antibodies listed in Table 
5 were used for human MSCs.  
Table 4: The staining of porcine MSCs for flow cytometry measurement was performed with the 
following fluorophore-conjugated antibodies and 7-AAD. All stainings were performed as single stains to 
reduce compensational work. All antibodies were generated from murine cell lines as declared by the 
manufacturer. 
Mix Antigen Dye Isotype Volume [µL] Company 
1 
(Isotype 
Control) 
N/A 
7-AAD N/A 15 Beckman-Coulter 
APC IgG1 20 BD Bioscience 
FITC IgG1 20 Beckman-Coulter 
PE IgG1 20 Beckman-Coulter 
PE IgG2a 20 BD Bioscience 
2 CD45 FITC IgG1 10 AbD Serotec 
3 CD90 APC IgG1 10 BD Bioscience 
4 CD29 PE IgG1 20 Abcam 
5 CD44 APC IgG1 10 Novus Biologicals 
6 CD105 PE IgG2a 20 Novus Biologicals 
7 HLA-DR PE IgG2a 10 Novus Biologicals 
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Table 5: The staining of human MSCs for flow cytometry measurement was performed with the following 
fluorophore-conjugated antibodies and 7-AAD. The stainings were done by multiple stainings per tube, so 
called master mixes. All antibodies were generated from murine cell lines. Accurate compensation was done as 
needed. 
Mix Antigen Dye Isotype Volume [µL] Company 
1 
(Isotype 
Control) 
N/A 
FITC IgG1 22 
Beckman-Coulter 
PE IgG1 22 
PE IgG2a 22 
PE IgG3 11 
ECD IgG1 11 
PC7 IgG1 11 
2 
CD90 FITC IgG1 22 
CD73 PE IgG1 22 BD Pharmingen 
CD34 PC7 IgG1 11 
Beckman-Coulter 
3 
CD235a FITC IgG1 22 
CD105 PE IgG3 22 
CD45 ECD IgG1 11 
4 
CD3 FITC IgG1 22 
CD14 PE IgG2a 22 
CD19 PC7 IgG1 11 
5 
CD41 FITC IgG1 22 
CD61 PC7 IgG1 11 
6 N/A 7-AAD N/A 20 
7 HLA-DR ECD IgG1 11 
 Intracellular staining of the HA-tag 6.6.2
The insertion of the suicide gene HSV-TK was performed under controlled conditions as 
described before (see 6.3). The rate of transduced cells per population was quantified by 
HA-tag staining and measurement by flow cytometry. TNFα and IFNγ were added in a final 
concentration of 3 ng/mL each that induced the RANTES promoter and increased the HSV-
TK expression. Not earlier than 48°h after the transduction or completion of the selection 
(see 6.4), the cells were detached (see 6.2) and the cell count was determined (see 6.2.4). 
After washing twice with PBS, cells were fixed with Cytofix/Cytoperm® for 20-30 min at 
+4 C. Afterwards, the cells were washed twice with Perm/Wash Buffer® to enhance the 
permeability of the membrane for intracellular staining. While being protected from light, the 
antibodies were added and incubated for 30 min at +4 °C. Then, the cells were washed 
twice with PBS and suspended in FACS buffer before they were measured by flow 
cytometry. 
The same assay was performed make sure whether the puromycin selection was 
completed or not. 
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Table 6: The staining of the HA-tag for flow cytometry measurement was performed with the following 
fluorophore-conjugated antibodies. The antibody was generated from a murine cell line as declared by the 
manufacturer.  
Mix Antigen Dye Isotype Volume [µL] Company 
1  
(Isotype Control) 
N/A PE IgG1 11 Beckman-Coulter 
2 HA PE IgG1 11 Miltenyi 
 Differentiation of apoptotic and dead cells in a single or several cell 6.6.3
populations 
To determine the amount of apoptotic and dead cells in a population, all adherent and non-
adherent cells were saved for preparation. First, the supernatant was transferred into a tube 
to save all non-adherent cells. In a next step, the adherent cells were detached following 
6.2.3 and transferred into the same tube. 7-AAD was added and – protected from light - 
incubated for 10 min at room temperature. Then, the cells were centrifuged at 600 g for 
5 min, the supernatant was deleted and the cell pellet was suspended in a 200 µL Annexin-
V binding buffer® (Ca²+ enriched saline, isotonic buffer). This Ca²+ enriched buffer mediated 
a proper binding of Annexin-V to phosphatidylserine. 5 µL of Annexin-V were added to the 
suspension and incubated for 10 min at room temperature, protected from light. 400 µL 
binding buffer were added to this solution (for dilution only) and directly measured by flow 
cytometry. Since 7-AAD and PE-Cy7 have an overlap in their emission spectrums, accurate 
compensation was performed to avoid false-positive signals.  
Table 7: The staining of apoptotic and dead cells was performed utilizing Annexin-V and the dye 7-AAD. 
These markers / dyes allow a distinction of apoptotic and necrotic cells. Mediated by Ca
2+
, Annexin-V binds 
phosphatidylserine on the cell´s surface if presented. Apoptotic cells can not be stained with 7-AAD since these 
cells still have an intact lipid bilayer.  
Mix 
Target 
molecule/structure 
Agent Dye Volume [µL] Company 
1 
Phosphatidylserine Ca
2+
 enhanced Annexin-V PE-Cy7 5 eBioscience 
Intercalation into double-
stranded DNA 
7-AAD 20 Miltenyi 
 
The morphological alterations of cells undergoing apoptosis were also considered in the 
gating strategy. Due to condensation effects, the MSCs appeared smaller and more 
granular resulting in a population shift in the FS/SS scatter. Accurate settings were 
evaluated and the gating strategy allowed a measurement of this shift (see Figure 21).  
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In 6.7.3, MSCs were co-cultured with cell lines, which were transduced with a GFP 
expressing gene according to 6.3. This GFP-tag allowed the differentiation between cell 
lines and MSCs during the flow cytometry measurements. This was done for all bystander 
killing assays. 
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6.7 Treatment of Cell Populations with GCV 
 Titration of cell sensitivity to GCV by using the MTT-assay 6.7.1
HSV-TK expressing cells are more sensitive to GCV than naïve cells. To provide proof of a 
functional expressed protein, the increased sensitivity was quantified by an MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) staining assay. 
MTT is a water-soluble, yellow dye (tetrazolium salt), which is converted into the purple 
formazan by reductive compounds of viable cells. This conversion occurs if reduction 
equivalents are available e.g. NADH or NADPH. These molecules are produced during 
glycolysis of viable cells. Formazan shows a characteristic absorption spectrum between 
500 nm and 600 nm and a maximal emission at about 630 nm. Here, the absorption was 
measured at 570 nm.  
On day 1, cells were detached and counted as described before (see 6.2.3 and 6.2.4). 
Then, the cells were seeded into 5 wells of a 96-well plate (0.32 cm² per well) in accordance 
to Table 10. The cell lines HT1080 and K67 were seeded with a cell density of 
7500 cells/cm². On day 2, the pro-inflammatory cytokines TNFα and IFNγ were given into 
the media in a concentration of 3ng/µL each. GCV was added in a serial dilution as shown 
in Table 8. On day 3 and 4, half of the medium was changed and GCV was added to the 
medium to maintain the desired concentration. 
Table 8: GCV was given into a serial dilution and added to the media to quantify the GCV sensitivity. All 
cells were treated following the same GCV dilutions.  
Dilution Step GCV concentration [µM] 
A 
(Negative Control) 
0 
B 0.001 
C 0.01 
D 0.1 
E 0.5 
F 5 
G 50 
H 200 
I 2000 
J  
(Positive Control) 
16000 
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Table 9: Each cell line and each batch of MSCs was measured for GCV sensitivity in a 96-well plate. Five 
parallel cultures were generated to take the assay variance into account. The accordant GCV concentrations are 
listed in Table 8. A staining control (st ctrl) without any cells was performed to consider staining artefacts. PBS 
was given in the outer rows and columns to reduce evaporation effects. 
PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS 
PBS A 1 B 1 C 1 D 1 E 1 F 1 G 1 H 1 I 1 J 1 PBS 
PBS A 2 B 2 C 2 D 2 E 2 F 2 G 2 H 2 I 2 J 2 PBS 
PBS A 3 B 3 C 3 D 3 E 3 F 3 G 3 H 3 I 3 J 3 PBS 
PBS A 4 B 4 C 4 D 4 E 4 F 4 G 4 H 4 I 4 J 4 PBS 
PBS A 5 B 5 C 5 D 5 E 5 F 5 G 5 H 5 I 5 J 5 PBS 
PBS St ctrl St ctrl St ctrl St ctrl St ctrl St ctrl St ctrl St ctrl St ctrl St ctrl PBS 
PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS 
 
On day 5, the controls were checked to show that no more adherent cells in column “J” 
were visible (positive control) and that attached cells were visible in column “A” (negative 
control) (see Table 9). The staining was performed in accordance to the kit´s 
manufacturer´s instructions, adding 15 µL of MTT-containing dye solution and 100 µL 
cultivation media after the deletion of the supernatant. After 4 h of incubation, the “stop 
solution” was given into the wells and the solution was thoroughly mixed by pipetting up and 
down. The measurement was performed by photometric absorption at 570 nm in reference 
to the absorption at 650 nm. An additional staining control was performed to exclude any 
artificial staining errors. The mean absorption value of column “J” was used for 
normalization: 0% viable cells. Column “A” was used to normalize to 100% viable cells. The 
EC50 value was calculated using the Graph Pad Prism® software. 
 Mono-cultivation: characterization of apoptosis under the treatment with GCV 6.7.2
Activated GCV leads to the apoptosis of a cell. To characterize both species in their 
apoptotic pathway, all human and porcine batches of MSCs were seeded, treated with GCV 
and measured by flow cytometry (see 6.7.3 for flow cytometry measurements).  
On day 1, the cells were detached and counted as described before (see 6.2.3 and 6.2.4). 
The cells were seeded in 12-well plates (4 cm2) in triplicates. The confluency was less than 
15-25% to assure enough plastic surface for proliferation. The used seeding densities are 
presented in Table 10. The amount of cells seeded per batch differed since the size of the 
MSCs depended on species, donor and passage. An additional visual check was done 24 h 
± 4 after seeding to assure that the confluency was not higher than 30% and that the cells 
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successfully adhered. HEPES was additionally given into the medium (in a final 
concentration of 2.5%) for a sufficient pH buffering because GCV shows alkaline attributes. 
Table 10: To characterize the apoptotic pathway under the treatment with GCV, the cells were to reach a 
confluency of less than 25%. Because the size of a cell also depends on its origin, species and “in vitro age”, 
different cell seedings were chosen. 
Species / Batch Cells Seeded [cells/cm²) 
Human 1 
1000-3000 
Human 2 (HSV-TK) 
Human 3 
Human 4 (HSV-TK) 
Human 5 
Human 6 (HSV-TK) 
Porcine 1 
4000-5000 
Porcine 2 (HSV-TK) 
Porcine 3 (HSV-TK) 
Porcine (HSV-TK) 
 
On day 3, TNFα and IFNγ were added to the medium with a concentration of 3 ng/mL each 
to induce the expression of HSV-TK (RANTES activation). Then, GCV was added in a final 
concentration of 25 µM (this concentration was on the results from 6.7.1 as shown in 7.4.3). 
On day 4 and 5, half of the medium was changed and GCV was added to maintain a 
concentration of 25 µM. Next, the supernatant was saved; the cells were detached, 
counted, (see 6.2.4) stained and measured in accordance to the previously described 
procedure (see 6.6). 
 Co-cultivation: proof of the bystander effect 6.7.3
All batches were co-cultivated with the porcine (K67) and the human cell line (HT1080) to 
evaluate the bystander effect (see 1.6). Except for day 1, the assay was performed in 
exactly the same way as described in 6.7.2. The MSCs and the cell line were equally 
seeded into the 12-well plates. Following Table 10, half of the described cell count was 
used for each cell line and the accordant MSC batch. All following steps were performed as 
described before (see 6.7.2).  
The MSCs and the cell lines were discriminated by GFP (see 6.6.3). Bio-M was used for the 
cultivation of human MSCs instead of Bio-1 to enable the proliferation of the cell lines. 
HEPES was additionally given into the medium (in a final concentration of 2.5%) for a 
sufficient pH buffering because GCV shows alkaline attributes.  
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6.8 Isolation and Quantification of DNA 
 Isolation of DNA from cells and photometric quantification 6.8.1
The DNA isolation was performed with a commercial kit (Quiagen Blood & Tissue Kit) 
according to the manufacturer’s instructions. In short: the cells were lysed, protein and RNA 
were digested, and the DNA was precipitated with ethanol. Then, the DNA was washed with 
an ethanol containing saline buffer before it was eluted with TRIS buffer in at least 50 µL.  
If the DNA of porcine blood samples was to be isolated, an additional lysis step was 
performed. The 10x RBC Lysis Buffer was diluted to the working concentration (1x) and 
750 µL of blood were mixed with 15 mL lysis buffer to lyse erythrocytes and thrombocytes. 
After an incubation time of 10-15 min, a centrifugation was performed with 350 g for 5 min. 
Then, the supernatant was aspirated and discarded before the cells were suspended in 
PBS. Finally, the DNA was isolated following the protocol described above. 
The whole DNA-containing solution was unspecifically quantified by photometric 
determination. A volume of 4 µL was sampled and given onto the photometric unit of the 
photometer. The absorption at 260 and 280 nm was measured. In general, an extinction of 
1 at 260nm correlates to approximately 50 µg/mL DNA. Any absorption at 280 nm 
represents possible protein contamination. The quotient of both extinctions indicates a high 
contamination if the value is <1.8. If the quotient was less than 1.8, another precipitation, 
washing und elution procedure was conducted.  
If the concentration of the eluted DNA was >150 ng/µL, the solution was diluted with TRIS 
buffered water to ≤150 ng/µL. 
 Quantification of genomic DNA or a sequence of interest by real-time PCR 6.8.2
To quantify a defined sequence of DNA in a sample, real-time PCR was performed thereby 
amplifying the targeted sequence. Single copy genes were chosen with appropriate primers 
to determine the amount of genomic porcine and human DNA (see Table 11).  
Standards containing a determined amount of genomic DNA of a species were 
logarithmically diluted and amplified by real-time PCR. The measured cycle threshold (CT) 
values represented the quantity of amplification cycles before the fluorescent signal was 
detected. This fluorescent signal was generated by a probe (specific amplicon 
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complementary fluorescent reporter dyes) that was hydrolyzed during amplification or by 
double- strand-intercalating dyes (e.g. SYBR green).  
This value was put into correlation to the absolute number of sequence copies before 
amplification by the logarithmic transition of the CT values and the known number of 
sequences. Following formula was used for the linear regression: 
𝑦 = −𝑚 ∗ 𝑥 + 𝑛 
Table 11: Single-copy genes or a defined sequence of interest allowed the quantification of DNA by 
specific real-time PCR. Because photometric measurements unspecifically measuree the whole DNA in a 
sample, the defined quantification of a DNA or a sequence of interest was performed by real-time PCR [281]. To 
measure the insertion rate into a population, the therapeutic gene was quantified by the amplification of the 
transgene enhancer WPRE [278], which generally is not present in naïve cells. 
Species / Origin Pig Human Woodchuck hepatitis B virus 
Single-Copy Gene / 
Sequence of Interest 
Zar1  Factor VII WPRE 
Genome Weight [pg] 6.0 6.5 N/A 
Primer forward 5´-ACGATGCAG 
CGTCTTATTCC-3´ 
5´-GCCAAGCAA 
GGCACTATCTC-3´ 
5´-TCATGCTAT 
TGCTTCCCGTA-3´ 
Primer reverse 5´-TCATACAGG 
CAAGGGGAAAG-3´ 
5´-GGCTGTGCC 
GAAGTAGATTC-3´ 
5´-AAAGAGACA 
GCAACCAGGATTT-3´ 
Probe 5´-AAACAAACCCAG 
GTTCAGGAACCCTG-3´ 
5´-AGGACCTCC 
GCCAGGGTTCA-3´ 
UPL Probe ® #63 (sequence 
not known) 
 
The primers and probes, respectively dyes, were used in the following mixes as shown in 
Table 12. 
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Table 12: The following master mixes were used for the quantification of single copy genes or the 
transgene sequence WPRE. All mixes were tested with different concentration of primers and probes / dyes to 
optimize the amplification and the robustness of the result. 
Master Mix Species / Gene Primer / Substance / Dilution volume [µL] 
#1 
Pig: 
Zar1 
PCR-Grade H2O 4,2 
Primer: Pig Zar1 for 300nM 0,3 
Primer: Pig Zar1 rev 300nM 0,3 
Probe Pig Zar1 200nm 0,2 
Probes Master 480 (FAM) (Roche) 10 
Sample 5 
Sum 20 
 
#2 
Human: 
Factor VII 
PCR-grade H2O 4,25 
Primer: human FVII for: [300nm]  0,3 
Primer: human FVII rev: [300nm] 0,3 
Probe human FVII [2x] 0,15 
Probes Master 480 (FAM) (Roche) 10,0 
Sample 5 
Sum 20 
 
#3 
Therapeutic 
Gene: 
HSV-TK 
(WPRE) 
PCR-Grade H2O 4,1 
Primer: WPRE for 300nM  0,3 
Primer: WPRE rev 300nM 0,3 
Probe: UPL #63 150nM (Roche) 0,3 
Probes Master 480 (FAM) (Roche) 10 
Sample 5 
Sum 20 
 
The ratio of WPRE sequences to the amount of cells result in the vector copy number 
(VCN). A successful selection of population must show a VCN ≥1. 
 Determination of the mean retroviral vector insertion rate of a population 6.8.3
The transgene HSV-TK was inserted into the MSCs by retroviral vectors carrying a WPRE 
sequence. To determine the mean insertion rate into a cell population, the cells were 
analyzed after transduction (see 6.3) and selection (see 6.4.1) by real-time PCR. After the 
preparation procedure as described before (see 6.8.2), the DNA-containing samples were 
measured by amplification with the master mixes #1 (for porcine MSCs) or #2 (for human 
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MSCs) and additionally with master mix #3 (WPRE sequence). Based on the standard 
curve, the generated CT values were used to calculate the quantity of DNA copies before 
amplification. The quotient of the transgene copies and the single-copy genes resulted in 
the mean transduction ratio: the vector copy number of a population. 
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6.9 In Vivo studies and Histopathological Staining 
 Infusion of MSCs into pigs, clinical observation and pathology 6.9.1
A veterinarian, a member of the Institut für Molekulare Tierzucht und Biotechnologie der 
Ludwig-Maximilians-Universität München, was responsible for the animals involved in the 
study. She performed all surgical interventions and observed the mini-pigs for clinical 
relevant symptoms. The competent regulatory authority allowed the animal trial in 
accordance to the Tierschutzgesetz. 
HSV-TK expressing porcine MSCs were manufactured in accordance to the protocol 
described in Figure 2 and were verified for all identity criteria checked in 7.2. The batches 
were stored in 2 mL cryopreservation vials containing 10x106cells/mL in the vapor phase of 
liquid nitrogen. The absence of mycoplasma and sterility was tested to assure the safety of 
the product. 
On the day of infusion, the vials were transported from the laboratory in a dry shipper to the 
study site and were thawed in a 37°C water bath. The thawed cells were counted with 
trypan blue and prepared for infusion under aseptic conditions. The filled syringes were 
transported to the stables. Before the cell were infused, the animals were narcotized and a 
catheter was implanted into the jugularis vein by surgery. This catheter was used for the 
infusion of the cells only. The wound was stitched up and the access was thoroughly pasted 
at the neck with an accordant catheter expansion. In addition, an intravenous access to an 
ear vein was established with a short catheter for blood aspiration only (see Figure 29). This 
configuration of the catheters was intentionally set up to prevent a sampling of just infused 
cells. Before the cells could reach the ear vein, the cells had to distribute throughout the 
whole bloodstream and including the passaging of the lungs. 
Blood samples were saved in EDTA-containing tubes at ambient temperature, which were 
transported to the laboratory the same day. The DNA isolation of the MNCs was performed 
as described before (see 6.8.1) 
At the end of the in-life phase, the veterinarian necropsied the animal by previous 
anesthesia and following euthanasia. Veterinary Pathologists of the Institut für 
Tierpathologie of the Ludwig-Maximilians-Universität München performed the pathological 
investigation. Tissue preservation and IHC staining was performed as described in 6.9.2. 
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 Immunohistochemistry (IHC) on porcine tissues 6.9.2
During the pathological investigation, squarish tissue samples of 3-5 mm size were 
generated and embedded in formalin for 3-7 days. Afterwards, the samples were fixed in 
paraffin. The blocks were sent to the external laboratory (Indivumed) for 
immunohistochemical analysis and were stained following the established protocol. In short, 
the formalin-fixed paraffin-embedded tissue (FFPE) tissue samples were sliced into 3 μm 
sections and mounted on positively charged glass slides. The FFPE slides were 
deparaffinized and immunostained with the rabbit monoclonal antibody Anti-HA (clone 
C29F4, Cell Signaling Technology). Positive Control runs were performed in each run as 
well as an accordant isotype control of the neighbored tissue slice as negative control. As 
second negative control, naïve porcine tissue was stained using the Anti-HA antibody to 
identify potential artefacts. 
Afterwards, the slides were manually washed using hot water supplemented with detergent, 
followed by tap water and dH2O. For dehydration, the slides were transferred to an 
ascending ethanol series (2x 80%, 2x 96%, 2x abs. EtOH; 1-3 min each). After dehydration, 
the slides were transferred to xylene (3x 2 min) and embedded in Pertex®. Finally, the 
stained sections were analyzed by microscopy for positively stained cells and manually 
counted.  
6.10 Statistical Analysis of Results 
For statistical analysis and plotting of graphs, the software Graph Pad Prism 7® was used. 
All statistical results stated in this work based on calculation of the Graph Pad Prism 
software.  
If normal distribution was assumed, the D`Agostino & Pearson normality test, Shapiro-Wilk 
normality test or Kolmogorow-Smirnow normality test was performed. The student´s paired 
t-test was performed, if two data sets were compared by their mean and they derived from 
the same population. Unpaired t-test was performed for data sets that did not derive from 
the same population but were compared by their mean and had the same variance. Welch's 
unequal variances t-test was performed for data sets that did not have the same variance 
and therefore did not derived from the same population.  
An Analysis of Variance (ANOVA) was performed in a so called “one-way” or “two-way”. 
The One-Way ANOVA (Tukey´s or Dunnett´s multiple comparison test) was performed for 
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comparison of more than two data sets to one control and to identify if any statistical 
difference from any of these data sets to the control could be observed. Two-Way ANOVA 
(Tukey´s or Sidak´s multiple comparison test) compared all data sets to each other and 
aimed to identify any significant differences between any sets of data. Linear Regression 
was performed based on the normality tests that were described above.  
Differences of two normal distributed data sets were described as statistical significant or 
not following Table 13. 
Table 13: This overview summarizes the difference between data sets that were entitled as statistically 
significant or not. If the assumed normal distribution of two data sets differed for more than 95% from each 
other, the difference was assessed to be significant. If the statistical differences of the distributed values were 
even 99% or higher, it was described with the accordant symbol to underline this difference. 
p value described as symbol 
p >0.05 Not significant ns 
p <0.05 and >0.01 Significant * 
p <0.01 and >0.001 Significant ** 
p <0.001 and >0.0001 Significant *** 
p <0.0001 and >0.00001 Significant **** 
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7 Results 
7.1 Strategy and Batch Production 
Testing homologous, preclinical cell therapy products requires sufficiently characterized 
cells from the chosen species. Therefore, good in vitro characterizations have to be 
completed before in vivo experiments are ethically reasonable and generate valid results 
allowing a translation to the human setting.  
Following strategy was pursued: Bone marrow was aspirated out of the iliac crest from three 
human donors. The mini-pig´s cells were taken by scraping out the marrow of both femur 
and tibia after necropsy of one mini-pig. The MGH mini-pig in question (Massachusetts 
General Hospital mini-pig) derived from an isogeneic brood animal [282]. The generated cell 
populations were described as “Porcine 1 (naïve)” and “Human 1, 3 and 5 (naïve)” (see 
Table 1). The three ISCT requirements: plastic adherence (and fibroblast-like morphology), 
differentiation potential and a defined set of surface proteins should be confirmed in both 
species. In addition, a typical characteristic of human MSCs was investigated: showing 
HLA-DR on the surface, especially after pro-inflammatory cytokine induction. The 
population doubling time was also assessed. 
A suicide gene was inserted with the same SIN-γ-retroviral vector into both species’ cells. 
Three HSV-TK expressing, porcine batches were generated (“Porcine 2, 3 and 4”) as well 
as one HSV-TK expressing human batch from each donor (“Human 2, 4, and 6”). The 
transduction rate was determined as well as the mean transgene insertion rate of a 
puromycin-selected population. The functionality of the human-derived promoters in the 
porcine MSC was quantified in comparison to human MSCs. The functionality of the gene 
was quantified by an MTT assay evaluating the GCV sensitivity. A characterization of the 
apoptotic cell death was performed by flow cytometry regarding morphological and surface 
changes after GCV treatment. The therapeutic effect was assessed by in vitro co-cultivation 
of HSV-TK expressing MSCs with cell lines and the addition of GCV. Finally, experimental 
in vivo studies were performed. Porcine MSCs were intravenously administered to evaluate 
the biodistribution of the cells in the mini-pig´s bloodstream and representative tissues.  
Figure 2 shows the performed strategy in a flow chart. 
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Figure 2: This flow chart presents the comparison approach of the human and the porcine-derived cell 
therapy products. Both species cells derived from the bone marrow and were produced in the same way. After 
the first detachment, the cells were split into a naïve line and into a line that was transduced with the HSV-TK 
vecotor. Testing was performed on several different steps of the MSC product. In vivo studies were performed 
with porcine MSCs only. 
  
C
o
m
p
ar
ab
ili
ty
 o
f 
M
SC
s
Porcine & Human 
Bone-Marrow
Isolation by 
Adherence
Growth of Colonies
And Detachment
Retroviral 
Transduction 
(HSV-TK)
Naive TD
Selection and 
Expansion
Thawing 
And 
Pre-Cultivation
Performance
Of
Assays
Identification by:
Adherence
Surface-Markers
Differentiation
Induction of HLA-DR Presentation
Transduction Rate
Population Doubling Time
Mean Insertion Rate per Cell
Functionality Selection Gene
Functionality Therapeutic Promoter
Detachment and
Cryopreservation
Functionality Therapeutic Gene
Characterization of Apoptosis
Therapeutic Effects Intra-/Interspecies
Expansion
Thawing 
And
In-Vivo Studies
Batch Production Process Comparison Studies
C
o
m
p
ar
ab
ili
ty
 o
f 
th
e 
P
ro
d
u
ct
io
n
 o
f 
th
e 
C
el
l T
h
er
ap
y 
P
ro
d
u
ct
C
o
m
p
ar
ab
ili
ty
 o
f 
th
e
 
P
e
rf
o
rm
an
ce
 o
f 
th
e 
C
el
l 
Th
er
ap
y 
P
ro
d
u
ct
St
ag
e
 o
f 
Fi
n
al
 P
ro
d
u
ct
Results 
 
 
 
 
 54 
7.2 Adherent Bone-Marrow MNCs from the Pig are MSCs 
 Porcine and human MSCs were plastic adherent and showed similar 7.2.1
morphology 
The isolation process is the most critical production step in the eyes of many working 
groups and crucial for the amount and quality of MSCs as described before. To mitigate 
non-desired effects on the MSC properties, the same isolation protocol was used for all 
human donors. The freshly aspirated marrow was cultivated in less than 24 h. After initiating 
the cultivation, the culture media showed a reddish colour due to the massive presence of 
erythrocytes. 
Figure 3: Before the first media change, no adherent cells were visible (A) since erythrocytes completely 
masked the plastic surface. The succesive media changes reduced the amount of suspension cells 
dramatically until only adherent cells remained in the cultivation flask. Here, stromal cells (B) built up adherent 
colonies that showed a circular proliferation with a high cell density at the inner part. Within days, the colonies 
grew up until they got in touch with each other. Not later than 14 days, the cells were split and scattered for 
further proliferation. Scale bar: (A) 100 µm and (B) 500 µm. 
In the first hours of seeding, MSCs started to adhere. The supernatant was changed every 
2-4 days to assure sufficient amounts of nutrients in the media e.g. glucose. Although the 
erythrocytes were diluted step-by-step and finally not present in culture anymore, no 
obvious cell colonies could be detected by visually screening during the first week of 
cultivation.  
A B 
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Figure 4: Porcine (A, batch: Porcine 0) and Human MSCs from donor 1 (B, batch: Human 1) in low-
density seed showed fibroblast-like morphology. Microscopy showed that human MSCs tended to be larger 
than their porcine counterparts and were slightly more spindle-shaped. After seeding, both species showed 
nearly complete adherence in less than 2 h. Scale bar: 250 µm. 
After 6-12 days, proliferating colonies could be observed. These colonies were typically 
confluent in the middle and looser at the outer edge. Not later than 14 days, the colonies 
were split. 
Figure 5: The human donor 2 (A, batch: Human 3) and donor 3 (B, batch: Human 5) were comparable in 
morphology to donor 1 and the porcine MSCs. Comparing donor 2 to the other human donors, a more 
flattened and enlarged size was visible. Scale bar: 250 µm. 
The cells showed a fibroblast-like morphology and strong adherence to the plastic since 
slight movement of the culture flasks did not lead to any detachment. Partially, these cells 
were more flattened or showed single thin and long forms. The morphology of porcine and 
A B 
A B 
Results 
 
 
 
 
 56 
human MSCs was quite comparable. All batches of both species showed good adherence 
and spindle-shaped morphologies, especially donor 1 and 3. Donor 2 was noticeable 
regarding the more flattened morphology and the relatively large and broad cells.  
 Surface markers of both species were nearly identical 7.2.2
A single surface marker identifying the MSC population has not been described yet. The 
ISCT demands a check for CD90, CD73 and CD105 and for several hematopoietic cell 
markers to exclude possible impurities. The isolation by adherence eliminates 
hematopoietic cells normally after regular media changes (as described before, see 7.2.1) 
since hematopoietic cells out of the marrow do not show sustained adherence during 
cultivation.  
All batches (listed in Table 1) were stained with a panel of antibodies to check their surface 
profile (see 6.6). Therefore, the cells were cultivated for at least 48 h before detachment 
and stained with an accurate isotype control and the accordant antibody. Measurement was 
done by flow cytometry. If needed, accurate compensation was done.  
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Figure 6: In general, porcine and human MSCs showed a similar set of surface markers (also viability). 
The criteria of the ISCT were fulfilled. In contrast to CD90, CD105 was significantly less presented on porcine 
MSCs, which was further evaluated in Figure 7. CD45+, a typical haematopoietic marker, was not present on 
both species. HLA-DR was found on human MSCs (see Figure 8) but not on porcine MSCs. More comparison 
stainings could not be performed due to the lack of commercially available antibodies for porcine cells. Statistics: 
two-way ANOVA. 
The positive markers CD90 and CD105 showed strong expression in both species in 
contrast to the pan-leukocyte marker CD45, which was not measurable in any species. 
HLA-DR could be detected on human MSCs but not on porcine MSCs. The presentation of 
this surface protein was quite different between the human donors (see also Figure 8) 
resulting in high standard deviations between the batches. Interestingly, a small sub-
population of CD105 negative porcine cells showing no expression could be identified. 
Further negative sub-populations could not be observed for any other surface marker. 
Results 
 
 
 
 
 58 
Figure 7: In contrast to other positive MSC markers like CD90 (A), a small sub-population of CD105 
negative porcine MSCs (B) could be observed (see arrow). The porcine MSCs showed a single population 
overlapping with the isotype control. A second population of positive cells could be discriminated. 
Beyond the markers that were available for both species, an additional panel of antibodies 
was tested  (Table 14) to assure the MSC surface profile based on publications and known 
markers for other cell types (see 1.2 and 8.1 for more details). 
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Table 14: Here, a detailed list of all measured, present and absent marker of both species is shown (as 
well as viability in the measured populations). For porcine cells, the variety of commercially available 
antibodies was very low in contrast to human MSCs. Most of the markers were described before (see 1.2). 
Hematopoietic markers e.g. CD45 and CD34 were absent for both species (CD34 could only be measured for 
human MSCs). Statistics: With the exception of batch Porcine 1, all groups are described by their mean value 
and standard deviation. 
Viability / 
Surface Marker 
Porcine 1  
[%] 
Porcine 2-4  
(HSV-TK)  
[%] 
Human 1,3,5 
[%] 
Human 2,4,6 
(HSV-TK) 
[%] 
Dead Cells 2,1 2.4±1.8 3.2±2.1 2.5±1.5 
CD44+ 98.0 99.6±0.4 N/A N/A 
CD90+ 98.5 99.2±0.3 99.1±0.5 99.1±0.1 
CD105+ 91.9 91.7±6.3 99.0±0.2 98.6±0.9 
CD29+ 98.5 99.3±0.1 N/A N/A 
CD45+ 1.9 0.4±0.5 0.5±0.5 1.5±1.3 
CD34+ N/A N/A 0.3±0.3 1.6±2.8 
HLA-DR+  
(MHC II) 
0.2 1.0±0.4 24.5±9.6 20.1±10.3 
CD73+ 
N/A N/A 
98.8±0.4 98.8±0.7 
CD235a+ 1.0±0.7 0,3±0.4 
CD3+ 0.5±0.4 0.1±0.1 
CD14+ 0.3±0.3 1.2±2.1 
CD19+ 1.0±0.9 0.4±0.4 
CD41+ 5.9±5.0 1.4±0.7 
CD61+ 95.8±4.7 96.4±3.2 
 
 HLA-DR presentation on human MSCs was inducible – not in porcine MSCs 7.2.3
Although the ISCT suggests that MSCs are HLA-DR negative, several publications 
demonstrated the inducible HLA-DR presentation on MSCs (see 1.3). This presentation can 
be induced by addition of pro-inflammatory cytokines and was investigated in addition to the 
ISCT criteria. 
All porcine and human batches were tested for HLA-DR presentation on their cell surface 
with or without stimulation. Cells were seeded in confluence of 10-20% and stimulated with 
IFNγ and TNFα. HLA-DR presentation was measured by flow cytometry.  
Results 
 
 
 
 
 60 
Figure 8: The presence of TNFα and IFNγ induced no up-regulation of HLA-DR on porcine MSCs in 
contrast to human MSCs. MSCs of both species were cultivated w/wo pro-inflammatory cytokines and stained 
for HLA-DR. The naïve and genetically modified batches were grouped. Porcine MSCs did not show any HLA-
DR presentation on their surface whether stimulated or not. Human MSCs increased HLA-DR presentation 
under stimulation significantly. Statistics: two-way ANOVA. 
Figure 8 shows that it was possible to identify HLA-DR on human MSCs in contrast to 
porcine MSCs. All batches of human MSCs showed a HLA-DR presentation whether 
without stimulation (20%) or significantly increased with stimulation (86%). Porcine MSCs 
did not show any reaction. 
 Porcine MSCs differentiated with human stimulation media  7.2.4
The third ISCT criterion is the successful proof of the differentiation potential of the cells. It 
is well-described that MSCs are able to build up lipid vacuoles or to enrich calcium as 
indicators for an adipogenic or osteogenic differentiation (see 1.1). 
The differentiation of the porcine MSCs was conducted with the same protocol that was 
used for human MSCs. Over 14-21 d of induction, the same stimulation media were utilized. 
The cells were stained for liquid, lipophilic droplets with red oil and for enrichment of calcium 
with alizarin red. In addition, control cells were cultured with standard media (6.5 for method 
description).  
It was possible to differentiate porcine MSCs as well as human MSCs following the same 
protocol. All batches cultivated with standard media showed no differentiation. The visual 
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analysis showed differences in the amount of differentiated cells between the lots and 
species. The porcine MSCs were less sensitive than their human counterparts for adipocyte 
stimulation. If the porcine cells were additionally transduced, selected and hence longer 
expanded (Porc1-3 TD), the amount of lipophilic droplets was additionally decreased (see 
Table 15). 
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Figure 9: Both porcine (A) and human (B) MSCs showed an adipogenic lineage potential. Defined 
stimulation media induced the cell differentiation. After 10 d, first fat vacuoles were observed. Not earlier than 
14 d after the start of differentiation, the cells were washed and stained. The reddish colour of the droplets was 
caused by the red oil, which was used to detect the fat vacuoles more easily. The same commercial 
differentiation media were used for both species (the used media were indicated for human MSCs only). The 
human donors generally showed more lipid vacuoles than the pig (see Table 15). The human batch 1 (C) 
showed a significantly higher sensitivity for differentiation because the appearance large fat vacuoles was 
observable. In addition, small vacuoles lined up in a row (see arrows) at the edge of nearly all cells. (D) 
Appropriate controls showed no red oil staining although very small vacuoles could be observed in some 
sections. Scale bar: 250 µm for (A,B,C) and 25 µm for (D) (all sections had the same optical magnification). 
The osteogenic lineage potential was nearly identical in all species and batches and no 
differences could be observed. The homogeneous distribution of calcium enrichments on 
the cells was stained with alizarin red, which enhanced a strong color of the complexed 
Ca2+ Ions. 
A B 
C D 
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Figure 10: Both species (porcine (A), human (B)) showed strong calcium enrichment. No signifcant 
difference between the batches and species could be observed. The porcine MSCs were equivalent to the human 
MSCs in their osteogenic potential with the human stimulation media. (C porcine, D human) Controls for both 
species showed no calcium enrichment if cultivated with the accordant standard media. Scale bar: 250 µm.  
The visual rating of the differentiated cells is shown in Table 15. For adipogenic 
differentiation, three representative sections (approximately 750 µm × 1000 µm) were 
chosen and the amounts of cells that showed fatty vacuoles were counted. This was 
performed three times for each staining.  
 
A B 
C D 
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Table 15: Overview of differentiation potential of both species. All batches were differentiated following the 
same protocol. After differentiation, the populations were fixed, stained and representative sections (~750 µm × 
1000 µm) were counted for differentiated cells. All batches kept their differentitation potential whether 
transduced or not. If the cells were cultured with standard media, no signs of differentation could be observed. 
The porcine cells could be differentiated following the same protocol and same differentiation media designed 
for human MSCs. After the induction time, porcine MSCs generally showed less adipogenic potential than 
human MSCs. Only donor 2 (Human 3 / 4) was as weak as the porcine MSCs. Coloration: red ≥25, orange 15-
25, yellow ≤15. 
Batch 
Cultivation time before 
differentiation start [d] 
Adipogenic 
Stimulation 
Osteogenic 
Stimulation 
Standard 
Culture Media 
(Control) #1 #2 #3 
Porcine 1 10 6 10 8 + 
No 
differentiation. 
Porcine 2 (HSV-TK) 32 7 9 6 + 
Porcine 3 (HSV-TK) 26 6 5 7 + 
Porcine 4 (HSV-TK) 37 4 7 4 + 
Human 1 13 29 32 21 + 
Human 2 (HSV-TK) 23 22 25 19 + 
Human 3 14 24 22 28 + 
Human 4 (HSV-TK) 35 21 24 18 + 
Human 5 20 24 25 21 + 
Human 6 (HSV-TK) 34 26 23 20 + 
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 Doubling time of porcine MSCs was comparable to human MSCs 7.2.5
Based on the cell counts after the first passage and just before cryopreservation, the 
population doubling time for each batch was calculated (see 6.2.6) as an additional 
parameter for comparison.  
Figure 11: The mean population doubling time (PDT) of porcine and human MSCs was comparable. The 
mean PDT of the porcine batches was 62 h and while it was 58 h for the human batches. Obviously, a donor 
dependency could be observed indicating different doubling times for each donor. The porcine batches showed 
a similar population doubling time. Both batches of each donor showed similar population doubling times varying 
fron 30 h to 100 h. Statistics: two-tailed, unpaired t-test. 
Both species showed a mean doubling time of 60 h (mean PDT of porcine batches: 62 h 
and mean PDT of human batches: 58 h). But the doubling time for the human batches 
varied heavily from 30 h to 100 h. If both batches of each donor are depicted, a clustering 
can be observed. It is obvious that the time needed for the production of one batch is 
strongly dependent on the proliferation speed of the donor´s cells. 
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7.3 Insertion of the Therapeutic Gene into Porcine MSCs was 
Controllable and Comparable to Human MSCs 
A SIN-γ-retroviral vector inserted the suicide gene HSV-TK (see Figure 1 for schematic 
description of the inserted transgene). After transduction, the cells were selected using the 
also inserted transgene PAC (regulated by the constitutive promoter PGK). Then, the HSV-
TK expressing population was expanded to generate the desired cell count (see 6.3). 
 Same vector / cell ratios lead to comparable transduction rates 7.3.1
After the first detachment of the freshly procured MSCs, the transduction process was 
started. For this, the SIN-gamma retroviral supernatant with a determined load of viral 
particles was used. 
Based on the titer and the cell count just before transduction, the viral supernatant was 
mixed with the cells suspended in a PLL containing serum-free medium and seeded into 
culture flasks (method A). The chosen viral particle load per cell was three (MOI = 3). The 
other methods B and C differed in the methodological approach (see 6.3 for detailed 
description). 
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Figure 12: Successful transduction was identified by flow cytometry measuring a second population (B) 
in contrast to a single population of naïve cells (A). (A) Naïve cells showed a typical negative population in 
the SS / flourescence plot. (B) The heterogeneous cell population of transduced and naïve cells showed a partial 
shift creating a diffuse second population. Isotype-controlled gating showed more than 46% cells expressing the 
transgene. 
Pro-inflammatory cytokines stimulated the RANTES-regulated transgene cassette to 
increase the HSV-TK expression (see 7.4.2 for induction of RANTES in porcine 
environment). The heterogeneous population of naïve and transduced cells was stained 
with an anti-HA antibody and quantified by flow cytometry (see Table 16). 
Table 16: Different transduction methods led to different transduction rates although the vector / cell 
ratio was equal. Method C and A showed transduction rates that obivoulsy did not differ as much as method B. 
Statistics: none, descriptive only. 
Transduction Rate Porcine 4 Porcine 3 Porcine 2 Human 2 Human 4 Human 6 
Viral Particle / Cell 
Ratio (MOI) 
3 
Transduction Method A B C 
Fraction of  
Transduced Cells [%] 
5 46 3 7 11 3 
 
Method C showed comparable results in regard to transduction rate (see Table 16) and 
VCN (see Figure 13 (A)). If the cells were transduced in suspension (method A), there was 
a slight increase from 3% to 5% in porcine MSCs. If the viral supernatant was centrifuged 
onto PLL containing culture flasks, there was an increase up to 42% (method B). 
The vector copy number was determined by real-time PCR (see 6.8.3) after the selection of 
the transduced population (see Figure 13). 
naive ind
pMSC 0008 TD 1 11 HAPE vorSel 00006858 002 - Imported
Page 1
[Ungated] FS /  SS
FS
0 200 400 600 800 1000
S
S
0
200
400
600
800
1000
A : 96,86%
Gate Number
All 8.531
A 8.263
[A] HA_PE /  SS
S
S
0
200
400
600
800
1000
HA_PE
100 101 102 103
HSV-TK posit ive : 0,58%
008 TD ind
pMSC 0008 TD 1 11 HAPE vorSel 00006858 002 - Imported
Page 1
[Ungated] FS /  S
FS
0 200 400 600 800 10 0
S
S
A :  97,16%
Gate Number
All 8.528
A 8.286
[A] HA_PE /  SS
S
S
0
200
400
600
800
1000
HA_PE
100 101 102 103
HSV-TK posit ive :  46,85%
A B 
Results 
 
 
 
 
 68 
Figure 13: (A) Transducing MSCs with the same vector/cell ratio and the same method led to comparable 
mean transgene rates in both species. The human batches 2 and 6 had slightly reduced insertion rates, 
whereas Human 4 was quite similar to Porcine 4. (B) If only the method of transduction was changed (same 
vector / cell ratio), the insertion rate varied significantly. Method B showed the highest efficiency while method A 
and C did not show any statistical relevant changes. Statistics: (A) ordinary One-Way ANOVA and (B) ordinary 
Two-Way ANOVA. 
Method C showed no significant difference for both species in all human batches (VCN = 
1.4; 1.7; 1.4) and porcine batch 4 (VCN = 1.8). But method B (VCN = 4.2) differed 
significantly from method A (VCN = 1.4) and C (VCN = 1.7), enabling higher transduction 
rates although the amount of viral vector supernatant was not increased (see Figure 13 (B)). 
  
P
or
ci
ne
 4
 (C
)
H
um
an
 2
 (C
)
H
um
an
 4
 (C
)
H
um
an
 6
 (C
)
0.0
0.5
1.0
1.5
2.0
2.5
m
e
a
n
 t
ra
n
s
g
e
n
e
 i
n
s
e
rt
io
n
s
 p
e
r 
c
e
ll
ns (p=0.10)
ns (p=0.11)
ns (p=0.98)
A B 
Results 
 
 
 
 
 69 
7.4 Human-derived Promoters worked comparably in Porcine 
MSCs 
 Proof of functional human PGK promoters in porcine MSCs 7.4.1
The constitutive PGK promoter is required to work constantly and has to express the PAC 
resistance gene correctly for a successful selection of not-transduced cells. This system 
also has to be functional in the foreign porcine cell if a model system is to be applicable. 
Puromycin was given into the cultivation medium obviously killing the not-transduced 
population (see Figure 14). After 24 to 48 h, the selection process started since the 
accumulation of spherical cells in the supernatant could be observed. The majority of cells 
was depleted from the plastic surface and only small numbers of adherent were still visible 
(see Figure 14). Five days later, the medium was completely changed and all non-adherent 
cells were depleted. Now, the remaining cells started to proliferate again in the standard 
medium without the selection agent puromycin and a cell growth could be observed clearly. 
Figure 14: (A) The selection by puromycin killed most of the adherent cells visible as detached, spheric 
units. (B) As soon as the selection medium was depleted and a standard medium was given into the culture, the 
MSCs started to proliferate again, indicated by small, not flattened cells. Scale bar: 250 µm.  
Proliferating cells were identified by a small, less flattened and less fibroblast-like 
morphology, showing a fast increase in the number of cells in the surrounding area the 
following days (Figure 14 B).  
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The selection procedure was verified by flow cytometry as shown in Figure 15. HA-tag 
staining was performed and measured as described before (see 6.6.2).  
Figure 15: (A) Naïve porcine cells showed a typical population distribution in the flourescence / SS 
depiction. (B) After transduction and selection without RANTES activation, background expression of the not 
induced promoter was detectable (37%). Here, the cells distributed on both sides of the gate. (C) If pro-
inflammatory cytokines were given into the medium, a single population of porcine HSV-TK expressing cells was 
identified. 
No second population could be observed during measurement indicating a complete 
selection process (see Figure 15 (C)). The corresponding control of naïve cells (A) was 
clearly definable in contrast to positive cells (C). Without any pro-inflammatory activation, 
the population drifted slightly into the positive gate and could almost not be defined against 
the control (B). It can be concluded that the selection was sufficiently effective and 
transduced cells were resistant because the PGK-regulated PAC resistance gene was 
successfully expressed. 
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 Up-Regulation of RANTES in porcine MSCs was feasible 7.4.2
Since RANTES is an inducible promoter, an up-regulation in porcine MSCs should be 
possible. Therefore, the naïve and HSV-TK expressing batches were stained with / without 
a previous pro-inflammatory stimulation and measured by flow cytometry. The geometric 
mean of the fluorescence-emitting population was normalized to the corresponding naïve 
cells of the batch.  
Figure 16: Stimulation of the human RANTES promoter with pro-inflammatory cytokines led to increased 
HSV-TK expression in both species. Although the RANTES promoter was isolated from human cells, it 
showed functionality in porcine MSCs. Slight background expression was detectable in both species in 
comparison to naïve cells as the negative control. Statistics: paired t-test for columns A/B and C/D and Welch´s 
test (unpaired t-test, non-equal stdv) for the comparison of porcine to human batches. 
Background expression without any pro-inflammatory activation could be measured for 
porcine MSCs (0.4-fold increased expression) as well as for human MSCs (0.3-fold 
increased expression). Although the RANTES promoter was isolated from human cells, it 
also worked in the porcine MSC with inflammatory activation (1.4 fold increased 
expression). The up-regulation in human MSCs (2.2 fold increased expression) was even 
stronger compared to porcine MSCs although it showed a larger variance. 
 Porcine HSV-TK expressing cells showed higher sensitivity to ganciclovir 7.4.3
GCV is a prodrug and highly activated by viral kinases. HSV-TK expressing cells should be 
more sensitive to GCV than naïve cells (as described before 1.6). The HSV-TK expressing 
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cell should become apoptotic under treatment with GCV, which then leads to cell death if 
the enzyme is working properly. 
To determine the GCV sensitivity of naïve and HSV-TK expressing batches, the cells were 
seeded in 96-well plates and exposed to different, logarithmically distributed GCV 
concentrations. After five days, the substrate tetrazolium dye MTT (see 6.7.1) was given 
into the medium. The more living cells were available, the more formazan was synthesized. 
After a defined incubation time, photometric measurement allowed the quantification of and 
a comparison between the naïve and HSV-TK expressing batches. All batches and the cell 
lines HT1080 and K67 were quantified for their GCV sensitivity represented in the amount 
of absorption by formazan. 
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Figure 17: Porcine (A) and human MSCs (B-D) expressing HSV-TK showed a higher sensitivity to GCV 
than their naïve counterpart. Increasing the GCV concentration in a logarithmic scale showed an earlier effect 
on transduced MSCs, decreasing the amount of living cells. The cell line HT1080 and the porcine cell line K67 
did show a GCV sensitivity profile (E) like naïve MSCs. Statistics: nonlinear regression (dose response 
inhibition), goodness of fit for each figure A-E: R>0.9.  
To determine the sensitivity, the half-maximal efficacy concentration (EC50) was calculated 
based on the approximation for a dose response inhibition (see Figure 17). The response 
curves showed that HSV-TK expressing MSCs were more sensitive to GCV than their naïve 
counterpart and naïve cell lines. The resulting EC50 values are shown in Figure 19. 
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Figure 18: The EC50 (half-maximal effectivity of GCV) of all non-transduced MSCs and cell lines were 
more than 100-fold lower than HSV-TK expressing cells. The porcine cells showed sensitivity differences of 
nearly 1000-fold. Statistics: standard deviation bases on the 95% confidence interval of the nonlinear regression.  
The EC50 value of HSV-TK expressing porcine MSCs lay between 0.2 µM and 0.7 µM, 
whereas the naïve batch was measured with more than 500 µM GCV, which represents a 
sensitivity that was 1000-fold higher. The naïve human batches showed differences in the 
GCV sensitivity between 67 µM and 1400 µM while the transduced batches were in the 
range of 0.5 µM to 1.1 µM – a more than 100-fold higher sensitivity. The cell lines were only 
slightly more sensitive than the naïve batches with 109 µM to 163 µM GCV. 
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7.5 Porcine MSCs showed the same Mode of Action under GCV 
Treatment 
In 7.4 it was successfully shown that the insertion of the transgene was successful and 
quantifiable. Also, the functionality of the selection cassette PGK-PAC and the inducible 
RANTES promoter could be shown. In this section (7.5), the apoptosis as an effect pathway 
due to the treatment is to be characterized and compared between the species. 
 Activated GCV initiated the apoptotic cascade in both species in a comparable 7.5.1
manner 
As introduced before (see 1.6), there are several kinds of cell death that could end the cells’ 
life cycles: necrosis, autophagy, mitotic catastrophe and apoptosis. In contrast to others, 
apoptosis is a self-regulated cell death initiated by internal (e.g. DNA damage) or external 
signals (e.g. FAS activation). The apoptotic death of a cell is complex and the process is 
characterized by different changes: morphological alteration into spherical and granular 
cells, detachment, appearance of phosphatidylserine (PS) on the surface and loss of the 
cells’ integrity making it possible for dyes to get into the cell and stain the DNA (e.g. 7-AAD).  
Here, the characterization of the apoptotic pathway initiated by GCV in human and porcine 
HSV-TK expressing MSCs was investigated. All batches were seeded and treated with pro-
inflammatory cytokines on day two and GCV on day two, three and four. GCV was added in 
a concentration of 25 µM. This value was chosen based on the results generated in 7.4.3. 
The highest sensitivity to GCV showed the batch Human 5 with an EC50 value 64 µM. 
Therefore, the chosen concentration was less than half the EC50 value of Human 5. 
On day five, the cells were harvested and stained with Annexin-V as apoptotic marker as 
well as 7-AAD as dead marker. The cells were counted and analyzed regarding 
morphological and membrane surface changes through flow cytometry.  
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Figure 19: (A) Naïve porcine MSCs did not react with massive apoptosis if GCV was added to the 
medium. The naïve cells showed good adherence and only occasional deatchment was visible although GCV 
was present. (B) The treatment of HSV-TK expressing MSCs with GCV led to a massive accumulation of cells 
and cell debris in the supernatant, which could be seen on day five. (C) Depleting the medium only occasionally 
showed adherent cells. Scale bar: 250 µm. 
Throughout the treatment, the visual analysis showed no effects on naïve MSCs because 
only single cells were in the supernatant. In contrast, the majority of HSV-TK expressing 
cells detached already one day after the start of the treatment. A massive congregation of 
cells and cell debris could be observed, which accumulated in the supernatant. Depleting 
these cells by changing the cultivation medium showed that nearly no adherent cells were 
on the surface. Some cells still attached to the plastic although they partially showed signs 
of apoptosis due to their spherical morphology. 
To determine the inhibitory effects of the pro-inflammatory cytokines and GCV, cell counts 
were performed after five days of cultivation and three days of treatment. The treated naïve 
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and HSV-TK expressing cells were compared to their non-treated controls considering the 
proliferation capacity over five days. The cell count differences between standard cultured 
cells and treated cells were calculated and are shown in Figure 20.  
Figure 20: The treatment (pro-inflammatory cytokines + GCV) of HSV-TK expressing cells showed 
significant reduction in cell proliferation in contrast to also treated naïve cells. All groups were additionally 
cultivated without treatment as negative control. At the end of the assay, the cell counts of the treated groups 
were normalized to the negative control and the reduction was calculated. Both species showed a comparable 
percentage of killed cells during treatment for HSV-TK expressing and naïve cells. Statistics: paired t-test for 
columns Porcine 1 / Porcine 2-4 (HSV-TK) and Human 1,3,5 / Human 2,4,6 (HSV-TK) and Welch´s test 
(unpaired t-test, non-equal stdv) for the comparison of porcine to human batches. 
The cell count reduction of porcine (-3.34 fold) and human (-2.75) HSV-TK expressing 
MSCs did not differ significantly and was therefore comparable. In both species, the 
reduction of HSV-TK expressing cells is significantly higher than their naïve counterpart 
(porcine: -0.74 and human: -0.6). The alterations by apoptosis are characterized by a 
reduction of the cell´s size, a change of its surface profile and a loss of the cell´s integrity. 
As shown in Figure 19, the death of cells corresponded with a small and spherical 
morphology and the loss of adherence to the plastic surface. To give a clear proof of an 
apoptotic pathway for porcine MSCs, the cells were analyzed through flow cytometry. For 
this, all batches were seeded, cultured and treated with GCV as described before (see 
6.7.2). On day five, the supernatant and the cells were harvested, stained with Annexin-V 
and 7-AAD and measured by flow cytometry. 
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Figure 21: GCV-treated, HSV-TK expressing porcine MSCs in contrast to non-treated MSCs: 
Morphological changes correlated with different stages of apoptosis. (A) Non-treated MSCs were 
characterized by one population in the FS / SS plot. (B) If this population was stained for 7-AAD and Annexin-V, 
a slight drift to Annexin-V positive cells was observable. Very small amounts of cells were 7-AAD positive 
indicating dead cells. (C) Since no further populations were visible, the gating showed no cells. (D) Treatment of 
HSV-TK expressing cells generated a second, smaller but more granular population in the FS / SS plot. (E) 
Staining with 7-AAD and Annexin-V for cells gated on the “normal population“ showed mainly Annexin-V positive 
cells and a smaller Annexin-V and 7-AAD negative population indicating living cells. 7-AAD cells were increased 
if compared to the amount of 7-AAD in (B). (F) Gating on the smaller and more granular population (here 
“shrunken population“) showed that nearly all cells were 7-AAD and Annexin-V positive. A smaller sub-
population was Annexin-V positive only. 
Figure 21 shows that morphological changes correlated with different stages of apoptosis. 
One population in the FS / SS plot, a small amount of Annexin-V positive and a very small 
amount of 7-AAD cells characterized non-treated MSCs. If these HSV-TK expressing cells 
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were treated with GCV after promoter induction, a significant change in the morphology 
could be seen. The cells started to become smaller and showed more granularity. These 
shrunken cells were positive for Annexin-V and 7-AAD, which is typical for late-apoptotic 
cells. In contrast to necrosis, a population with Annexin-V positive and 7-AAD negative cells 
indicated an apoptotic pathway. 
Figure 22: Porcine and human HSV-TK expressing MSCs became smaller and more granular if they were 
treated with pro-inflammatory cytokines and GCV. In this figure, the distributions of the cells in the FS / SS 
are summarized for all batches after treatment following the gating strategy of Figure 21. Naïve cells of both 
species primarily showed a normal morphology in the FS / SS with more than 80% in the “normal population” 
gate in spite of the treatment. HSV-TK expressing MSCs showed a change to more granular and smaller cells. 
Human HSV-TK MSCs showed about 30% of shrunken cells but porcine HSV-TK MSCs showed up to 70% of 
shrunken cells. Statistics: two-way ANOVA; following comparisons did not show a significant difference: Porcine 
1 and Human 1,3,5 for normal and shrunken population (p=0.34 and p=0.56); Human 1,3,5 and Human 2,4,6 for 
shrunken population (p=0.05). All other comparisons did show a significant difference (p<0.05). 
Figure 22 describes the drift in the morphology induced by GCV treatment for all batches. 
93% of porcine and 82% of human naïve cells showed no change in morphology despite of 
the treatment. The amount of shrunken cells was 5% for porcine and 14% for human naïve 
cells. If the treated cells expressed HSV-TK, the percentage in the “shrunken population” 
gate increased: human MSCs showed 31%, porcine MSCs even 74% of shrunken cells. 
Besides cell count reduction and morphological change, the surface profile changed during 
apoptosis. These observations were quantified for Annexin-V and for 7-AAD in Figure 23. 
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Figure 23: (A) Annexin-V stains phosphatidylserine as apoptotic marker and was significantly higher 
presented on HSV-TK expressing MSCs under treatment. All naïve and HSV-TK expressing batches were 
cultured with or without treatment on day three, four and five. On day five, the cells were detached and stained 
with Annexin-V. In contrast to naïve cells under treatment, the increase in Annexin-V for all HSV-TK expressing 
batches was significant. If naïve cells were treated, they showed a trend to be more Annexin-V positive although 
this was not statistically significant. (B) HSV-TK expressing cells showed also a statistically significant shift to 7-
AAD. All batches were treated the same way as described in section 7.5. Here, only Annexin-V positive cells 
were gated for 7-AAD following the described gating strategy (see Figure 21). This increase was statistically 
significant only in porcine cells. Human MSCs expressing HSV-TK showed the tendency to be more 7-AAD 
positive, which cannot be confirmed statistically (p=0.23). Statistics: two-way ANOVA. 
All batches were cultured in standard media and compared to cultivation in standard media 
with treatment (see Figure 23). There were no significant differences between treated or 
non-treated naïve cells in both species. If HSV-TK MSCs were treated, a significant up-
regulation of phosphatidylserine could be detected. Non-treated HSV-TK MSCs served as 
control. 
The amount of 7-AAD as well as Annexin-V positive cells increased under treatment. 
Porcine HSV-TK expressing MSCs differed significantly from the corresponding control of 
naïve cells showing more dead cells than under standard treatment. Human HSV-TK 
expressing MSCs did not show a significant increase (p=0.23).  
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 Population doubling time correlated with the efficacy of HSV-TK induced cell 7.5.2
death 
It was examined whether the population doubling time correlated with the amount of killed 
cells or not. Therefore, the same protocol as described before (see 6.7.2) was used and the 
proliferation during the assay was calculated based on two cell counts: at the beginning and 
the end of the assay. The amount of killed cells was normalized to the amount of living cells 
in the corresponding control culture without any treatment. The normalization was 
necessary to facilitate a comparison because all batches had highly varying population 
doubling times. Figure 24 shows that a correlation between the proliferation speed and the 
amount of killed cells was probable (R2=0.92). 
 
Figure 24: The growth speed of a population correlated with the reduction of cells due to GCV-initiated 
apoptosis. All HSV-TK expressing batches were counted before seeding and after cultivation in the standard 
medium (after harvest). This growth is described by percentage in the horizontal axis. All HSV-TK expressing 
batches were treated over five days. The amount of killed cells of each batch was normalized to the seeded cells 
cultivated in the standard medium. Irrespective of the species, the killing efficacy correlated with the growing 
speed of a population. Statistics: linear regression, R
2
=0.92. 
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7.6 Proof of a Therapeutic Effect in vitro for Porcine MSCs 
The most important aim of providing a valid model system is furnishing proof of a 
comparable potency. The therapeutic effect - the bystander killing with activated GCV - 
must initiate the apoptosis in MSCs as well as in the target tumor cells in both species. 
 Inter species killing: porcine and human HSV-TK MSCs killed human cell line 7.6.1
(HT1080) and porcine cell line (K67) 
The most critical parameter in this suicide gene system is the killing of the target cells. The 
intended bystander killing was realized in vitro by co-cultivation of HSV-TK MSCs and the 
target cell line following the protocol as described in 6.7.3. In short, cells were seeded 
equally and treated with pro-inflammatory cytokines and GCV. After detachment, the cells 
were counted in accordance to 6.2.4. All cells were stained with Annexin-V and 7-AAD and 
measured by flow cytometry. The GFP expression of the cell lines allowed discrimination 
between the cell lines and MSCs during flow cytometry.  
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Figure 25: Porcine and human HSV-TK MSCs reduced the amount of the porcine and the human cell line 
during co-cultivation and treatment. (A) If HT1080 were co-cultivated with naïve cells, no significant shifts 
could be observed between porcine and human cells. But there were less HT1080 cells present in the 
population if cultivated with porcine cells. The killing of HT1080 cells by both species was comparable. (B) K67, 
the porcine cell line, was killed by both species with the same efficacy. In contrast to naïve porcine MSCs, the 
naïve human cells also showed anti-proliferating effects: the batch Human 5 and, partially, Human 1 showed an 
inhibition of the proliferation since less than 50% K67 cells were left after treatment although no HSV-TK 
expressing cells were present. This effect was species-specific as no similar observations could be made if co-
cultivated with naïve porcine MSCs. Statistics: ordinary one-way ANOVA for each graph, referring to first column 
in graph A and to second column in graph B. 
HSV-TK expressing MSCs of both species killed the human HT1080 and the porcine cell 
line K67 in a comparable manner (see Figure 25). Human and porcine naïve cells did not 
show a significant difference in the amount of HT1080 cells during co-cultivation. Batches 
that expressed HSV-TK killed significantly more cells than their naïve counterparts. Here, 
both species showed the same mean of 22% remaining cells of the cell line HT1080.  
The amount of K67 cells was highly varying if co-cultured with naïve human cells. Measured 
values ranged from 21% to 76%. In presence of porcine naïve cells, the percentage of K67 
was 59%. This effect was annihilated if HSV-TK expressing MSCs were present. Then, the 
percentage share of K67 was reduced to less than 20% for both species. Here, porcine 
HSV-TK MSCs were able to kill the human and porcine cell line HT1080 and K67 in a 
comparable manner during co-cultivation.  
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 Both species induced the apoptotic cascade in co-cultivated cell lines 7.6.2
The Killing of cells is the main goal of a suicide gene system. If the cytostatic agent induced 
cell death in the neighboring cells, an apoptotic pathway should be traceable. Therefore, the 
cells´ apoptotic reaction as described in 7.5.1 was examined.  
Figure 26: MSCs of both species induced the apoptotic cascade in HT1080 as shown by a simultaneos 
increase of Annexin-V and 7-AAD. (A) Naïve porcine or human MSCs did not induce any significant increase 
of Annexin-V or 7-AAD in HT1080 cells. HT1080 cells in mono-cultivation served as control. HSV-TK expressing 
human and porcine MSCs raised the mean percentage of Annexin-V positive HT1080 to 93% respectively 88%. 
(B) Also, the amount of 7-AAD positive cells increased in the presence of HSV-TK expressing MSCs. Human 
HSV-TK expressing MSCs did not induce a statistically significant increase (p=0.06). Porcine HSV-TK 
expressing MSCs caused an accumulation of 7-AAD positive cells of 40%. Statistics: two-way ANOVA.  
Following the five day protocol as described before (see 6.7.3), all batches were co-
cultivated with each cell line.  
The presence of HSV-TK MSCs of both species caused a high increase of Annexin-V 
positive cells in contrast to naïve cells (see Figure 26). If naïve cells were co-cultivated, less 
than 15% of all HT1080 cells were positive for Annexin-V. The bystander effect induced 
more than 85% of all cells to be positive for Annexin-V. The same observations were also 
true for 7-AAD. Although the human batches 2, 4 and 6 did not increase the amount of 7-
AAD positive cells significantly (p=0.06), the porcine batches 2-4 were able to raise 7-AAD 
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positive HT1080 to 40%. This was significant in contrast to porcine naïve cells. HT1080 
showed an apoptotic character if treated while HSV-TK expressing MSCs were present. 
Figure 27: As well as HT1080, K67 cells were killed by in an apoptotic mode of action by both species. 
(A) Annexin-V was significantly increased for HSV-TK expressing, porcine and human MSCs. But also naïve 
human MSCs showed an increase of Annexin-V positive K67 cells in contrast to naïve porcine MSCs. This effect 
differed significantly from HSV-TK expressing human MSCs. (B) 7-AAD was increased, too, although it was 
overall lower than observed for HT1080. Statistics: two-way ANOVA. 
In the case of K67 (see Figure 27), the results differed from those with HT1080 co-
cultivation (see Figure 26). Basically, the target cell line in mono-cultivation or co-cultured 
with porcine naïve cells showed about 20% of Annexin-V positive K67 if GCV was added. 
Human naïve cells raised this percentage share significantly to 47%. If the treatment was 
done while HSV-TK expressing cells were present, the Annexin-V positive percentage 
share was additionally increased to 79% for both species.  
These results could not be observed for 7-AAD on a statistical basis. Here, human naïve 
cells did not induce a significant increase from mono-cultivation K67 (3% 7-AAD positive) to 
K67 co-cultivated with human naïve cells (7% 7-AAD positive). A relevant increase could be 
observed if HSV-TK expressing MSCs were present: the human batches 2, 4 and 6 showed 
13% and the porcine batches 2-4 16% of 7-AAD positive cells. As well as HT1080, the 
porcine cell line K67 showed the same mode of action following the apoptotic cascade. 
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7.7 Experimental in vivo Studies: Biodistribution of intravenously 
infused MSCs in the Mini-Pig 
The systematic in vitro comparison of porcine and human MSCs was used to allow an in 
vivo approach to assess the biodistribution of the cells in the mini-pig. After administration of 
a determined amount of cells, blood and tissue samples were collected. The DNA of 
peripheral MNCs were isolated and analyzed by real-time PCR. Furthermore, an 
immunohistochemically analysis of representative tissues should be done. 
 Freshly thawed MSCs were stable for 90 min in the cryopreservation medium 7.7.1
All used batches for the in vivo studies were cryopreserved after having been produced 
successfully as described before (see Figure 2). Before the cells were administered, they 
had to be thawed, counted, formulated and filled into the syringe under aseptic conditions. 
Afterwards, the cells were transported to the pigs and infused. This preparation needed time 
and the thawed cells were exposed to the DMSO-containing cryopreservation medium at 
ambient temperature. Due to the DMSO in the medium and the lack of nutrition and plastic 
adherence, the cells became impaired over time. The procedure described here is also 
relevant for a setting in clinical trials with human cell-based products. 
To assure that most of the administered cells were functional, a kinetic considering possible 
impairment was performed. For this, one vial of each batch was thawed, counted and left in 
the accordant cryopreservation medium at ambient temperature (see Table 3). Every 
30 min, a defined amount of cells was sampled and seeded with an equal confluence of 
20±10%. The latest seed-out was performed 180 min after thawing. After four days, all 
batches were harvested and counted (see Figure 28). This approach was chosen to 
simulate the protocol of thawing and preparing the MSCs for infusion at the study site.  
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Figure 28: Porcine MSCs (A) and Human MSCs (B) showed no significant reduction in proliferation if 
they stayed in the cryopreservation medium for 120 min (A) or respectively 90 min (B) after thawing. On 
day one, one vial of each batch was thawed and left for 180 min in the cryropreservation medium. A defined 
amount of cells was sowed out in triplicates every 30 min. After four days, all wells were harvested and counted. 
(A) Porcine MSCs showed a significantly reduced amount of cells, if the cells were left for 150 min. Human 
MSCs already showed a significant difference after 120 min in contrast to the same amount of cells, which were 
sowed out immediately after thawing. Statistics: one-way ANOVA (all data were compared to point in time 
0 min). 
Porcine MSCs did not show any impairment if they were left in the medium for 90 min. After 
120 min, a slight trend could be observed although it was not statistically significant 
(p=0.71). After 150 min the harvest differed from the harvest at 0 min which indicated 
impairment. The harvest at 180 min confirmed the previous result. Human MSCs seemed to 
be more sensitive to the lack of nutrition, adherence and the exposure to DMSO. After 
90 min, the cell yield became lower (p=0.21) and differed significantly after 120 min. 
Following harvests confirmed this impairment with even lower yields. 
During the in vivo studies, all infusions were performed in less than 90 min (animal #1: 
62 min and animal #2: 51 min). 
 Intravenously infused MSCs were detectable in the peripheral blood stream 7.7.2
The aim of the in vivo studies was to perform a protocol in accordance to ethical and 
scientific demands. Therefore, the protocol was designed in close collaboration with the 
responsible veterinarian. Due to the limited stability of the cells (see Figure 28), the 
narcotization and surgery of the animal were performed simultaneously with the preparation 
of the cells. 
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Table 17: This table shows all relevant facts about the pigs and the cells used for the biodistribution 
study. Two clinically healthy mini-pigs were chosen for the study. Two intravenous catheters were implanted 
into each pig to seperately inject the cells into the jugularis vein and aspirate blood samples from the ear vein 
(see Figure 29). After positive results were generated in the first animal (see Figure 30), the amount of blood 
samples was increased and the second animal´s life-time was expanded to five days. After three, respectively 
five days, the pigs were euthanized and necropsied at the Institut für Tierpathologie der Ludwig-Maximilians-
Universität München.  
Animal Gender 
Weight 
[kg] 
Infused 
Cells 
Quality 
check 
Amount 
of cells 
Injected 
[×10
6
] 
Dosage: 
MSCs /kg 
Bodyweight 
[×10
6
 / kg] 
Day of necropsy 
after 
Cell Infusion [d] 
#1 
male 
82 
HSV-TK 
expressing, 
isogenetic, 
porcine 
MSCs 
fulfilling 
ISCT  
criteria 
(see 7.2) 
422 5,1 3 
#2 58 343 5,9 5 
 
All cells were infused in less than 90 min after thawing. The infusion lasted one to three min 
and the catheter was washed with PBS to reduce cell residues in the tube. All details are 
listed in Table 17.  
Immediately after the completion of the infusion, the first blood sample was taken followed 
by sequential aspirations in the first hour. The next aspiration was performed 6 h after the 
infusion. 
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Figure 29: (A) Blood samples were aspirated through a peripheral venous catheter, which was implanted 
into an ear vein (see arrow). (B) The cells were infused into the jugularis vein by a catheter that was fixed at 
the nape to reduce possible damage by the pigs´ movement after waking up. (C) A sleep-inducing drug was 
injected to allow the correct placement of the intravenous access and to reduce the stress for the animal. The 
sleeping agent´s activity lasted for about two to four hours until the pigs woke up again. This immobilization 
allowed for a simplified blood sampling during the first hour of infusion. From day two on, the blood sample 
counts were deliberately low. Otherwise, the stress for the animals would have been too high. On day three, 
respectively five, the animals were euthanized in the Institut für Tierpathologie der Ludwig-Maximilians-
Universität München and pathologically examined.  
The blood was directly aspirated into vacutainers, stored at room temperature and brought 
back to the laboratory on the same day. The Isolation of DNA was performed in accordance 
to the isolation protocol of blood samples, in short: lysis of thrombo- and erythrozytes with a 
hypotonic buffer, centrifugation of mononuclear cells and the start of DNA isolation with 
accordant solutions (following protocols 6.8). The eluted DNA was solved in TRIS-buffered 
water. Samples of these DNA-containing solutions were amplified by real-time PCR.  
The resulting CT-value was regressed to a defined amount of DNA copies (considering a 
standard curve). This number of copies correlated with an extrapolated value of MSCs per 
mL blood. This extrapolation considered the following aspects: blood sample size, real-time 
PCR sample size and DNA loss due to the isolation and washing procedure. Also, the real-
time PCR method had a specified sensitivity resulting in a defined detection limit of 
approximately 5-10 copies. The amounts of cells identified in the blood of both pigs are 
described in Figure 30 and Figure 31.  
A B C 
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Figure 30; Pig 1: Intravenously administered cells could be detected in the peripheral blood stream by 
accurate isolation and quantification through real-time PCR. Pig 1 received a dosage of 5.1x10
6
 MSCs / kg 
bodyweight. Blood samples were aspirated at different points in time before and after injection. The detection 
limit of the method was 450 MSCs per mL due to the preparation of the sample for measurement. Assuming an 
even distribution of all cells in the blood stream, the maximal expectation would be about 22,000 MSCs per mL 
blood (supposing 6% blood volume / bodyweight). MSCs could be identified at 2 min and 6 min after infusion. In 
the following minutes to hours, infrequent signals could be detected. In the end, a strong signal could be 
identified after 30 h. Statistics: none, descriptive only; three analysis (each consisting of five measurement) are 
depicted. 
Figure 31, Pig 2: In contrast to pig 1, no significant consistent signals could be detected in the 
peripheral blood. Pig 2 received a dosage of 5.9 × 10
6
 MSCs / bodyweight. Although the dosage was 
increased, only signals next or under the detection limit were identified. At no point in time the measured signals 
were higher than the detection limit. Statistics: none, descriptive only; three analysis (each consisting of five 
measurement) are depicted. 
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Immediately before and after infusion, no signals were detected in pig 1. After 2 min, MSCs 
could be identified. This signal was confirmed at 6 min, 20 min and 6 h, although there were 
less MSCs present in the sample. 30 h after infusion, a single strong signal could be 
identified which was not confirmed at 48 h.  
In contrast to these results, no consistent signals above the detection limit could be 
detected in pig 2 although the dosage per kg bodyweight for this pig was increased. As a 
consequence of the results from pig 1, it was possible to manage more blood sample points 
in collaboration with the veterinarian at around 30 h: at 29 h and at 31 h. Also the life-time of 
the animal was expanded from three days to five days to see if the MSC presence from pig 
1 at 30 h would occur to a later point in time in pig 2. No signals could be detected on day 3, 
4 or 5. 
 Pathological report showed pneumonia in pig 2 7.7.3
On day three, respectively day five, the animals were narcotized in the stable and brought 
to the Institut für Tierpathologie der Ludwig-Maximilians-Universität München. In the 
institute of veterinarian pathology, the last blood sample was taken before the pigs were put 
down to sleep. The weight of the pigs was measured and the dissection was performed. 
Table 18: At the end of the life-time, both animals were necropsied for histo-pathological examination. 
The main anatomical and histological findings and the final pathological expertise are described in the table. Pig 
1 showed a pericarditis and pig 2 showed a high-grade pneumonia and a chronic gastritis. During the study, no 
clinical observations by the responsible veterinarian (member of the Institut für Molekulare Tierzucht und 
Biotechnologie der Ludwig-Maximilians-Universität München) were noticeable. The pathological and histological 
assessment was performed by members of the Institut für Tierpathologie der Ludwig-Maximilians-Universität 
München. 
Mini-
Pig 
Clinical 
Observation 
Anatomical / 
Pathological 
Observations 
Histological  
Findings 
Final Pathological 
Expertise 
#1 
No clinical 
observations 
-well-fed 
-calcification of 
the aorta 
-Pericarditis 
- heart: Pericarditis 
- lung: weak binding of the bronchus-associated 
lymphoid tissue (BALT); light lympho-cellular infiltration  
-spleen: multi-focal proof of eosinophilic granulocytes 
-lymph nodes: slight hyperplasia 
-liver: no findings 
-Fibrotic Epi- and 
Pericarditis 
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Mini-
Pig 
Clinical 
Observation 
Anatomical / 
Pathological 
Observations 
Histological  
Findings 
Final Pathological 
Expertise 
#2 
No clinical 
observations 
-well-fed 
-lung: moderate, interstitial pneumonia with high-grade 
activation of BALT 
-stomach: high-grade, chronic follicular gastritis 
-lymph nodes: moderate hyperplasia 
-liver: slight lympho-cellular infiltrations 
-kidneys: slight lympho-cellular infiltrations 
-Interstitial 
Pneumonia 
-Chronic Gastritis 
 
Besides the observations during the dissection, tissue samples were fixed in formalin and 
embedded in paraffin. A pathologist analyzed these sections. A confirmed pericarditis was 
identified in pig 1 as well as slight inflammatory findings regarding lymph nodes, spleen and 
lung. Pig 2 showed an interstitial pneumonia and also a chronic gastritis. This inflammatory 
process is also reflected in the hyperplasia of the lymph nodes. 
 Immunohistochemically analysis showed MSCs in lung and spleen 7.7.4
The generated tissue samples of lung, liver and spleen were analyzed by 
immunohistochemically staining. The workup and the staining of the tissues are described 
in 6.9.2. In short, the FFPE tissue blocks were sliced into several sections, deparaffinized, 
stained with an Anti-HA antibody or an appropriate isotype control and fixed before 
microscopy. The sections were visually analyzed and the brownish-red stained cells (HA-
tag positive) MSCs were counted.  
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Figure 32: Anti HA-tag immunohistochemistry detected HSV-TK expressing MSCs in spleen (A; animal 1) 
and lung (B, animal 2); identifiable by a brownish colour (see arrow). Lung, spleen and liver of both animals 
were sent into an external laboratory for immunohistochemical examination. Several histo-pathological sections 
were analyzed to detect any MSCs in the tissues in question (see Table 19). In addition, three tissue samples of 
a mini-pig that received no MSCs were sent as control, too. As a second negative control, all stainings were 
compared to an appropriate antibody isotype (C, D). 
The recognition of MSCs was simple due to the brownish-red colour. Appropriate isotype 
control from directly neighboured slices showed no MSCs as well as no artefact staining 
proven by MSC-free tissue sections. 
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Table 19: The immunohistochemical analysis of lung, spleen and liver showed MSCs in both animals. 
Several sections were analyzed before MSC-positive slices were identified. The number of sections represents 
the count which was positive for MSCs. Pig 1 showed MSCs in lung and spleen. Pig 2 showed MSCs in the lung 
only.  
Animal 
Lung Spleen Liver 
MSCs 
 in total  
Number of 
Sections 
MSCs 
 in total 
Number of 
Sections 
MSCs 
 in total 
Number of 
Sections 
Pig 1 4 2 1 1 0 1 
Pig 2 4 2 0 1 0 2 
Pig 3 
(Control, 
no MSCs infused) 
0 1 0 1 0 1 
 
In Table 19, the number of MSCs identified by histological staining is shown. The amount of 
MSCs in the tissue was relatively small because in two sections of pig 1 four HA-tag 
positive cells could be identified. In two sections of pig 2, four MSCs were identified. 
Additionally in pig 1, one MSC was identified in the spleen. In all other sections, no MSCs 
could be found. Figure 32 shows the detection of MSCs in the tissue. The appropriate 
isotype control of the directly neighboured slice is shown, too.  
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8 Discussion 
8.1 The Identity of Humans´ and Pigs´ MSCs – Comparing Apples 
and Oranges? 
The current ISCT approach is not sufficient to determine a defined MSC sub-population with 
the same properties in one population [33]. Secondly, the differences between the tissues 
from which MSCs are isolated and varying cultivation protocols complicate the comparability 
of MSCs generated in different laboratories, or companies [283]. Adding a new species to 
this field – the pig – further increases complexity. Nevertheless, the need for large animal 
models is high since pharmacokinetic and pharmacodynamic questions have to be 
answered to satisfy regulatory [204, 230, 275] and scientific demands [211-213, 220]. For 
that reason, the general approach of this work was to generate as few differences as 
possible between both species while setting up the methods and assays for the isolation, 
the manufacturing of the MSC batches and the evaluation of their therapeutic efficacy in 
vitro (see Figure 2). This was supposed to have the best comparability testing of both 
species regarding the cell therapy product. 
The isolation procedure from the marrow only differed regarding the method of withdrawal 
and the aspirated volume. The iliac crest of the human donors was punctuated while the 
pigs´ femur and tibia were scraped out directly after narcotization. The marrow volume 
procured from each human donor was not larger than 100 mL. The pig´s marrow volume 
was not determined as the whole bone marrow was scraped out. Obviously, a higher 
volume of marrow increases the probability of more progenitor cells being cultivated, in turn 
leading to a higher cell count. Since the volumes of cultivated marrow were different, a 
comparison at this point could not yet be made. Although the amount of marrow was not the 
focus of this work, this objective can be critical for the cell count of a finalized cell drug 
product as marrow aspiration is still a challenge [284, 285]. 
Both marrows were cultivated in 2D culture flasks with serum containing media. The media 
differed because the patented Bio-1 (containing human plasma and platelet lysate) was 
used for human MSCs, while for porcine MSCs on the other hand, a medium containing 
fetal bovine serum was used. Even though both isolations were conducted from bone 
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marrow and cultivated in the same manner, the different sera (platelet lysate / FCS) might 
have a possible impact [286, 287]. As described before, the immunological properties and 
proliferation speed of MSCs are highly affected by present cytokines [31, 40]. That is why 
the population-doubling time was hardly comparable due to the fact that the MCSs were 
cultured in different media (see Figure 11). Also the fact that the marrow of the pigs was 
taken after they were narcotized may have an influence on the cell quality since the 
cessation of oxygen supply may have a negative impact. Thus, well-founded statements 
about the comparability of the population-doubling speed can´t be made easily. 
Nevertheless, it was possible to observer that batches of the same donor had a comparable 
population-doubling time while the doubling times of batches procured from different donors 
seemed to vary Figure 11. Whether this was caused by different used Bio-1 media batches, 
different properties of the donated cells or the quality of the aspirated marrow can´t be 
determined. As different Bio-1 batches were used at different stages of the cultivation 
process for all donor cells, it is likely that this effect is a result of the donors´ cell biology or 
the marrow quality. Moreover, the aspiration technique of the physician can also lead to 
significant variations in the amount of progenitor cells available for seed-out [288]. 
The microscopy observations (as shown in Figure 3, Figure 4 and Figure 5) confirmed the 
expectations of adherent, fibroblast-like cells as MSCs [5]. This could be shown for both 
species without significant differences in a subjective visual evaluation. However, the 
batches Human 3 and 4 that were derived from one donor showed a more flattened 
morphology. This conspicuous size and altered form correlated with a low population-
doubling time (see Figure 11) – an observation already described in other publications 
regarding senescence and ageing [289, 290]. Following this correlation, proliferating cells 
are easily recognized as small, more granular cells, as shown in Figure 14 B. 
Currently, isolating MSC by adherence is the standard procedure because no sole marker 
has been identified yet [31-33], which could be used for cell sorting. The insufficient set of 
surface markers and the ability of the MSCs to show adipogenic or osteogenic properties, 
which are also common in other cell types, weaken the importance of the ISCT approach 
(see chapters 1.1 and 1.2 for a more detailed explanation). Nevertheless, the ISCT 
demands currently are the best practice to identify MSCs in donor tissue. That is why the 
identification of the porcine adherent cells as MSCs was done in the same manner as it is 
described for human MSCs. The same set of antibodies carrying defined fluorophores was 
used for the identification of MSC markers on porcine and human MSCs (see Figure 6). 
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Due to commercial limitations, the choice of antibodies available for staining porcine MSCs 
was relatively small. Anyways, it was possible to obtain relevant antibodies for the 
determination of CD45, CD105 or CD90. Since CD45 is a pan-leukocyte marker, no 
hematopoietic markers were expected in the adherent culture. This could be confirmed for 
both species. Small percentages of positive cells could be observed as a byproduct of the 
flow cytometry method. The presence of non-adherent cells (e.g. monocytes that are 
CD45+) was highly improbable after several trypsin detachments and medium changes. It 
can be concluded that no other cells than MSCs were cultivated for both species. 
Although the whole population of porcine cells was positive for the described marker, a sub-
population did not show CD105. This phenomenon has already been described for murine 
MSCs [263], but, to my best knowledge, not for porcine MSCs (no publications were found). 
Murine, CD105 negative MSCs show functional changes regarding their immunoregulatory 
properties [263]. Immunological properties were not in the focus of this work, so further 
investigation could correlate this partially absent marker on porcine MSCs with 
immunoregulatory changes. However, this drift in the surface profile also confirms the 
heterogeneity of porcine MSCs ex vivo. Comparing the extent of this phenomenon with 
murine MSCs, porcine MSCs (8% negative for CD105, see Figure 7) seem to be more 
similar to humans, since this drift is stronger in murine MSCs (30-40% negative for CD105, 
[263]). The lack of CD105 could potentially indicate other cell functions that were not in the 
focus of this work. It could also be argued, that this was only caused by the ex vivo 
cultivation and is not inherent in in vivo porcine MSCs in the light of the fact that ex vivo 
cultivation can highly affect MSC populations [32, 35]. 
Others of the expressed markers tested for MSCs are described in the relevant publications 
(porcine MSCs: CD29, CD44: [231, 233, 251] and human MSCs: CD73, CD235a [3, 5, 46]). 
Other available markers were tested to assure the absence of those on MSCs. They were 
provided in Table 14 for information only. Although these confirmed the established surface 
profile, CD61 was also found on human MSCs. This is a typical thrombocytes marker in 
combination with CD41. But, CD41 could not be shown on MSCs. In addition, thrombocytes 
are quite small with 2–3 µm and would be apparent in the FS/SS during flow cytometry as 
an extra population. This could not be confirmed. In addition, microscopy showed no further 
cells (see Figure 4 and Figure 5), eliminating the possibility of any thrombocytes being 
present. 
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HLA-DR (MHC-II complex) is expressed in antigen-presenting cells like macrophages, 
dendritic cells or B-lymphocytes. MSCs are described to be HLA-DR negative [5]. Pro-
inflammatory cytokines like IFN-γ on the other hand may induct a HLA-DR presentation 
(see Figure 8 and [64]. This can also be initiated by a high cell density (see 1.3 and [63]). 
Although confluence of more than 80% was mitigated during the assay run, it cannot be 
excluded that this parameter potentially had an influence on the results due to partial 
confluence. On porcine MSCs, no HLA-DR could be identified, whether stimulated with IFN-
γ or not. As a positive control, porcine blood was stained successfully with the anti HLA-DR 
antibody proving its functionality (data not shown). Interestingly, in contrast to murine [63] or 
canine MSCs [62], the absence of MHC-II complexes seems to apply for porcine MSCs. 
HLA-DR presence on human MSCs showed high variances (see Figure 8). As potential 
reasons for this, it is very likely that the donor variety and confluence could have impacted 
the outcome. The total absence of HLA-DR on porcine MSCs is interesting and a significant 
difference between human and porcine MSCs. 
The differentiation of porcine and human MSCs into adipogenic and osteogenic cells could 
be proven (Figure 9 and Figure 10). A numeral comparison based on visual sections was 
performed (see Table 15). Interestingly, a differentiation medium that was formulated for 
human MSCs also showed a successful differentiation in porcine cells. In contrast, 
commercial companies often offer extra murine differentiation media. It was not further 
investigated during the course of this work if murine media are able to induce any 
differentiation in porcine MSCs. Despite the same strength of differentiation into the 
osteogenic lineage for both species (see Figure 10), adipogenic cells were quite different 
(see Figure 9). Comparisons are hard to make, for the reason that the medium was not 
designed for porcine MSCs – otherwise, another medium would not allow any comparisons 
to human MSCs. The fact that porcine MSCs also showed an adipogenic differentiation 
potential caused by the human-conditioned medium was a good proof of comparability at 
this point. An improvement of the differentiation potential due to better differentiation media 
would surely result in more adipogenic cells but not enhance the understanding of the 
comparability. In the end, the ISCT criterion for adipogenic differentiation potential was 
fulfilled – by a medium that was designed for human MSCs.  
The fundamental comparability regarding identity is difficult. The inherent heterogeneity [33] 
of human MSCs does not define a clear, singular identification. This lack of knowledge 
affects the identification of porcine MSCs, too. The insufficient description of human MSCs 
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renders an assessment of the porcine MSCs and their comparability more difficult. Albeit, 
the origin of the cells (bone marrow), the isolation procedure by adherence and the fulfilled 
ISCT criteria are strong arguments to define the porcine cells as MSCs. The absence of 
HLA-DR in accordance to the ISCT can also be confirmed for porcine MSCs. Recent 
publications underlined the inducibility and presence of HLA-DR on human MSCs [63], 
which could not be shown for porcine MSCs. As described before, this was already 
established for canine MSCs [62]. The sub-population of CD105 negative cells is also part 
of the discussion regarding the surface profile of porcine MSCs. Since the description of 
markers on porcine MSC is sparse [234, 291, 292], it is unclear whether other groups will 
confirm these findings or show diverging results. In spite of these controversies considering 
HLA-DR and CD105, porcine MSCs comply with all other characteristics of human MSCs. 
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8.2 Controllability of Gene-Modification Realizable in Porcine MSCs 
comparable to Human MSCs 
The controllability of gene modification is highly important for the safety of a gene-modified 
cell therapy product. Insertional mutagenesis may induce a clonogenic proliferation that can 
lead to cancer [293, 294]. Therefore, the safety of gene-modification is generally based on 
two major factors: the choice of the inserting viral particle and the insertion rate per cell. 
Here, a SIN-gamma retroviral vector introduced a suicide gene into the human cell therapy 
product.  
In contrast to murine MSCs, the same type of retroviral vector could be used for human and 
porcine MSCs because the used GALV (gibbon ape leukemia virus) can infect human, 
simian but also porcine and other mammalian cells [295]. Murine MSCs normally are 
resistant to GALV-carried infections [296]. If the infection of murine cells had been in the 
focus of this work, the production of another viral supernatant would have been necessary 
(e.g. MLV envelope (murine leukemia virus) [297]). From a regulatory point of view, a critical 
raw material would have been changed potentially altering the product properties. Here, 
comparison studies would be necessary to give proof of the comparability. From a scientific 
point of view, the determination of the viral supernatant titer would be different. Both would 
have complicated any meaningful comparisons. 
For these reasons, using porcine MSCs instead of murine MSCs can be advantageous, 
because it opens the possibility of employing the same retroviral vector, thereby reducing 
the differences to the human cell therapy product. Considering GMP production, this is 
clearly a very strong argument from an economical, scientific and regulatory perspective for 
all preclinical and following clinical studies. The development of only one gene delivery 
system saves costs as well as being no potential cause for differences in the scientific 
results in the preclinical phase in vitro and in vivo. Finally, the transfer of preclinical results 
onto clinical study design is easier. 
In this work, porcine MSCs were transduced with the same virus particle / cell ratio as 
human MSCs. The successful transduction was proven and quantified by flow cytometry 
and real-time PCR. The transduction rate determination by flow cytometry took the whole 
population into account. The resulting single values cannot be compared on a statistical 
basis (see Table 16) but they represent strong values due to their methodological approach 
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on a single-cell-based analysis evaluating a whole cell population. The porcine batch 2 was 
transduced in the same manner as the human batches 2,4 and 6 showing transduction 
rates in the range of 3 to 11%. This is consistent with the real-time PCR measurements. 
Here, the values did not show any significant differences between the species after 
transduction for this method – still, slight drifts with p values <0.2 suggest that there could 
be differences (see Figure 13 and Table 13).  
The transduction process itself is influenced by many variables. Although the same batch of 
vector supernatant was used, all cell transductions were performed on different days after 
isolation from the tissue due to the expansion procedure. The thawing of the supernatant, 
cell counting and cell preparation, timing, the mixing of the supernatant with the cells and 
the seeding are many work steps that had impact on the transduction efficiency. In addition, 
a SIN-gamma retroviral vector only infects dividing cells. The fact that the cell division rate, 
respectively population-doubling time in all batches highly varied (see Figure 11) led to 
additional variances. Confirming these reservations, the mean insertion rate and the 
transduction efficacy were highest for batch Human 4, although the population-doubling 
time was the slowest during the whole production. It stands to reason that the whole 
transduction approach is more important than the single aspect of a cell division rate. 
Method optimization to increase transduction efficiency is an ongoing challenge in the field 
of cell-based gene therapy [298-300]. This argument is supported by the fact that method B 
showed the highest transduction efficiency even though the MOI stayed the same. The 
methods were basically the same but were manipulated during the joining of viral 
supernatant and cells. Method A, the method with the lowest transduction efficacy (3%), 
was the simple dispersing of cells and virus. If the viral supernatant was centrifuged on PLL-
containing plates and the cells were seeded into these wells (method B), the percentage of 
transduced cells multiplied (46%). This was accomplished despite using the same virus / 
cell ratio. These results show that the way through which virus and cells are joined affects 
the transduction efficiency more than the numerical virus / cell ratio.  
The results also show that the porcine MSCs are comparable to human MSCs regarding 
their transduction efficiency. Using the same retroviral supernatant simplifies many 
questions. The fact that the change of the method and not a change of the species showed 
significant differences might help to establish robust transduction processes – also when 
utilizing porcine MSCs as model cells.  
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8.3 Functionality of Human-Derived Promoter and Therapeutic 
Gene in Porcine MSCs 
Tissue-specific promoters are attractive for cell-based gene therapy (see detailed in chapter 
1.5) – here, the RANTES promoter was used as an inducible control unit [156]. If MSCs 
home to the site of the tumor stroma, present pro-inflammatory cytokines activate the 
promoter. The translation of the prodrug would then take place next to the cancer cells. This 
approach reduces systemic toxic effects of cytostatic agents because these drugs are only 
locally activated. The also inserted PGK promoter served as a constitutive promoter 
expressing the puromycin resistance gene (for transgene cassette see Figure 1 and Figure 
33).  
Due to the fact that the PGK promoter is constitutive, no effects related to different MSC 
species had to be expected [155]. This assumption was confirmed by the observations 
made in this work. As shown in Figure 14 and Figure 15, the selection of transgene-
expressing cells was successfully proving a functional PGK cassette in MSCs of both 
species. The absence of any second population in the flow cytometry measurements 
affirmed the full selection of non-transduced cells. 
To compare the in vitro efficacy of the therapeutic gene (see 7.6), a functionality of the 
RANTES promoter in the porcine cell had to be demonstrated before, as shown in Figure 
16. Although the results are quite clear showing an increase of expression after induction, a 
high variance of the human batches could be observed. This variance could be a result of 
the varying cell morphology regarding size and granularity (as shown in Figure 4 and Figure 
5) during flow cytometry measurement. The cells` morphology depends on the donor as 
well as different “in vitro ages” of the cell populations [289, 301, 302]. These effects have 
influence on the auto fluorescence and may lead to higher or lower emission signals [303]. 
In addition, the staining procedure can bring up differences because there are several 
washing and preparation steps necessary before measurement (see 6.6). Interestingly, the 
difference between induced and not induced porcine cells was statistically significant. These 
data did not include any donor variance since, as mentioned before, one isogeneic pig was 
used as the donor animal. This may underline the effect of different donors and potentially 
help to explain the high variance. In fact, an up-regulation of the RANTES activity could be 
seen and it is plausible to assume that RANTES worked correctly in both species. 
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HSV-TK was already used as a suicide gene for the treatment of oncological diseases with 
a bad prognosis (see detailed in 1.6) over 20 years ago. The presence of HSV-TK strongly 
increased the sensitivity to GCV as shown in Figure 17. The EC50 values were summed up 
in Figure 18. The cell lines K67 and HT1080 showed low sensitivities to GCV like naïve 
MSCs. The amount of living cells after treatment was determined by consumption of 
reductive elements like NADH that facilitated the chemical reaction of MTT to formazan. 
Dependent on the activity of glycolysis and the following citrate acid cycle, reductive 
elements are build up. The generated values based on the optical density values (OD 
values) after normalization as shown in Figure 17. During development and establishment 
of the assay it was observed, that the OD values for living MSCs - especially human MSCs - 
were lower than for cell lines and also porcine MSCs. These results suggested that 
differences between a well of dead cells and a well of living cells would be quite small (in 
the case of human MSCs). The OD values were in a range from e.g. 0.03 to 0.16 for human 
MSCs (Human 2) and for porcine MSCs from 0.15 to 0.81 (Porcine 3). The cell lines 
showed OD values from 0.02 to 2.02 e.g. HT1080. Small OD values implicate more 
variance in the assay since the difference between measured values is smaller. This fact is 
also reflected by the R-values for the goodness of fit; exemplary: Human 2: 0.94; Porcine 3: 
0.99 and HT1080: 0.98. The variance for humans is higher and therefore the goodness of fit 
smaller. In Figure 17, these differences in the goodness of fit can also be visually 
recognized for e.g. the human naïve cells. The half-effective GCV concentrations are 
depicted in Figure 18. This figure visualizes the differences of the GCV sensitivity on a 
logarithmic scale in a descriptive manner. The variance of the assay weakens the 
quantitative meaningfulness although the R-values are still quite high.  
Nevertheless, the increased sensitivity was substantial higher of all HSV-TK expressing 
MSCs, including the porcine cells. The correct expression of HSV-TK and the increased 
sensitivity could be clearly proven for both species.  
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8.4 Programmed Cell Death by GCV– Do Both Species Go the 
Same Way? 
Apoptosis is complex - as described before, countless intrinsic as well as extrinsic pathways 
may lead to programmed death [191, 304, 305]. In contrast to regulated apoptosis, 
accidental damage can harm the cells´ integrity and immediately lead to irreparable damage 
and cell death (necrosis). In the past few years, the differences between apoptosis, necrosis 
and autophagy became more and more indistinct because the pathways regulate each 
other by cross-talking [304, 305]. Nevertheless, the basic steps of a cell´s apoptotic process 
are relatively well-defined. The cell shows a condensation (decrease of size and increase of 
granularity) and the mitochondria lose their ATP production due to a mega-channel 
opening. This ATP loss can be observed by phosphatidylserine (PS) presentation on the 
surface and ends with the cell death thereby losing all cellular structure (generation of cell 
debris) and generation of countless apoptotic bodies (see detailed in 1.6). 
In this work, the successful killing of cells by GCV could be easily observed by microscopy 
(see Figure 19) as well as by trypan blue cell counting (see Figure 20). Also naïve cells 
showed a cell count reduction after five days. This could be confirmed for both species. The 
accordant assay was performed over five days and included the addition of pro-
inflammatory cytokines. Especially IFNγ is well known to have antiproliferative effects on 
many cell types [306, 307]. In addition, GCV is also marginally translated in unmodified cells 
and leads to the inhibition of the cell´s replication process. Finally, the seeding and harvest 
always include cell losses. These reasons may have caused the loss of cells despite the 
five days of cultivation. Therefore, the cell loss was not normalized against the seeding of 
the HSV-TK cells but rather against non-treated cells, which represented a more 
appropriate control. The observed killing was still statistically significant. Interestingly, the 
cell loss of HSV-TK expressing porcine and human MSCs is quite comparable indicating 
that the GCV affects both species in a similar strength. 
The assumption of an apoptotic pathway was confirmed by flow cytometry. A protocol was 
developed that considered morphological aspects as well as the apoptosis and death of a 
cell (see Figure 21). It could be observed that both species showed a condensation and the 
majority of cells became granular (see Figure 22) compared to untreated cells. Both species 
showed statistically significant changes during treatment (except of the human shrunken 
population: p=0.05). These clear observations were made possible through the successful 
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staining with Annexin-V and 7-AAD. Both species showed an increase of PS presentation 
and loss of cell integrity (see Figure 23).  
Furthermore, the results revealed a clear indication that the addition of cytokines and GCV 
does not lead to a considerable increase of dead naïve cells in vitro. Only the presence of 
HSV-TK and its massive translation of GCV inflicted a cell DNA damage that led to the cell 
death by apoptosis. Porcine MSCs correlated with the expectations made during the 
observation of human MSCs. It could even be said that if the changes in the cells´ 
morphology as well as the amount of 7-AAD positive cells are compared in detail, porcine 
MSCs represented the apoptotic characteristics more clearly. 
It is difficult to find out why these changes are more distinct in porcine cells. The five-day 
cultivation protocol that was used for all apoptosis characterization assays included a flow 
cytometry measurement on day five. Although apoptosis is an ongoing process, the 
measurement assesses the cell population status at a singular point of time only. It is 
conceivable that the chosen timeframe did not show the peak of apoptosis in the human cell 
population [187, 189, 303]. For this reason, the possibility that this “peak of apoptosis” was 
later or earlier and was missed in this assay setup exists. It is also thinkable that the results 
would have shifted if the flow cytometry measurement had been done on day four or six. 
Since the accordant clinical trial [81] was designed to have a treatment with GCV on days 
three, four and five after MSC infusion on day one, it made sense to evaluate the cell killing 
on day five. 
Of course the cells of both species were treated following the same protocol to allow valid 
comparisons. However, one parameter had to be considered and was adapted: the seeded 
cell density. As shown before (see Figure 11, Figure 4 and Figure 5) the cell size highly 
varied throughout the species and donors. An equal seeding of all batches and species 
would not have considered the resulting confluency. Especially for the batches Human 3 
and 4, the whole plastic surface would have been covered with cells if the same amount of 
cells as for Porcine 1-4 had been seeded. This was actually observed during development 
of the assay. The assumption that the GCV killing efficacy is dependent on cell´s replication 
speed and therefore on the growth of a population was strongly indicated (see Figure 24). If 
no surface is available for growth, no replication will happen and no apoptosis will occur 
after GCV incorporation. This is why the cell density after seeding and not the cell count 
was constant throughout the assays. This makes comparisons between the species and 
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batches more meaningful although the correct setup of the assay was more complex. 
Counting cells is more easily than a visual assessment on the confluency from a 
methodological point of view. 
The observed correlation of the growth of a population and its killing rate (see Figure 24) 
makes sense in regard to the mode of action of GCV. Any correlation between VCN and 
killing efficacy could not be made within the scope of this work although there are 
publications that mention an increased efficacy with higher VCN for the HSV-TK system 
[308]. This publication clearly shows that more HSV-TK leads to more activated GCV and 
therefore to more killing efficacy. But potential “growth effects” are not addressed. 
Furthermore, it is unclear which effects the chosen promoter might have had. Higher 
expression rates by e.g. viral constitutive promoters (or other [155]) may negate the 
necessity of further gene copies. Here, an enzyme kinetic of the expressed gene would help 
to understand the amount of enzymes necessary to allow a sufficient translation of GCV. A 
single increase of the copy number per cell is apparently only one parameter of many. In 
general, the presented results confirm the apoptosis as a reaction on present and activated 
GCV. MSCs of both species show the same behavior under GCV treatment and the killing 
rate of a population correlates with its proliferation speed (see Figure 24).  
As described before, the therapeutic approach of the suicide gene HSV-TK is based on the 
bystander effect (see detailed in 1.6). Although it was not in the focus of this work, latest 
publications raise the questions to what extent gap junctions or other biological systems are 
responsible for the transport of cytostatic agents like GCV between cells. Extracellular 
vesicles e.g. exosomes seem to play an important role in inter-cellular communication as 
well as in the transport of agents, proteins or other substances [309-311]. However, while 
establishing the assay it could be observed that a killing effect on the target cell lines was 
nonexistent if the cells were seeded in low confluence of less than 10% resulting in nearly 
no cell-cell contacts. Confluences of 10-25% were chosen to assure sufficient empty 
surface for cell proliferation as well as cell-cell connections. 
A human and a porcine cell line were examined to find out whether neighbored HSV-TK 
expressing MSCs from both species kill the cell lines or not. The already described “five-day 
protocol” was used to maintain consistency with previously performed assays and with the 
clinical trial design. The cell lines could be differentiated from the MSCs by their GFP 
expression (see 6.7.3). Figure 25 clearly demonstrates that the cell count of both cell lines 
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was reduced significantly by HSV-TK expressing batches of both species. A transport of the 
activated GCV to the target cell line was facilitated independent of the species because the 
effect did not differ between porcine and human MSCs underlining the comparability.  
One interesting observation occurred in column one of Figure 25 (B). The resulting cell 
count of the K67 cell line highly varied and was lower than expected although the naïve 
human cells were used as control for the HSV-TK expressing human MSCs. This was 
observed for the combination of human naïve MSCs and the porcine cell line K67. Overall, 
there were fewer cells than observed in the other control (see second column of Figure 25 
(B). Depending on the donor, the resulting cell counts grouped around a lower or higher 
level. This is why the donor-separated depiction was only chosen here. This anti-
proliferative effect of the human naïve MSCs was negated as soon as HSV-TK expressing 
MSCs were present.  
Obviously, human naïve MSCs inhibited the proliferation of the cell line. It could be 
excluded that this happened due to a limitation of space. Microscopy rather showed cells in 
the supernatant and enough surface space for expansion. The possibility of the medium 
itself being the cause can also be disregarded because all cells were growing well in the 
used media. It can be assumed that the MSCs secreted cytokines that had an anti-
proliferative effect on the K67 cell line. MSCs are known to secrete a large panel of trophic 
factors and immunological active cytokines [312-314] and thus can show anti-proliferative 
effects on tumor cell lines [315, 316]. These cytokines could have had anti-proliferative 
effects on the K67 cell line. Because the cell line was originally generated from an MSC 
which was isolated from a Pietrain Landrasse pig [276], it is open for discussion if this cell 
line is even more sensitive to cytokines or not [317]. Whether soluble factors are 
responsible for the inhibition of the proliferation or not was not proven within the scope of 
this work. However, it can be assumed that the secreted cytokines of the human MSCs 
were responsible for the reduction. 
Figure 26 and Figure 27 show the successful induction of apoptosis in the target cell lines 
HT1080 and K67 by co-cultivated porcine and human HSV-TK expressing MSCs. In Figure 
26 (A), HT1080 cells showed a very large increase of PS presentation if HSV-TK 
expressing MSC of both species were co-cultivated. Interestingly, a slight increase of 
Annexin-V positive cells could be seen if naïve human MSCs were co-cultured – an 
observation that wasn´t true for naïve porcine cells. It could potentially indicate the anti-
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proliferating effects of the naïve human MSCs that were observed before (see Figure 25 
(B)), although this increase was not statistically significant. The amount of 7-AAD positive 
HT1080 cells was generally lower than the amount of Annexin-V positive HT1080 cells. This 
was in accordance to earlier observations made for apoptotic MSCs (see Figure 23), which 
suggests that the cell lines also underwent GCV-induced apoptosis. 
The anti-proliferative effects of naïve human MSCs on the cell line K67 (see Figure 25) 
could be confirmed as shown in Figure 27 (A). Annexin-V positive K67 are not only 
significantly increased if co-cultured with HSV-TK expressing MSCs of both species, but the 
amount of apoptotic cells was also significantly increased by naïve human MSCs . This 
result confirms the assumed effects on the cell count: naïve human MSCs have an anti-
proliferating effect on the cell line K67. The 7-AAD staining of K67 generally showed lower 
percentages. The increase of 7-AAD positive cells however was comparable for porcine and 
human HSV-TK MSCs on a low level and therefore shows the successful induction of 
apoptosis in K67.  
The low 7-AAD values could compromise the usefulness of performing a staining to 
determine the dead cells. It could be presumed that more 7-AAD dead cells were detected 
because a suicide gene system was used. The fact that the cells undergo apoptosis and 
loose all cellular structure in the end makes it hard to identify these cells in the flow 
cytometry. Here, the manual cell count has more significance because only the remaining 
cells are taken into account and the cell number reduction can be calculated. As described 
before, the measurement by flow cytometry was only a single point of time measurement on 
one day. This “snippet” on day five was probably too late to capture more apoptotic HT1080 
cells. It is thinkable that most of the cells died before the flow cytometry measurement. 
Furthermore, it can be assumed that the secretion of soluble factors enhanced the apoptotic 
process and possibly reduced the time before the cells´ integrity was lost. Finally, it can be 
said that the remaining amount of HT1080 was comparable between porcine and human 
MSCs whether expressing HSV-TK or not (see Figure 25).  
The characterization of the GCV-induced apoptosis is important to generate an 
understanding to what extent the suicide of the neighbored cell lines is induced in a 
comparable manner. A model cell should fulfill the expectations to show comparable effects. 
Here, the suitability of porcine MSCs as apoptosis-inducing bystander cell could be shown 
clearly. The observed additional effects of naïve human MSCs on the K67 cell line have to 
Discussion 
 
 
 
 
 109 
be considered separately. Similar observations for porcine MSCs were not made and can 
raise questions on the different secretome of porcine and human MSCs. The result that 
HSV-TK expressing MSCs of both species showed the same efficacy in vitro and induced 
apoptosis in a similar manner is a strong argument for porcine MSCs as a model cell in 
apoptosis-inducing approaches.   
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8.5 Infusion of MSCs into Mini-Pigs indicate Lung-Passage 
Dependent Delay  
All batches used for the in vivo studies were stored and transported in the vapor phase of 
liquid nitrogen. Before infusion, the cells were thawed, pooled, counted, filled into the 
syringe for administration and transported from the laboratory to the stables. During the 
whole preparation time, the cells were in suspension in the DMSO-containing medium (see 
Table 3), which could have had a negative impact on the cells´ biological functionality 
because MSCs pursue adherence and DMSO is a surface-active agent [318, 319]. In 
general, it is important to know whether functional and living cells or impaired cells are 
infused in in vivo studies. Here, it was unclear how long they would survive in the 
cryopreservation medium after thawing without a significant reduction of their functional 
activity. This risk of a methodological error due to non-functional cells should be mitigated. 
A growth kinetics assay (Figure 28) indicated possible impairments as described before 
(see 7.7.1). A significant decrease of proliferation was not shown for porcine MSCs until 
150 min. All infusions were performed in less than 90 min hence no impact was expected.  
The human MSCs were compared with the porcine MSCs and obviously showed an earlier 
decrease of the proliferation capacity than their porcine counterpart. A significant reduction 
in the proliferation capacities after 120 min was observable. Furthermore, a decreased 
functionality was indicated after 90 min although the differences were not statistically 
significant (p=0.21). It could not be clearly concluded if this observation was only related to 
the species or caused by other factors. Negative post-thaw effects can be caused by 
several parameters. First, the cryopreservation medium differed between human and 
porcine cells. Both media used 45% hydroxyethyl starch solution and 10% DMSO. For 
porcine MSCs, porcine serum and for human MSCs, a defined human albumin solution was 
used. In contrast to pure albumin, sera are a very heterogeneous and in general a more 
nutritious composition. It is quite likely that this medium could have enhanced the cell 
viability because more nutritional ingredients were available. Secondly, a thawing and 
seeding protocol naturally includes potential variabilities. The cryopreservation vial with the 
MSCs was put into the 37°C water bath and thawed until no more ice crystals could be 
seen. This can result in slightly varying thawing times. The following re-suspension may 
also lead to potential cell damage because the surface-active DMSO may strengthen the 
effect of shear forces. Finally, the status of the cells before cryopreservation is sure to 
Discussion 
 
 
 
 
 111 
influence the result which is influenced by the last medium change before cryopreservation, 
confluency, the in vitro age of the population, passage etc. This is why – on the one hand -  
the generated results were a good indication for the subsequent in vivo studies but on the 
other hand it is highly probable that other working groups or companies come to other 
conclusions due to their specific cell therapy product and their chosen cryopreservation 
procedures [279]. Considering the effects of DMSO, a single publication of Mock et al. 
implicated even better results for porcine MSCs after thawing if the DMSO concentration is 
reduced to 5% [320]. This was taken into consideration during this work because a further 
change in the cryopreservation medium would have reduced the value of the comparison 
studies additionally. Appropriate cryopreservation and thawing is a critical topic in the field 
of the clinical application of MSCs [133, 319, 321]. Special attention was paid to the usage 
of identical equipment and medium, due to the many possibilities of influencing the results 
of the growth kinetics assay without intention. 
In contrast to mice or other rodents, the manipulation of a large animal model to allow e.g. 
the aspiration of a blood sample is difficult to be put into practice. The development of an 
ethically acceptable and scientifically reasonable in vivo testing protocol in collaboration 
with the responsible veterinarian was a major challenge. For blood sampling, a permanent 
catheter was necessary because a kinetic of the cells in the bloodstream had be measured. 
The fast blood coagulation of the pigs’ blood and knowledge of the tendency to shy 
behavior (based on expertise and experience of the responsible veterinarian) of the 50 to 
100 kg heavy mini-pigs impeded stress-free treatment. It was decided to reduce the stress 
of the animals and to narcotize them for two to three hours. During the sleeping phase, the 
catheters were implanted as described before (see 6.9.1 and 7.7.2) to allow the blood 
sample collection for the planned kinetics. Most of the samples were taken during the first 
hour of the pigs´ sleep (see Figure 30 Figure 31). The number of the following blood 
samplings was minimized to reduce the stressful procedure for the animal as far as possible 
because the pigs were awake. 
The choice of an appropriate method to detect the cells in a tissue or blood sample is 
continuously discussed by different working groups [89-93]. Here, three arguments led to 
the choice of real-time PCR as the tracking method for this work. Firstly, an already well-
characterized protocol was established to determine the vector copy number of a 
transduced porcine cell population. Secondly, real-time PCR has a very high sensitivity and 
specifity in general allowing the detection of single DNA sequences. Thirdly, this approach 
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did not need any alterations of the cell product itself. As described before (see 1.4), other 
tracking methods needs major alterations of the cell e.g. transduction with a marker gene 
(like GFP or luciferase), an iron particles loading or a marking with radioactive substances. 
The use of magnetic resonance or X-ray imaging would have allowed full in vivo studies but 
would also have increased the costs. Additionally, both methods were not available on-site. 
A disadvantage of the real-time PCR method is that a differentiation between viable and 
dead cells is not possible because only DNA sequences are measured. Furthermore, the 
blood sample volume for DNA isolation was limited to 750 µL and the real-time PCR 
measurements could be performed with only 5 µL of the isolated DNA solution containing 
not more than 100 µg/µL of DNA. This methodical limitation made it necessary to perform 
multiple analyses consisting of five measurements each (see Figure 30 and Figure 31).  
During the planning of the in vivo studies, it was assumed that signals around the detection 
limit of the method would occur. Spiking experiments with transduced cells in porcine blood 
revealed that at least five copies per reaction well were necessary to generate a valid result. 
This value was extrapolated to 1mL of blood and the calculation showed that at least 450 
MSCs in one sample were necessary to be detected by real-time PCR. The loss during 
preparation of the sample, isolation of the DNA as well as the very sample size used per 
reaction well (5µL) required this number of cells. 
Figure 30 shows the recovered MSCs in the blood per mL in the first animal and Figure 31 
in the second animal. From a “convential” pharmacokinetics point of view, intravenous bolus 
injections of small chemicals are distributed throughout the whole bloodstream after a few 
seconds. Here, the intravenously infused MSCs could not be found in the blood stream 
directly after infusion. It was already described in detail why the fact that the cells were not 
immediately available in the peripheral blood makes sense (see 1.4). A delayed distribution 
is to be expected because the sizes of the infused agents (small molecule vs. cell) 
obviously differed significantly.  
In pig 1, a relatively strong signal could be identified in after 2 min. This signal became 
weaker, but it was – relatively - consistent the next few hours. After 36 h, an extra-ordinary 
recovery was observed. This result was next to the maximum of MSCs that was to be 
expected if an even distribution throughout the bloodstream was assumed. Afterwards, the 
signals became as weak as before and were next to the detection limit.  
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The special pharmacokinetics of MSCs – a delay in the systemic distribution - is an often 
described phenomenon. MSCs are temporarily located in the lung´s vascular system before 
they enter the peripheral bloodstream. Here, the results generated in this work are exactly 
in accordance with the publications that discuss the biodistribution of MSCs in most rodents 
and humans [85, 88, 94, 99, 100, 105, 106]. It is open for discussion whether the high signal 
after 36 h was also caused by MSCs that were locally enriched at the catheter or not. The 
fact that the following measurement after 48 h did not show any MSCs anymore weakens 
this potential assumption. Furthermore three single analyses consisting of five 
measurements were performed for each sample to increase the reliability of the results. 
After 48 h, the last blood sample was taken and the animal was necropsied. Tissue samples 
were frozen on dry ice as well as put into formalin for further analyses. The protocol was 
intentionally designed to have a 48 h in-life phase after the intravenous infusion to increase 
the probability of detecting MSCs in the saved tissues, which is going to be discussed later 
in this chapter. If the tissue samples had been taken to a later point of time, it could have 
been assumed that the MSCs wouldn´t be identifiable anymore in the prominent tissues e.g. 
the lung.  
Based on the proven feasibility of the protocol and the positive results of pig 1, the study 
design of the second pig was extended to potentially allow more insight into the 
pharmacokinetics. Two additional samples were added around the 36 h point of time and 
the in-life phase was prolonged for two days. For this study, unexpected results were 
generated observing nearly no MSCs in the blood (see Figure 31). Minor signals next to the 
detection limits probable indicated MSCs in the bloodstream. However, there was no result 
that showed all signals above the detection limit. Several investigations were performed to 
find causes for this possible methodological error. But spiking experiments confirmed the 
validity of the method showing that the transgene DNA could be recovered in the samples 
of pig 2. It had to be concluded that if MSCs were present, there were less than 450 cells 
per mL blood because all samples were practically negative. The following report of a 
veterinarian of the Institut für Tierpathologie der Ludwig-Maximilians-Universität München 
identified a distinct pulmonary infection in contrast to the first animal (see Table 18). This 
may explain that the amount of MSCs available in the bloodstream undercut the detection 
limit because MSCs are well known to remain in pro-inflammatory tissue environment [87, 
91, 93, 322]. These inflammatory processes could have additionally caused an increased 
retention in the lung.  
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To further confirm the results of the in-house real-time PCR measurements, histological 
slices were sent to an external laboratory for immunohistochemical staining. The 
expectations of finding several MSCs in one tissue slice were low because only pieces of a 
few grams of the apex of the lung were sent. The whole lung of one mini-pig in the study 
had a weight of ca. 500 g.  
The procured pieces were cut into smaller slices. To prevent false-positive results, the 
tissue of a third “MSC-free” mini-pig was treated the same way. A second control with 
antibody isotypes was performed on the directly neighbored slices to identify staining 
artifacts in the tissue (see Figure 32). Table 19 summarizes the results. Both pigs that 
received intravenous infusion showed cells positive for HA-tag staining in the lung. The 
prevalence of MSCs to accumulate in the lung could be confirmed in both pigs although the 
identified amount of MSCs ultimately was low. Other tissues were negative except for the 
spleen of animal 1 because a single signal could be identified. The recovery of MSCs in the 
spleen was already published as described before (see detailed in 1.4) and is therefore not 
in conflict with the results of this work.  
Altogether the results generated in the mini-pigs are in accordance to publications on 
MSCs´ biodistribution. However, only two pigs were used in these studies. A low number of 
animals naturally accompanies large animal studies. In general, the generation time large of 
animals and their small number of offspring limits these studies in contrast to studies using 
rodents. In addition, isogeneic MGH mini-pigs were part of the study and therefore previous 
nuclear transfers had to be performed, which naturally have a failure rate and challenges 
the planning. Even though there were just two animals, the results of both animals fulfilled 
the expectations of MSCs pharmacokinetics and are not in conflict with published results. 
Finally, the feasibility of the mini-pig as a useful and beneficial model animal for 
assessments of the biodistribution of MSCs could be shown. 
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8.6 Conclusions and Outlook 
The aim of this work was to show that the pig and its MSCs are a useful model system for a 
therapeutic MSC-based product. Here, porcine HSV-TK expressing MSCs are described for 
the first time. To prove the validity of this model system, the cells of both species were 
systematically characterized comparing the identity, the controlled insertion of the suicide 
gene, the functional proof of the transgene cassettes and the apoptosis caused by GCV as 
well as the bystander killing of cell lines. The conclusions of all in vitro assays are 
summarized in the following Table 20.  
Table 20: This overview concludes all in vitro tested parameters and the generated results within this 
work. For both species, all tested parameters were assessed against each other. Porcine MSCs showed to be a 
well-usabe platform for human MSCs because they had many similarties regarding identification, production and 
therapeutic efficacy in vitro. Most of the in vitro generated results showed the comparability of both species.  
Parameter Human MSCs Porcine MSCs 
Compar
able? 
Remarks / Conclusion 
Population 
Doubling Time 
(PDT) 
highly varying from donor to 
donor, intra-donor variation 
low 
only one donor available, 
batches equal 
+ 
mean PDT similar, more pig 
donors helpful, batch 
production time probably 
similar 
Morphology 
fibroblast-like, one donor 
more flattened 
fibroblast-like ++ 
typical morphology for both 
species 
Differentiation 
adipogenic and osteogenic 
line successful 
adipogenic and osteogenic 
line successful, adipogenic 
differentiation weaker 
++ 
same medium induces 
differentiation 
Surface 
Marker 
confirming ISCT suggestion, 
HLA-DR present and 
inducible 
confirming ISCT suggestion, 
but CD105 negative sub-
population and HLA-DR not 
present 
+ 
two main surface marker 
show (partial) changes in 
expression, may limit 
meaningfulness 
Gene 
modification 
successful insertion, 
selection and therapeutic 
cassette functional 
successful insertion, selection 
and therapeutic cassette 
functional 
++ 
same retroviral vectors 
inserts therapeutic gene in a 
comparable manner with 
same VCN; selection 
feasible, RANTES inducible 
GCV 
sensitivity / 
Cell Count 
Reduction 
HSV-TK expressing cells 
show increased sensitivity 
and higher cell count 
decreases  
HSV-TK expressing cells show 
increased sensitivity and 
higher cell count decreases 
++ 
porcine MSCs are even more 
sensitive to GCV 
Apoptosis  
significant increase of 
Annexin-V and 7-AAD if 
HSV-TK expressing 
significant increase of 
Annexin-V and 7-AAD if HSV-
TK expressing 
++ 
porcine MSCs show stronger 
apoptotic behavior 
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Parameter Human MSCs Porcine MSCs 
Compar
able? 
Remarks / Conclusion 
Bystander 
Killing  
significant decrease of cells, 
also anti-proliferating effects 
of naïve cells 
significant decrease of cells + 
human MSCs have negative 
proliferation effects on 
porcine cell line 
Bystander 
Induction of 
Apoptosis 
successful induction of 
apoptotic cascade in both 
cell lines 
successful induction of 
apoptotic cascade in both cell 
lines 
++ 
porcine and human MSCs 
can induce apoptosis in both 
species 
 
The results of these assays showed that nearly all measured parameters are comparable 
for porcine and human MSCs. The only differences between both species occurred during 
the measurement of the surface markers and the bystander killing assays. It could be 
observed that there was a porcine MSC sub-population lacking CD105, that porcine MSCs 
generally do not show HLA-DR on their surface and that naïve human MSCs showed anti-
proliferative effects on the porcine cell line K67. Although these results show differences 
between the species, they are not conflicting existing results. Previously mentioned 
publications underline the variability of murine MSCs in regard to CD105 [263]. The anti-
proliferating effects of human MSCs [315, 316] as well as the presence of HLA-DR were 
already controversially discussed [62-64]. In that respect, the results observed for porcine 
MSCs seem to complement existing descriptions and are not in conflict with these. 
The subsequent in vivo studies underlined the usefulness of the mini-pig. Here, it could be 
shown that intravenously administered MSCs were detectable in the bloodstream and that 
the porcine MSCs showed the “MSC-typical” pharmacokinetics profile. Although there were 
only two animals involved in the study, the time-dependent retention in the lungs before the 
cells distributed throughout the body could be clearly observed. The measurements of the 
second animal showed no signals above the detection limit. The identified severe 
pneumonia was a strong indication that MSCs potentially homed to the pro-inflammatory 
environment in the lung reducing the amount of MSCs in the peripheral bloodstream. The 
knowledge about the pharmacokinetics profile is essential for any medicinal product – also 
for ATMPs [76, 77]. As examined in mice before [100], the easier and faster passaging of 
the lung could increase the homing and the efficiency of the MSCs´ therapeutic effects. The 
pig and its anatomy and physiology regarding lungs size, structure and weight are more 
comparable to humans [209, 211, 323]. Therefore, these animals may promise more 
valuable insight into the biodistribution than rodents. 
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Nevertheless, during the early phases of the development of a potential cell product, mice 
or rats have a clear advantage over LAMs: lower costs, faster reproduction cycles, low 
dosages (fewer cells needed) and more animals per study group make statistically relevant 
studies easier. In addition, established immune-deficient rodents are available to test the 
human-based “original” product that enhances proof of concept studies. Immune-deficient 
LAMs are rarely found, although it was shown that e.g. SCID pigs are realizable [227].  
LAMs could be more helpful in a second phase of the development after the proof of 
concept was shown in rodents. Then, the product may be tested under more serious and 
more challenging conditions simulating the clinical setting. To allow studies in LAMs, 
questions asking for the right dosage, potential toxic effects and appropriate treatment 
schemes have to be answered. These are the same questions that have to be addressed 
when clinical trials with humans are initiated. It is obvious that the treatment schemes and 
dosages of a 0.02 kg mouse are less comparable to humans than those of a 75 kg pig. The 
assumed dosages extrapolated from rodents to LAMs could be tested on these before 
humans are treated.  
Another consequence is the fact that the increased dosage for LAMs requires an up-scaling 
of the production, which might be understood as a disadvantage at first glance. The need of 
higher dosages for LAMs as well as humans requires further efforts in the development of 
e.g. bio-reactors [324-326], as reviewed by de Soure et al. [327]. Because of the versatile 
and sensitive biology of cells, especially of MSCs, this up-scaling may have an impact on 
the cells biology. The earlier cell alterations can be characterized before humans are 
treated, the lower the risk that clinical trials fail. Thorough established potency assays may 
help to clarify whether new manufacturing methods have a significant impact or not [36, 41, 
328, 329].  
The complexity of cell therapeutics challenges all working groups and companies facing the 
development of an ATMP. Heterogeneous and versatile biological functions of cells meet 
regulatory expectations that were shaped by the classical, chemical compounds. The 
European Medicines Agency is still struggling to establish adequate GMP-guidelines for 
ATMPs and is still not in agreement about the necessary prerequisites [330]. The small 
number of ATMPs authorized for the market in the EU shows that (genetically modified) 
cells as a medicinal product are still a new therapeutic form, which is underlined by the fact 
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that merey three gene therapy medicinal products and three somatic cell therapy products 
were authorized as of the beginning of 2017 [331]). 
The pig is not only interesting for toxicological testing. The increase in available disease 
models e.g. SCID [227], diabetes [226], neurodegenerative diseases [332] or adenomatous 
polyposis coli (APC) [333] resulting in cancer offers better testing of new therapeutic 
approaches. During this work, the treatment of pigs carrying this APC gene defect that 
develops intestinal tumors was evaluated. However, the successful gene defect led to 
multiple neoplasms. Homing MSCs would have been distributed throughout all neoplasms 
limiting the anti-proliferative effect of the therapy. In addition, these pigs were not mini-pigs 
as they were landrace pigs with a weight of approximately 200kg. The required dosage 
would have been much higher in contrast to 58kg and 82kg heavy mini-pigs. Further 
adjustment of the model´s disease progress could increase the usability of these disease 
models. Still, the local implantation of tumor developing cells is a potential alternative. 
For future cell therapeutics, the mini-pig and its MSCs represent a useful model system. 
The cost-intensive human MSCs may be replaced by porcine MSCs for defined 
development phases. The high comparability to humans, the possibility to perform 
toxicological testing without undesired immunological interactions and the compliance to 
regulatory demands [204] supports this conclusion. They can support or even lead the 
preclinical development of a functional MSC-based ATMP. 
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11 Supplemental 
Figure 33: Construct #65 was used as plasmid for the clinical grad vector carrying the therapeutic gene 
HSV-TK under the control of the Rantes promoter. HSV-TK was fused with HA to allow an identification of 
the enzyme by flow cytometry mediated by antibodies. The selection gene for degrading the antibiotic puromycin 
is controlled under the constitutive promoter hPGK that shows continous expression. The WPRE enhances the 
mRNA stability of the transcripted gene. 
Figure 34: The eGFP containing plasmid was used to tag the cell lines HT1080 and K67. The GFP signal 
was used during flow cytometry analysis to distinguish cell lines and MSCs. The expression of GFP was under 
control of the EFS, a constitutive, promoter.  
